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My thoughts, at the time of writing this chapter, -go back to the time 
when, fresh from housemanship duties in June 1968, I confronted the 
world of 'SCIENCE', This confrontation was initiated more by 
accident than by design, by an invitation from Professor E. Dowdle, 
at that time head of the Radio Isotope Diagnostic Services of 
Groote Schuur Hospital, to come and 'learn to think like a scientist' • 
Whether or not I have acquired this faculty · is debatable, b1 t by 
accepting his invitation, I have seen a world ·of excitement and 
reason, mixed with very hard work and a search for knowledg,a. In 
this world I have made friends, acquired certain skills, and 
developed an understanding of the limits of my knowledge, as well 
as the extremes of knowledge available. 
The choice of a project upon which I could work was directed by a 
happy coincidence. I had an interest in haematology and tne 
Department had no other individual with a particular interest 1n 
isotopic haematological investigations, The possibility of 
describing the pathophysiology of obscure anaemias, and of 
quantitating erythropoiesis seemed to me very exciting, and connnitted 
me firmly to this line of investigation. 
Having "fallen" for this project, I needed to develop the skills 
necessary for carrying out the work, 
associated with many happy memories. 
This period of my life is 
New friends were made and 
skills acquired. Particularly helpful during this period were 
Lyn Petersen 1 Heather Weir, Val Conneli, Egbert Herring, Keith Blake 
and Dennis Fenner. Their friendship and help saw me through the 
initial period of awe and mistrust, when all was strange and the 
laboratory seemed dominated by complicated machines. During this 
period I learned to use a pipette, to know when to use 'hot' and 
'cold' glassware, to manipulate counters, rate meters and scanners, 
to understand the vocabulary of radio-isotope work, and to acquire 
an understanding of what isotope decay is and how it is measured. 
Each day was a mixture of excitement and despair, elation and 
depression, anxiety and relief, as I moulded into the laboratory 
situation and pondered over my own ignorance. 
Once the basic skills had been acquired, the time came for setting 
up an experimental protocol and working with patients. I shall 
never forget my delight when our first experiment worked and 
meaningful data was obtained, nor the need to share this experience 
with anybody with an open ear. During this period I was extremely 
fortunate to have the technical assistance of Miss Heather Weir. 
Her sense of proportion and perspective, technical ability and 
coolness under pressure are well known to her friends. Her 
friendship and help were invaluable. 
With the experimental work runni.ng smoothly, the time came to 
elaborate on the basic work, and to question the meaning of my 
results. This period was spent browsing through the library 
reading papers, learning mathematics and statistics, and realising 
each day how little I really knew. At this stage I sought the 
help of mathematicians, and eventually became associated with 
Mr. Paul Haddingham, a Chemical Engineer doing post-graduate 
work at the University of Cape Town. His criticisms of my 
experimental protocol helped me to repair shortcomings in my 
data, and his expertise produced the mathematical model detailed 
in this thesis. 
Finally, the time came when it was necessary to write up the 
experimental work, and to interpret the data obtained. In some 
ways this was the most interesti_ng period of work, as theories 
were developed, tested and accepted or rejected on their merits. 
However, it is doubtful that I would ever have seriously started 
to write this thesis without the constant help and encouragement 
that I received from my wife. The debt that I owe t o my family 
is immense. They have been neglected, have seen me carry my papers 
away on weekends and vacations, and suffered through my period 
of writing up this thesis. Throughout they have been loving, 
helpful, reassuring and encouraging. 
At the end of this period I was left with an unt idy bundle of 
unedited notes. The sorting out and presentation of these notes 
in an acceptable form is due solely to Mrs. Angela Phillipf:, who 
has battled away at my writing through a rough draft and f i nally 
through the final copy of this work. This she has managecl to 
do with a smile always ready to appear, and for this alone ) I 
doubt I will ever forget her. 
A constant source of encouragement and help has been Dr. Ann Orren, 
who started working in the Department of Isotope Diagnosis at 
much the same time as I did. She has never been too busy to discuss 
a problem or to help in its solution. The expertise of her 
husband, Dr. Michael Orren, has likewise been particularly helpful 
and appreciated. 
In conclusion to this chapter, I would like to reaffirm my gr atitude 
to Professor E. Dowdle, who initially made this work possib l e and who 
has guided me constantly through rough patches, and has at all times 
been available for constructive criticism and help. Hi s own 
high standard of scientific enquiry and capability i & well known, 
and serves as a standard towards which all,who work wi th hin, reach. 
My association with him has been totally stimulating and enj oyable. 
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The work to be presented in this thesis took pl ace while I was 
working as a registrar in the department of radio-isotope di agnosis 
at Groote Schuur Hospital. During this period, I became 
interested in the ferrokinetic technique for attempting to 
quantitate normal and abnormal erythropoietis, and the possib le 
development of these techniques so as to allow more accurate 
quantitation of the data. At the time the study star ted , t he 
department was offering standard ferrokinetic investigations to 
aid in the diagnosis of abnormal haematological statei:. These 
studies did not, I felt, provide adequate i nformation for the 
referring clinician, particularly in regard to ineffective 
erythropoietic activity. 
The idea that the findings of the research labo::ator y, in terms 
of bone marrow function and ineffective erythropoiesis, could 
be applied to the clinical patient, appealed to me. Further-
more, existing procedures, while providing for t he measurement 
of the rate at which 59Fe label left the plasma and appeared in 
the circuladng blood, did not define what happened to this iron 
between these two processes. It seemed to me t hat, by appropriate 
experimental design and analysis, one could analyse this 
intermediary function, and this I have attempted to do. 
My thesis is written in five distinct chapters. Chapters two 
and three attempt to review the vast literature availab le on 
iron metabolism and erythropoiesis, both effective and 
ineffective. Chapter four attempts to define normal f erro-
kinetic parameters. I have found that body iron stores and 




in otherwise normal patients, and I have attempt ed to quantitate 
this variation with the aim of applying these modified parameters 
to disease states. 
The fifth part of my work is really a combination of work done 
by both myself and Mr. Paul Haddingham, who is a chemical engineer 
attached to the University of Cape Town. In this sect ion, a 
model of bone marrow function has been developed which attempts 
to relate input into the bone marrow and output from it i n a 
mathematical manner based upon our experimental findings and the 
research f i ndings of other workers. The resul ~s obtained using 
this method of analysis are also presented . 
The final section of my thesis details my resul t s in the s t udy 
of normals and a number of disease states. Thi s section attempts 
to determine the usefulness of the ferrokinetic technique I have 
developed, as well as to characterise the various di se.ase states. 
In this section a study has been made of 
(a) normal patients. 
(b) haemolytic anaemias 
(c) hypoplastic anaemias 
(d) iron deficiency anaemias 
(e) polycythaemias 
(f) myelofibrosis and reticuloses 
(g) neoplasms 
(h) infections and inflannnations 
(i) uraemia 
(j) cirrhosis 
(k) B12 and folate responsive anaemias 
(1) symptomatic porphyria. 
I-(6) 
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This section is completed by a combined assessment of the results 
in these groups. 
Three appendices are added to my thesis. The first of these 
details the methods I have used in all the patients studi ed. 
The second appendix contains the mathematical proof and development 
of our model describing bone marrow function, and the thi rd 
appendix details the bibliography referred to throughout the 
text. 
5 







The presence of iron in body tissues was first described 1n 1713 
(507) by Lemery and Geoffrey. Liebig(5l 8) published his theory 
of respiration in 1843, in which he postulated that combustion 
in the animal body was related to the presence of iion and took 
place in the blood where haemoglobin (Hb) iron oxidised biological 
substrates. In 1867, Hoppe-Syeler(4oo) crystallised Hb, and 
McMunn subsequently showed that all cells contained haem. <575) 
Non haem bound iron in the body was first described by Fontes 
arid Thivolle in 1925. <267) They described plasma iron and 
demonstrated that it was present in a form different from Hb iron. 
In 1927, Barkan<42> demonstrated that plasma iron was protein 
bound and showed that it was non dialysable at physiological pH. 
The iron binding properties of plasma were discovered by Holmberg 
and Laurell(396) as recently as 1945. In 1949 transferrin was 
isolated by Surgenov et al, (820) and in 1966 was characterised by 
Roberts et a1< 723> as a S1 glycoprotein with a molecular weight 
(820) of 74POO. Surgenov et al had shown transferrin to be a 
specific iron transporting protein in the plasma . Since this, 
approximately sixteen genetic variants of transferrin have been 
identified, but all have been found to handle iron in quantitatively 
the same manner. (841) 
The advent of radioactive iron saw the development of a new 
technique in exploring iron metabolism. Hahn, in 1939, published 
. f t· 1 (337)(338)(339)(342)(584) d showed that a series o ar 1c es an 
iron injected intravenously became distributed in the body, 





This work . was soon amplified by a vast number of authors. 
Dubach( 2ll) demonstrated the variability of distribution of 
intravenously injected iron in different disease states. 
7 
Up to this stage experimental techniques had been relatively c·rude, 
and had certainly not been of a tracer nature, i.e. amounts of 
10 mgs. of iron having been used. "Counting" techniques were 
also laborious, and subject to considerable experimental error. 
The development of well type scintillation counters with activated 
crystals and the deve,lopment of radioactive iron of high specific 
activity, coupled with increased understanding of the physiology 
of transferrin led, in 1950, to the development of qu,,ntitative 
ferrokinetics by Huff et al. <4o4)(4o5)(406) With various 
modifications, Huff's original techniques have since been 
employed by many workers. 
The early realisation that Huff's mathematical formula.e tended to 
overestimate the amount of iron daily being utilised for haemoglobi n 
synthesis led to the development of more complex 'models' or 
. . . (164) (399) (686) (864) mathematical analyses of the kinetic data. 
To a considerable extent, these models have relied upon increasing 
the accuracy of the data obtained by improvement in counting 
technique. The problems posed by the complexi t y of these models 
have mitigated against their use in routine laboratories, and 
Huff's original methods, slightly modified, are still used by 
most routine isotope services. These models have however, added 
considerably to our understanding of internal iron kinetics. 
Development of a basic 'model' of iron kinetics. 
As detailed in a review article by Hahn in 1937~336) the 
. . I 
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understanding of iron kinetics prior to the advent of radioactive 
iron was bedevilled by shortcomings in analytical techniques. It 
is evident that the incorporation of iron into Hb, and the regula-
tion of body iron balance by iron absorption was understood, as 
was the fact that, normally, iron loss from the body was minimal(
5G9) 
The advent of radioactive iron led rapidly to a more complete 
understanding of iron kinetics. 
II-b-2 Hahn(337) showed in dogs that labelled iron, given orally, was 
absorbed into the body and incorporated into Hb. Any iron 
absorbed and not incorporated into Hb was incorporated into 
body iron stores. Balfour et al (
38) showed that the an:.ount of 
the oral dose absorbed depended to a considerable extent upon the 
iron status of his experimental subjects, being increased by iron 
deficiency. After absorption he was able to show detectable 
radioactivity in the plasma and Hahn(
337) showed how this 
concentration in the plasma decreased as a funtion of time. In 
subsequent work, Hahn showed that the percentage of iron absorbed 
from an oral dose decreased as the size of the oral dose increased~
339) 
He also studied the distribution of intravenously administered 
. (338) 1.ron . However, non tracer amounts were given, i.E! , more than 
100 mg., and this obviously vastly exceeded the transferrin 
binding capacity of the plasma. As a result, he found some early 
urinary loss of Fe, but also found a continuous small faecal loss 
of intravenously administered radioactive iron. In addition he 
described biliary iron loss from the body, and showed how this was 





Subsequent work by Miller et al (SS4) confirmed tho t the 
circulating radio-iron, following absorption or intravenous 
injection, was in fact within the red cells, and incorporated into 
the haemoglobin. Hahn demonstrated(
34o)(34l) that this iron, 
once in the cell, was not released from the red cell until it 
was destroyed, confirming earlier work by Shiefley<
775) and 
Hawkins. (364) 
G · k h · d f · · . (309)(310)(311)(312) ranic c aracterise erritin as storage iron 
and, working with Hahn(342) showed that intravenously injected 
59Fe labelled ferric ammonium citrate or haemoglobin r esulted in 
labelling of ferritin. In addition these authors showed that 
colloidal and organic iron given intravenously accumul ated in 
the reticulo-endothelial system(RES) whereas inorganic iron 
tended to accumulate predominantly in parenchymous liver cells. 
Cruz et al( 176) showed, in 1941, that haemoglobin iron released 
from catabolised Hb was re-utilised for Hb formation. At this 
stage then, a fairly composite picture of internal iron kinetics 
(see Figure II-1) emerges which has been largely confirmed by 
later workers with more refined techniques. On the basis of 
the pioneering work mentioned, extensive study of indi vidual 
parts of the kinetic pathway of iron have been carried out 
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Perhaps no one aspect of iron metabolism has received as much 
attention as has iron absorption. Prior to the introduction 
of radioactive iron, absorption was measured by balance studies(336) 
which were, generally, time consuming, liable to considerable 
experimental error, and unpleasant to perform. The concept of 
intestinal regulation of iron balance by variable absorption was 
developed as a result of studies showing how iron absorption was, 
to a large extent, inversely proportional to the size of the body 
(38)(337) . iron stores, and that iron loss from the body was 
minimal, and not important in regulating iron balance. C579)(l58) 
(569) (338) Most of the work done on iron absorption since this 
time has been done in pursuit of an understanding of the mechanism 
and regulation of intestinal iron absorption .• 
These may be conveniently subdivided as follows:-
(a) luminal factors. 
(b) mucosal factors. 
(c) endogenous factors. 
Luminal factors regulating intestinal iron absorption. 
Food iron occurs mainly in the ferric form where it may be 
complexed with organic compounds or present in an inorganic 
(or ionic) form. These two forms (organic and inorganic iron) 
of iron appear t<> be absorbed by two different mechanisms, haem 
iron not being influenced by the factors normally influencing 
ionic iron absorption. 
12 
(a) Inorganic iron absorption. 
This occurs in the diet mainly in the ferric form and may or may 
not be complexed to other chemical groups. A number of studies 
have shown that inorganic iron is absorbed into the mucosal cell 
in the divalent state(426)(33)(4o) and in order for this to occur, 
complexed iron must be released and then reduced to the ferrous 
state. This process occurs primarily in the stomach, because of 
its acid secretions, and in the upper small bowel (4l)(99)(l60) 
and lumenal factors promoting or inhibiting both the release of 
complexed iron and its reduction to the ferrous state will 
obviously influence the amount of iron presented to the mucosal 
cell for absorption, and (as will be detailed later) this will 
influence the amount of iron absorbed. Figure II-2 details 
the important factors promoting or inhibiting the presentation 
of ferrous salt to the mucosal cell. 
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Table II-1 Factors effecting the presentation of ferrous iron 
to the intestinal mucosal surface. 
Factors Inhibiting the 
presentation of Ferrous 





A. hl h d, (750)(299)(421)(118) ~c or y r1a 
(389)(798)(843)(467) 
~esferrioxamine(33)(4l)(48 lb) 
K;obalt (749) (57) 
IFoo/394) 
~xcess food iron(394)(395)(555) 
Factors promoting the 
presentation of ferrous iron 
to the mucosal cell surface. 
A b . A 'd(394)(154)(120)(172) scor 1c c1 
(601) (603) ( 6 7 8) 
G t . A 'd't (120)(792)(426) (182) as r1c c1. 1. y 
(422)(594)(423)(424) 
(420)(105)(314)(366)(163) 
S .. A .d(394)(120)(346) UCCl.nl.C Cl. 
C t 
. (555) (346) ys e1.ne 
h . . 
(555) Met 1.on1.ne 
F t 
(138)(188)(681) rue ose 
Alcohol 0 4o) 
Decreased Pancreatic Secretions 
(185)(66)(186)(837)(870)(745) 
Iron deficient diets 
(453)(456)(616)(34) 
C. h . (171) (578) (157) 1.rr os1.s 
All these factors act by promoting or inhibiting the release 
of iron from complexed compounds and the reduction of ferric 
to ferrous iron. 
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(b) Organic Iron Absorption. 
Evidence that the absorption of organic iron compounds, notably 
haem, by a different process to that for inorganic iron absorption 
abounds. Haem iron absorption is, generally, not influenced by 
. . . . b . (33) (41) lumenal factors acting upon inorganic iron a sorption , 
and the reading of plasma radioactivity following 
59Fe labelled 
haem ingestion occurs later and persists for longer than that 
f 11 . l . . . l d. (40)(160) o owing ora inorganic iron oa ing. It is believed 
that haem iron is absorbed intact into the mucosal cell, the 
iron being split off the parent organic compound within t he 
1 11 
(189)(617) 
mucosa ce • A small amount of haem iron appears to 
(117) 
be absorbed intact into the plasma but the majority app~ars 
to be split up into the porphyrin ring and free iron by an enzyme 
whose activity can be inhibited by the presence of excesrdve iron 
locally. ( 87 5) This mechanism may be a regulatory process, 
determining not only the amount of iron released but also the 
eventual amount absorbed. Xanthine oxidase appears to be 
. . h 1 f . f h · <189) . important int ere ease o iron rom aem as it generates 
peroxidases that release the iron from haem. Once the i ron is 
separated from its parent organic compound, it appears to be 
absorbed in the same way as inorganic iron. 
II-c-3. Mucosal factors regulating inorganic iron absorption. 
Ferrous iron, once presented to the intestinal mucosal cell, is 
. (205)(426) 
transported across the cell by an active transfer process 
<54o)(54i)(542><543)capable of moving iron against both concen-
tration and potential gradients. This system is dependent 
upon oxidative metabolism and generation of phosphate bond energy, 
and because of this has a limited capacity. 
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Uptake by the mucosal cell of iron is rapid, occurs 1n all seg-
ments of gut, is non regulated and varies according to the a~0unt 
of iron presented to the cell. <88)(792)(99) Serosal transfer 
of iron is however a slow process, occurs predominantly in 
proximal gut segments and involves the transfer of divalent i r on 
only. This process is blocked by metabolic inhibitors because 
of its dependence upon oxidative hexose metabolism. (
8l) 
Transfer is stimulated by ascorbic acid and low pH. Increased 
transfer activity occurs in conditions associated with increased 
iron absorption whereas transfer activity is depressed 1n 
conditions associated with decreased iron absorption . 
Two iron pools are present within the intestinal mucosal cell . 
(i) 2+ A rapidly turning over Fe pool passing through the 
mucosal cell into the plasma and 
(ii) A slowly turning over Fe3+ pool, some of this iron being 
associated with ferritin. 
The activity of these iron pools is variable and decreased 
activity can be induced by inhibition of protein synthesis in the 
proximal small bowel. <327) 
Granick has shown(JlJ)(Jl4)(JlG) that the presence of iron in 
the intestinal epithelial cells is associated with the formation 
of ferritin. Apoferritin, the non iron containing protein 
precursor of ferritin, has been shown to .be actively synthesised 
and degraded within this epithelial cell, becoming stabilised 
only when combined with iron. Synthesis of apoferritin at this 
16 
site is considerably augmented by the presence of iron o
r where 
there are increased body iron stores. <
79 i) Crosby, in a 
, I 
beautiful series of experiments has shown how, by mucosa
l 
desquamation, ferritin is continuously being lost from t
he 
intestinal mucosa, and on the basis of this work postula
ted a 
. . . (172)(174)(173)(175) 
regulatory mechanism for iron absorption. 
(158)(359)(674)(874)(881)(882)(883) His work has now been 
confirmed by many workers, and postulates that a portion
 of the 
iron taken into the intact mucosal cell is rapidly trans
ferred 
across the cell into the plasma, the size of this portio
n being 
determined by a number of endogenous factors which I sha
l l detail 
at a later stage.(II-c-4) The characteristics of this 
i ron 
during transfer are not known. <
544)(668)(881) The remainder of 
the iron taken into the cell becomes complexed within th
e cell, 
h . ' b ' 1 d ' h f 
' ' f f ' · <139) 
t e maJority eing comp exe wit apo erritin, to orm 
erritin. 
(141) This is subsequently lost from the body by desquamation 
(158) (75). 
It is postulated that the determination of how much iron
 will be 
transported across the cell into the plasma is "built in
to" the 
mucosal cell at its conception and is dependent upon the
 amount 
of iron delivered to it by transferrin at this stage. 
This 
messenger iron stimulates the formation of apoferritin w
hich will 
complex absorbed iron in amounts proportional to its own
 
concentration. By varying the amount of iron complexed in this 
way, iron absorption can be regulated. The amount of 'messenger 
iron' delivered to the developing mucosal cell appears t
o depend 
upon the body's iron requirements(
88l)(882)(883) and the amount 
17 . 
of endogenous iron available for storage. Where excessive 
endogenous iron is available for storage increased amounts of 
'messenger iron' will be delivered which will, by increasing 
apoferritin synthesis also increase mucosal iron sequestration 
and diminish iron absorption. The reverse occurs where body 
. . h. h (543)(881)(883). iron requirements are ig. Transferrin 
preferentially transports iron to erythroid tissue in the presence 
of diminished body iron stores, and because of this, messenger 
iron deposition in the mucosal cell will decrease in iron 
deficiency or in conditions associated with increased erythro-
poietic activity (at given serum iron levels). 
apply where erythropoietic activity is decreased. 
The reverse will 
This postulate has been shown to describe the clini cal situation 
11 (177)(847)(678)(81)(679)(481)(159)(61)(737)(74) . very we in most 
cases. 
(212)(158)(881)(287)(393)(476)(252)(75)(453)(236)(156)(713) 
(746) (617) .although Bothwell's group have shown that this 
regulatory mechanism can be overcome by increasing the amount of 
iron presented to the mucosal surface. They have shown that 
although the percentage of an oral dose absorbed may decrease as 
the load increases, the absolute amount absorbed actually 
. (426)(80b) increases. This indicates that the amount of iron 
absorbed into the mucosal cell does influence the amount of iron 
actively transported across the serosal surface into the plasma 
thus over-riding physiological control of iron absorption. <898) 
(344)(97)(604)(791)(74)(172){394)(154)(252) Some workers however 
have been unable to determine any correlation between mucosal iron 
concentration and iron absorption. (l7)(35)(453)(739) 
II-c-4 
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The vast majority of the iron taken into the body appears to be 
absorbed by a controlled mechanism as described. Other pathways 
for iron intake into the body have been postulated including 
1 h . k (235) (602) d . . f . 
b . , dl yrnp atic upta e an ingestion o iron y inwar y 
migrating iron laden macrophages. (9o4)(l72)< 24) The amount tak~n 
from the gut by these pathways appears to be negligible. There 
does not seem to be an exchange of iron between body stores and 
intralumenal iron apart from the loss of messenger iron in the 
d t d 1 11 
(682)(791)(162)(423)(424)(750)(188)(681) 
esquama e mucosa ce s 
(33)(41)(481b)(l05)(314)(366)(163)(420)(422) 1th h · d a oug increase 
body iron loss via mucosal desquamation has been demonstrated in 
diseases associated with increased mucosal cell turnover. (3
26) 
(782)(171)(172)(822)(28)(75)(453) The mucosal regulation of 
iron absorption appears to be deficient or 'set at a l ower level' 
. "d" h" h h . (177)(172) in i iopat ic aemoc romatosis. 
Endogenous factors regulating iron absorption. 
There appears to be, as previously stated, a good corr.elation 
between iron absorption and a number of endogenous factors. 
Increased iron absorption has been found in conditionn associated 
with decreased body iron stores<82)(8l)(2l 2)(347)(599 ) (604)(679) 
and increased erythropoietic activity. (8l)(5l5)(7l5)( l 43)(874) (236) 
Changes in iron absorption, according to these authorn, appear 
to be unrelated to levels of Hb, serum iron, transfer1:in, Hct or 
transferrin saturation. 
Some studies however, have shown that anaemia alone may influence 
i·ron b t" (577)(578)(752)(906)(77)




Plasma Transfer of Iron. 
' f' d d. 1925(267) d f d b Plasma iron was irst emonstrate 1n an oun to e 
non dialysable and protein bound in 1927. <
43) Holmberg and 
Laure11<396) first recognised the iron binding properties of 
plasma in 1945, and Surgenov et a1(820) isolated transferrin 1n 
1949. Roberts et al characterised it as a S1 glycoprotein in 
1966. <723) To date approximately sixteen genetic variants of 
transferrin have been demonstrated, all handl i ng iron in the 
same way. (858)(841) 
II-d-2 In 1939 Hahn had demonstrated the presence of radioactive iron 
in the plasma following oral loading with labelled iron, and had 
showed how its concentration in the plasma diminished as a function 
of time, <337) and a number of authors have since shown hew iron 
transferred from the intestinal mucosal cell t o its seroEal surface 
becomes bound to transferrin~84l)(87b)(335)(500)(600)(69i)(702) 
(747)(783)(864) 
II-d-3 Chemically, transferrin is a S1 globulin (mucoprot,,dn, glycoprotein) 
with a molecular weight of approximately 74JJCXJ<
723) Ger_etic 
variants of transferrin, demonstrated by differences in electro-
h . . . (858) 1 f . . . . f p oret1c m1grat1on resu t rom var1at1on in a series o 
co-dominant autosomal alleles at one locus. All are , hcwever, 
antigenically related and bind, transport and deliver ircn in 
'd ' 1 f h' (S4 t) f ' h b - d an i entica as 10n. Trans errin as een ~oun a.t an 
early stage in foetal development, the main site 0£ synthesis 
being the liver(





. (793) (372) 
has also been described. 
Each molecule of transferrin is capable of binding two molecules 
of ferric iron, and in doing so, changes from a colourless to 
a salmon pink colour. (50l) The bound iron is extremely tightly 
held with an estimated affinity constant of 10
31 (l)(45) at 
physiological pH. In vitro, iron can be dissociated from 
1 H 1 (469)
(702)(501) 
transferrin only at very ow p va ues. 
The amino acid and carbohydrate composition of t1:ansferrin is 
k 1 h h h
. (328) 
nown at oug t e1r sequences are not. Two identical 
branched heterosaccharide chains are present terminating in 
sialic acid and containing galactose, N-acetyl gl ucosamine 
and mannose. These are linked to the protein moiety by an 
. l . d (428) asparag1ny res1 ue. The protein moiety itself consists 
f . 1 1 . d h . <328) o a singe po ypept1 e c a1n. Various ca1~bohydrate groups 
can be removed from the heterosaccharide chains uith no change 
. . b' l . f . (474) (612) 1n 10 og1c unction. 
Two metal binding sites are present on the trans i errin molecule 
which appear to be identical in their capacity to co-ordinate 
. (501) iron. 
t (1) (10) 
They are separated by a distance of more than nine 
Two histidyl and three tyrosyl groups are involved 
in binding the iron. Under ordinary circumstances three protons 
1 d f h f . . ( 3+) . are re ease or eac err1c iron Fe bound, and one bicarbonate 
ion (Hco
3
) is taken up(l0)(472)<52o)(894) although binding of 
3+ . (11) 
Fe can be effected 1n the absence of Hco3
• When this 
occurs however, heterogeneity exists for the two binding sites 





insensitive to blockage of free amino acid groups and changes 
in net charge although both of these manoeuvres effect protein 
. l (474)(114)(473) 
binding to iron receptor sites on reticu ocytes. 
When iron free transferrin (apotransferrin) binds with iron, a 
marked change in the physico-chemical properties of the protein 
1 1 
(475) (69) 
occurs due to changes in configuration of the mo ecu e. 
Recent investigations have questioned whether transferrin can 
exist in two different forms of iron binding i.e. with one or 
b h . b' d' . . d (
90l) h 1 b ot iron in ing sites occupie. It as a so een 
questioned whether the physically and chemically identical iron 
b . d" · · f b' l · 1
1 'd . 1(475) (263) (262) in ing sites are in act io ogica y i entica 
( 264)(265) but equality of delivery from either or both of these 
· b' d' · h b d d (494) (398) iron in ing sites as een emonstrate. 
Transferrin appears to be a true iron carrier. Alone it appears 
to have no enzymatic function(
5o2)(50l)(658) although it has been 
demonstrated to inhibit viral, bacterial and fungal growth, a 
capacity which appears to be related to its ability to bind 
iron(126)<245)(55l)(552) and which decreases as it beccmes 
. l d . h . (126)(793) progressive y more saturate wit iron. 
Another iron binding protein reversibly combining with two ferric 
ions has recently been demonstrated in body fluids and neutrophils. 
This has been called lactoferrin and is thought t o be important in 
resistance to infection. It binds Fe
3+ with a greater affinity 
than does transferrin and is stable down to a pH of 3. (
556) 
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II-d-10 Transferrin distributes itself approximately equa lly between 
intra and extra vascular extra cellular fluids, and has been 
found in lymph, ascites, cerebrospinal and oedema fluid< 27 )< 295) 
<435)(45o)(864) in studies where it has been labelled. 
Equilibration between these various compartments, following 
intravenous injection of labelled transferrin, t akes four to 
five days. After this, transferrin disappears exponent ially 
from the plasma with a half time of approximately nine days . 
No correlation exists between the turnover times of transferrin 
and iron , s upporting the thesis that transferrin is a true i ron 
. (500)(502)(501) carrier. There is some evidence that t ransferrin 
becomes transiently fixed to the reticulocyte membr ane during 
d 1 . f . . (501)(432)(434)(609)(606)(227) b . e 1.very o 1.ts 1.ron ut ts not 
consumed during this period and readily exchanges with plasma 
transferrin. Specific transferrin binding sites have ·:,een 
demonstrated on the cell membrane of maturing erythr oid cell s. 
These can be destroyed by trypsin and have been shown t0 be 
metabolically active, being blocked by metabolic inhibitors. <22 7) 
(432) (434) The amount of transferrin temporari l y sequ,:!stered by 
the reticulocyte membrane is small and insignificant wh:!n compared 
. (27)(382)(610) to the total transferr1.n pool. 
I I-d-11 Plasma concentrations of transferrin vary between 0.16 - 0.36 gm. 
(501) One gram of transferrin binds 1.25 mg. of iron. By 
convention, plasma transferrin concentration is express ,:!d in ter ms 
of the plasma iron binding capacity which varies betwee~ 200 
to 450 µgms/100 ml. depending upon the method used for i ts 
assay. (378) (702) (729) 
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The mechanismscontrolling the transferrin concentration are 
poorly understood. Transferrin synthesis occurs mainly in the 
liver(296) and its concentration is dependent upon both anabolic 
and catabolic functions. Lane has postulated that plasma trans-
ferrin levels may be dependent upon the status of body iron 
stores and the percentage of the circulating transferrin bound 
. h . . h l (492) (493) wit iron 1n t e p asma. Low levels of transferrin 
are present at birth, (500) the levels increasing to normal by 
adolescence(766) and remaining at this level throughout life. 
(122)(690) Factors influencing serum transferri n concentrations 
are detailed in Table II-2. No diurnal var iation in serum 
transferrin concentrations has been demonstrated . <
122>< 690)(679) 
Table II-2 
Factors influencing Serum Transferrin Concentrati ons. 
Factors increasing ·serum Factors decreasing serum 
transferrin concentrations transferrin concentrations 
1. 
H . (122) (608) (691) ypox1a 1. I f t. (79
6) (435) n ec 1011 
(809)(63) 
E d t . (445) (446) ( 447) 
. (492) 
2. n o ox1n 
2. Low iron stores 1· . d' (7S6) (493)(796)(679) 3. Ma 1gnant 1s,~ase 
3. Oestrogens(
4l 9)( 278) 4. Iron overloaded states 
(607) (112) (397) (547) (493) (755b) (63) 
(172) (175) 5. Nephrotic Syndrome ) 
) 
6. Uraemia ) (355) 
) 
7. Protein ) 
malnutrition ) 
II-d-12 Plasma iron levels represent a balance between pr ocesses adding to, 
or removing iron from, the plasma. Normally all the iron present 
in the plasma is bound to transferrin(
26) although, under 
exceptional circumstances iron may be present, unbound, in the 
plasma, as ferritin. This usually will only occur following 
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acute liver damage or occasionally in conditions associated with 
. . . . . . (248) (883) 
gross ineffective erythropoietic activity. 
II-d-13 Iron in the plasma is in a dynamic state, and its concentration 
in the plasma varies considerably with time. Marked di urnal 
variation of plasma iron concentration has been well documented, 
levels tending to be high in the morning and low in the evening. 
(78)(87)(351)(503)(662)(663)(794) This diurnal variati on seems 
· · d. <663) s · 1 1 d to disappear in isease states. erum iron eve :; ten to 
increase in the presence of decreased erythropoietic ac:ivity, 
haemolysis, ineffective erythropoiesis, acute liver dis ,?ase, and 
. . (134)(249)(539)(664)(548) 
where body iron stores are increased. 
(600)(607)(369)(702)(502)(662)(916) Levels of iron in the serum 
tend to decrease with infection, malignancy, after surg,=ry, i n 
conditions associated with accelerated erythropoiesis p~rticularly 
conversion of ineffective to effective erythropoiesis, ~nd in 
the presence of diminished body iron stores. (7o2>< 783)(l22)(690) 
(273)(548)(30)(50) 
II-d-14 The importance of transferrin in internal iron kinetics is well 
demonstrated in studies performed on patients with congenital 
atransferrinaemia~369)(72l)(368)(388) In these patients there 
is severe hypochromic anaemia refractory to therapy, excessive 
body iron stores, retarded growth and susceptibility to recurrent 
infections. Injection of iron intravenously into these patients 
results in extremely rapid indiscriminate clearing of iron from 
the plasma to iron storage sites with ·the later appearance of 
subnormal amounts of the injected iron in the circulating red 
cells. Interestingly, iron absorption in this situation is 
greater than in normal subjects showing that transferrin is 
not required for iron absorption. 
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(340) (258) . h f · · h 1 cells, nor is there any exc ange o iron, int e p asma, 
. f 1 1 f f . <258) between dif erent mo ecu es o trans errin. 
Exchange of iron between transferrin and iron receptor sites, 
and iron storage. 
The evidence for the uptake of iron from the intestinal mucosal 
cell by transferrin, and the deposition, by transferrin, into the 
developing intestinal mucosal cell, of messenger iron, has 
previously been reviewed. (Section II-c-3) and wil l not be 
repeated. 
The interchange of iron between transferrin and parenchymatous 
iron stores is poorly understood. The evidence for deposition, 
b f · f · h · , 
.d bl (248) (883) 
y trans errin, o iron at t ese sites is consi era e 
(564)(893) and is derived from 




or imaging techniques. 
(b) Anatomic dissection and organ counting following the 
intravenous injection of 
59Fe labelled transferrin. <253>< 252> 
(c) Observations of increased parenchymal iron stores in 
conditions associated with raised senna iron levels, and 
decreased parenchymatous iron stores in conditions associated 






The reticulo-endothelial cell appears to be incapable of taking 
up iron from transferrin as judged by these studies(
258)(434) 
(620)(609)(6l0)( 748)(908) except under exceptional circumstance8. 
(532)(535) 
That iron is taken up, by transferrin, from iron stores, whether 
parenchymatous or reticulo-endothelial, is undisputed. Perhaps 
the best demonstration of this has been the experimental induction 
of iron deficiency by repeated phlebotomy which ~s accompanied 
by progressive decrease in the histological evidence of iron 
d 1 d 
(384)(211)(360) 
storage until iron stores are totally ep ete. 
(61)(415)(252)(156) So reproducible is thi s technique that Finch 
1 h d h . h. 
b d . (252) 
et a ave use tis tee nique to assay o y iron store.s. 
Evidence is available to suggest that recently catabolised 
haemoglobin iron is more readily available t o transferrin than 
iron previously deposited in iron stores. (
2ll)( 257)(7o3)(361) 
(645)(255)(328)(757) Other authors however, feel that all forms 
f 
. . (360)(703)(224)(252) 
o storage iron are equally available. 
Iron stores appear to be poorly mobilised to transferr j.n in the 
presence of infection, (130)(698)(61)(361)(252)(916)(60: (645) 
neoplasia,<916)(60)( 36l) ascorbic acid deficiency(
860) ·s59) 
. (61)(252)(916) (61) 
uraemia, cirrhosis and chronic inflatnnatory 
t t 
(361)(916)(60) 
s a es. 
Iron is stored intracellularly as ferritin and haemosiderin in 
approximately equal amounts(
776)(838)(871) in both parenchymal 
and reticuloendothelial cells of many organs, particul.1rly liver, 
spleen and bone marrow. Ferritin is a macromolecule with a 
II-e-6 
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spherical core containing iron surrounded by a protein shell 
made up of approximately twenty identical spherical polypeptide 
h . b 't (356)(659) wi'th a h t . t
' c ain su uni s c arac eris ic appearance on 
electron microscopy. Ferritin is water soluble and contains 
a variable amount of iron. It stains poorly with Prussian blue. 
(777) Ferritins derived from different sites in the same 
animal have been found to have different electrophoretic mobilities 
due to differences in surface charge, but share antigenic 
't (13)(279)(280)(640)(720)(819) si es. Ferritin lacking fron is 
called apoferritin, and synthesis of this has been shown to be 
accelerated in the liver, in a dose dependent way, following 
. . . . f . (147) (209) (210) ' f intravenous inJect1.on o iron. The presence o 
iron in apoferritin appears to stabilise the molecule. 
(567) 
Mazur et al have demonstrated the presence of a number of 
2+ • . • • . 
Fe 1.ons on the surface of ferritin stabilised by the presence 
of surface sulphydryl groups. When these groups are oxidised 
to disulphide linkages the Fe
2+ also becomes oxidised tr) Fe
3+ 
and migrates into the central core of the ferritin molecJle. 
Surface Fe
2+ ions can dissociate from the surface sulphydryl 
groups in the presence of a suitable iron binding agent, this 
being facilitated by reducing substances and hypoxia. The 
mechanism whereby iron is taken up by storage sites from trans-
ferrin is porrly understood. Mazur et a1<
564)(565) showed 
that iron is preferentially taken up by iron poor ferritin 
molecules. This uptake appears to be dependent upon energy 




ascorbic acid. . f f . 3+ 2+ The reduction o trans errin Fe to Fe 
is stimulated by ATP in the presence of ascorbic acid. The 
2+ d' · f h f . d h b' d . h f Fe issociates rom t e trans errin an ten ins wit sur ace 
sulphydryl groups on apoferritin. 
Mobilisation of iron from ferritin is similarly poorly understood. 
Mazur(563)(567)(568) has postulated that xanthine oxidase is 
required for this to occur. The reduction of xanthine oxidase 
during its oxidation of hypoxanthine and xanthine to uric acid 
' d ' f 3+ 2+ ' h f ' . is thought to promote re uction o Fe to Fe int e erritin 
molecule (by transfer of an electron), liberating small amounts 
2+ of Fe • This process is stimulated by hypoxia, and adminis-
tration of xanthine substrates, raising the serum iron level in 
animals. Against this postulate is the apparent lack of effect 
upon iron metabolism of h ' 11 ' 1 d . . ' 0
33) c ronic a opurino a mJ.nistration 
<234)(88)(326) although the reverse has been shown in some 
. l . (693) anima experiments. 
Recent work by Bothwell's group has shown that ascorbic acid 
is important for the release of iron from iron stores, and that 
administration of ascorbic acid to iron overloaded Bantu patients 
increases serum iron levels and desferrioxamine induced urinary 
iron excretion. (859)(S60) Normal plasma is capable of oxidising 
iron at physiological pH and oxygen tensions, this action being 
. (652) 
based upon the ferroxidase activity of caeuloplasmin. 
Administration of caeruloplasmin causes prompt release of iron 
from reticulo-endothelial stores with no effect upon iron 
absorption. (653)(lOO) These processes are summarised 
diagrannnatically in Figure II-2. 
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Figure II-2 Diagramatic Representation of Redox System postulated 
for storage iron uptake and release from transferrin 
(See text II-e-6 + II-e-8) 
Apoferritin 
2+ ~ Ferri tin 












ATP •----- Acid 
II-e-9 




(659)(660) Pape et al have proposed an alternate method for the 
uptake and release of iron by ferritin, not involving redox 
systems. They propose that the iron micelle in ferritin is 
initially formed in the cell cytoplasm and subsequently becomes 
stabilised by the addition of the polypeptide subunits of 
apoferritin formed in the cell in response to the presence of 
iron. Removal of iron from ferritin can be carried out by a 
process involving specific low molecular weight chelating agents. 
S f h . h b . . <210> d f . . o art is as not een proven in vivo, an apo erritin 
synthesis has been shown to occur in the absence of an iron 
core(359) tending to cast some doubt about Pape's theory 
resolving the problem. 
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II-e-10 Haemosiderin occurs in granules and stains strongly with Prussian 
blue. The granules are visible under the ordinary light micro-
scope, and are not water soluble. Haemosiderin appears to be 
derived from ferritin( 557)(7l 7)(7l 8)(7l 9) but can occur in a 
number of different (890) physical and chemical fo·rms that appear 
to be aggregates of f . . (898) (878) (777) . . n·umber erritin containing a 
of additional compounds including porphyrins, lipids and pigments. 
II-e-ll There are functional differences between these two form:; of storage 
iron. In iron overload, the proportion of haemosiderin increases . 
Intravenously administered radioiron is incorporated in-:o ferritin 
initially, and not into haemosiderin, and following repeated 
venessection ferritin iron is more readily mobilised than is 
haemosiderin iron~778)(779) 
II-e-12 I have previously mentioned that reticulo-endothelial c,?lls are 
unable to take up iron from transferrin, except under exceptional 
circumstances (section II-e-2). However, the reticulo·-
endothelial system plays a major part in the delivery o:: iron to 
transferrin, providing from catabolised haemoglobin nea1~ly all 
the iron required for erythropoiesis under normal circumstances. 
(45) (645) 
Iron delivered to the reticulo-endothelial cell from 
haemoglobin is promptly and almost completely re-utilis,?d for new 
haemoglobin synthesis, particularly in iron deficiency. Where 
iron stores accumulate in the reticulo-endothelial cell:;, they 
occur as both ferritin and haemosiderin. Under certain 
conditions it appears as though release of iron from thEi reticulo-
endothelial cells is inhibited i.e. infections, inflammation, 
1 (361)(460)(656) neop asms. The reticulo-endothelial cell thus 




the plasma. It is important to remember that the majority of 
iron required for erythropoiesis is derived from this source, 
and that re-utilisation blocks may lead to significant anaemias. 
Why the variable avidity of the reticulo-endothelial cells 
exists, and how it is controlled in these different disease 
states, does not, at present, appear to be understood. 
Body loss of Iron. 
Measurement of body iron loss is hampered by a number of factors 
i.e. contamination of samples by non body iron, faecal J.oss by 
excretion as well as mucosal desquamation. The total claily 
b d · 1 b · l l /d (224) (213) o y iron oss appears to e approximate y mg ay, 
<255) 0 4l) the majority of iron being lost via the gastro-
(220) 
intestinal tract as blood, exfoliated mucosal cells and via 
h b 'l (141)(213)(782) t e i e. All cells contain iron, and for 
this reason, the loss of epithelial cells and leukocytev from the 
body, as well as hair and nails, result in body loss of iron. <782) 
Green et a1(326) calculated that gastro-intestinal iron loss was 
approximately 0.4 mgs/day, and Crosby has postulated additional 
loss of endogenous body iron via macrophages into the gastro-
intestinal tract, (l 75) particularly in iron overloaded ~:tates. 
Loss of intravenously injected radioactive iron bound to transferrin 
in the faeces has been recorded by~ number of workers. (782)(822)( 28) 
The loss of iron in the bile is thought to be app·roximately 
0.26 mgs per day, the source of this iron being uncertain. It 





large proportion of this iron, lost in the bile, may subsequently 
b b b d 
(782)(90)(213)(326) 
e rea sore • 
Under normal circumstances, loss of iron in the urine is usually 
less than 0.1 mg/day(l8l)(S
38) although the loss by this route 
may be vastly increased under abnormal circumstances such as 
intravascular haemolysis, particularly in conditions such as 
paroxysmal nocturnal haemoglobinuria. Iron loss also occurs 
f h b d . b
 h l . . t (2j5) (850) rom t e o yin sweat, ut t e amount ost is minu e. 
(326)(605)(76)(155)(48)(604)(741) (850) Vellar et al h,1ve 
found that loss via this route is not influenced by serum iron 
levels, although Green et a1(
326) have shown that iron deposition 
in the skin increases as serum iron levels increase. Host skin 
iron appears to be conserved(l3
2) and major loss of iron from the 
skin is considered unlikely. <326) 
Additional loss of iron from the body occurs in rr:enstruo1ting 
females, approximately 20 mgs. of iron being lost with each period. 
This increases daily endogenous body iron loss to appro:dmately 
(345) 
2 mgs/day. This amount may be greatly increased i n conditions 
associated with menorrhagia. Iron is also lost with lactation, 
approximately 1 mg/day being lost by this route. <
74o) 
Abnormal loss of iron will obviously occur in situation:; where 
excessive bleeding occurs, as well as in conditions associated 
with abnormal intravascular haemolysis where iron will he lost via 
desquamated haemosiderin laden tubular cells in the urine. 
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An obvious clinical maxim is to look for a source of bleeding 
in any patient with unexplained iron deficiency anaemia . 
... · .. 
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Blood forming cells are embryologically derived from undifferen-
tiated mesenchymal cells. For the first l-wo months of intra 
uterine life, blood formation occurs almost entirely in the yolk 
sac. Subsequently, the liver and spleen become major sites of 
erythropoietic activity until approximately the seventh month of 
intra uterine life. Bone marrow erythropoietic activity starts 
in the third month of intra uterine life and the propc,rtion of 
blood formed in the bone marrow 'organ' progressively increases 
until, by the seventh month of intra uterine life, it is the 
major site of erythropoiesis. By the tenth month, tt.e bone 
marrow is normally established as the only erythropoie.tic organ 
. h b d (193)(319) 1n t e o y. 
Production of red cells occurs extravascularly in the bone marrow 
stroma, outside the vascular sinusoids. I1aturing erythroid cells 
do have ready access to the nutrients contained in thE! circulation. 
Once formed, mature reticulocytes enter the circulation by 




Normal erythropoiesis may be conveniently defined as the 
generation from primitive undifferentiated cells called stem 
cells, of mature viable circulating red cells with minimal 
wastage of precursor material. During the period of differen-
tiation of a stem cell and the time at which mature cdls are 
delivered into the circulation, a number of sequentiaJ. processes 
occur in the bone marrow. These include:-
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(a) differentiation of the stem c.ell into morphologically 
recognisable types by a process we shall call maturation. 
(b) erythroblast proliferation, this being a process whereby 
mitosis increases the yield of a single stem cell so as 
to produce a number of daughter red cells and 
(c) iron uptake; heme formation and globin formation. 
III-b-2 To a large extent, the development of our model of bone marrow 
function has been based upon our interpretation of the l iterature 
in regard to these processes, and for this reason it is important 
to review the relevant literature in some detail. 
III-b-3 Differentiation or maturation. 
In this process, non morphologically recognisable erythroblast 
precursors become recognisable erythroblasts and, as they mature, 
eventually become reticulocytes. Current concepts of E!rythro-
poiesis favou·r the generation of all the elements of thE! blood 
from a 'pluri-potential stem cell'. This is called thE! colony 
forming unit by some workers and, although it has never been 
adequately or convincingly defined morphologically, it has been 
demonstrated convincingly experimentally. <708)(829)(593)(592) 
(480)(379)(707)(408)(104)(760)(68)(490)(115)(489)(581)(899)(903) 
(275)(409)(462)(51)(54)(529)(595)(618)(907)(268)(836)(558) 
A number of workers have, in addition, postulated, and E:hown 
experimentally, a stem cell committed to erythroid development 
which differentiates from the pluripotential stem cell under 
the influence of erythropoietin and itself differentiates into 
the first recognisable erythroblast. <49o)(829)(480)(593)(592) 
This stem cell can also be called the erythroid connnitted stem 
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cell, and .the size of the "pool" of these erythroid committed 




Evidence has recently been presented to show that stimulation 
of erythropoiesis depletes the stem cell "pool" whereas 
inhibition of erythropoiesis has the reverse effect. <
767) 
The stem cell pool is capable of self renewal and of 
differentiation so that it is self sustaining. Once the erythroid 
connnitted stem cell is forme~ however, it is processed 
irreversibly along a non self sustaining pathway terminating 
either in death or the production of viable red cells. This 
concept of stem cell kinetics has been detailed diagranunatically 
in figure III-1. 










Erythroid Recognisable Circulating 
Committed~~~~) Erythroid ----~) Red Cells 
Stem Cell Precursors 
Bone Marrow Circulation 
(C.F.U = Pluripotential stem cell - see text) 
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The C,F,U, has been shown to be very sensitive to irradiation 
and actinomycin( 379)( 7o7)(329)(4o3) whereas the erythroid 




Once the erythroid cOUllllitted stem cell has been formed, it 
progresses, by differentiation, into the next group of cells in 
the bone marrow, the recognisable erythrocyte precurso·rs. 
These have been variously named, either morphologically or on 
the basis of their position in time in the maturation 3equence 
i.e. : 
pronormob las ts 
+ early erythroblasts 
basophilic normoblasts + 
+ OR middle eryt:hrobla3ts 
polychromatic normoblasts + 




Regardless of the nomenclature used, for practical purJoses these 
cells are defined by histological criteria. The prOC·=S s 
whereby the first recognisable erythroblast proceeds t hrough 
the various morphological stages to that of a red cell is called 
maturation. The period required for this to happen c.m be 
called the 'maturation period' and during this period t he cell 
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alters its morphology, loses the ability to synthesi ze DNA and 
RNA, becomes haemoglobinised and extrudes its nucleus. This 
process is irreversible terminat ing only in cell death or the 
production of a mature red cell. 
Most authors seem to agree that the time required f or maturat i on 
. (379)(237)(559)(713)(240)(239)(243)(241)(18)(19) 
remains constant 
<830)(64l)(354) although recent evidence shows that t he whole of 
this period may not necessarily be spent in the bone ma rrow. 
Thus relatively innnature cel l s may be released i nt o t he 
circulation, but these cells sti ll seem to require the .rnme 
. d h t . (380) (381) (384) (385) · perio to reac ma urity. Evidence for 
the constancy of the maturation period is easily obtain,~d 
clinically while awaiting a reticulocyte respons e. followi ng 
specific haematinic therapy such as B12 in B12 def icient anaemia. 
Other evidence quoted as demonstrating the constancy of this period 
includes 
(a) the constancy of morphologically recognisab le 
erythroblast cell ratios despite varying degr ,~es 
t
. . t (254) (201) (706) of erythropoietic ac ivi y. 
(b) the recovery response following pretreatment of 
the bone marrow with inhibitors of stem cell 
differentiation i.e. hypertransfusion, colchicine 
. d (251)(651)(671)(707)(331) or nitrogen mustar. 
Most authors quote a maturation period of bet ween f our and six 
d 
(243) 
ays. Any change in erythropoietic pr oduction is not due 
to hastened maturation i.e. excessively rapid dif f er ent :Lation of 
cells with early delivery into the circulation, but is due to 
increased stem cell differentiation and /or increased pr oliferative 
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activity of the erythroblasts during their maturation period . 
(237)(817)(559)(240)(829)(240)(527) 
III-b-4 Erythroblast Proliferation (mitosis). 
Erythroblast proliferative activity can be defined as a proces s 
in which, from a limited number of primitive red cell pr ecursors, 
a vastly greater number of red cells is formed by a pro:ess of 
sequential mitotic division. This occurs during the m~turation 
period while the erythroblast is capable of DNA synthesis , and 
for this reason can only occur in nucleated erytb.roblas t s. 
Mitotic activity has ceased in polychromatic normoblasts.At this 
stage DNA synthesis has ceased and the nucleus i E becoming 
1 h t . (817)(2
01)(463)(889)(18)(19)(167)(488) 
po ye roma i.e. The process 
is most easily explained diagrammatically. (see l'i gure III-2) 
Figure IlI-2 Diagrannnatic Representation of Proliferative Activity. 
l 
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W~ have in a later section, while developing our model, referred 
to the basic unit of erythropoiesis. For our purposes, this 
refers to all the cells in the recognisable erythrocyte precursor 
compartment in the bone marrow derived from a single erythroblast 
committed stem cell during the maturation period. This is 
mentioned here only for convenience of description at a later 
stage. 
Interpretation of the literature would appear to sugges t that 
there may be a number of variables influencing proliferative 
activity. 
(a) Any erythroblast unit, as described above, may 
undergo a variable number of mitoses during its 
maturation period. Some pro-erythrob l asts may 
mature to reticulocytes with no demons t rable 
. . ·tt· t' 't (817)(486,(559) 1nterven1ng m1 o 1c ac 1v1 y. 
By means of DNA labelling with tritiated thyn:idine, 
studies of mitotic indices,and standard morpbological 
classification of cell maturity, the normal i:ro-
e·rythroblast has been shown to undergo three to four 
mitotic divisions during maturation. Each pro-
normoblast will therefore give rise, on the average, 
b . h d . 
(463) (271) 
to etween e1g tan sixteen red cells. 
(559)(240)(18)(19)(168)(436)(464)(811)(889)(560)(239) 
Assuming that each red cell produced is viable and 
contains normal amounts of haemoglobin, it if; easy to 
understand how variable proliferative activi l:y will 
proportionately vary total red cell production 
(817) (889) 
as has been postulated by many workers. 
(237)(559)(240)(829)(240)(527)(803)(804)(18)(19) 
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(b)· Some ten to twenty percent of all cells in the 
erythroblast series normally die during the period 
of maturation. (52)(418)(725)(628)(728) This process 
of destruction of bone marrow erythroblasts during 
their maturation period is referred to as ineffective 
erythropoiesis - i.e. wasted erythropoietic .ictivity. 
In various disease states (see later under ineffective 
erythropoiesis; section III-b-7) the propor:ion of 
total erythropoietic activity that is wasted by this 
process of intramedullary destruction is vas ;:ly 
increased. These conditions are associated with 
'maturation arrest' , abnormally delayed mi to ·dc 
activity, and a decrease in the effective re<l cell 
haemoglobin yield. 
It has been shown that there is normally no diurnal 
. . . h . . . . (560) var1at1on 1n eryt ropo1et1c act1v1ty. 
III-b-5 Erythroblast iron uptake. 
Iron uptake by erythroblasts has been studied both 'in vivo' 
and 'in vitro'. Two different types of erythroblast :~ron uptake 
have been described although, for practical purposes, uptake 
of iron from transferrin by maturing erythroblasts is i;ufficient 
for all the maturing erythroblast$ iron requirements. The 
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absence of transferrin demonstrates this well, being associated 
with a severe microcytic anaemia caused by impaired delivery of 
. h bl (432)(60)(227)(606)(609)(14) 




Studies utilising transferrin labelled with Fe injected 
intravenously have universally shown almos t immediate localisa-
. f h · · d d. t· ·t ·th· the bone marrow(
2l) tion o t e inJecte ra ioac ivi y wi in 
(846)(22)(730)(79)(164)(686)(688)(864) 
In vitro studies using doubly labelled transfer::in ha\ie 
conclusively shown a two stage uptake of iron f :com trc.nsferrin 
by reticulocytes, and this finding seems to apply equc.lly to 
th d 11 
(606)(609)(84)(434)(479 )(59) 
o er re ce precursors. 
Initially, transferrin is taken up onto specifi:: erytbroblast 
membrane receptor sites. This uptake has been shown to occur 
onto 'ghost cells' of haemolysed reticulocytes, is stimulated 
by ATP and ascorbic acid, and is necessary for iron uptake into 
the maturing erythroblast from transferrin. This haf: been 
shown by trypsin digestion of the membrane binding sites prior 
. b . . h 59 1 b 11 d f . <434) <22n to incu ation wit Fe a e e trans errin. 
Uptake of transferrin onto the specific membrane binding sites 
may also be prevented by metabolic inhibitors. <
432) 
Transferrin has been shown to be essential for normal iron 
uptake by erythroblasts. Freely ionised iron can be non 
specifically taken up onto the membranes of both erythroblasts 
and erythrocytes but this iron is readily eluted with mild 
chelating agents such as EDTA and is poorly utilised for 
haemoglobin synthesis. Non specific metallic cation uptake 
is well described and has been shown by Jandl to cause increased 
cell agglutinability. Uptake of iron from transferrin does not 
have this effect, and this iron is readily available for 
h 1 b
. f t' (432) (609) (231) (824) 
aemog o in orma ion. During cellular 
uptake of iron from transferrin no freely ionised iron could 
d f h . b . 
d' (432) (609) d 
be recovere rom t e incu ating me ium, an none 
of the iron taken up by the cells could be eluted with chelating 
agents such as EDTA. Membrane uptake of transferrin :i.ron 
appears to be independent of haem synthesis (as in lead poisoning 
where membrane uptake of transferrin is not blocked buc haem 
h . . . . 
d(432)) 
synt esis is impaire • 
Release of iron from membrane bound transferrin is tem?erature 
and pH dependent, and is also dependent upon oxidative metabolism, 
and the presence of free sulphydryl groups. <
432><434)( 566)(l4)(227) 
Total erythroblast iron uptake is largely dependent upon the 
iron content of the transferrin in the incubating medium up to 
serum iron levels of 100 µg% or+ 20% transferrin saturation. 
At levels of transferrin bound iron above this, the ra te and 
amount of iron uptake by the reticulocytes was independent of 
the iron level, implying an active process of iron uptake limited 
by the metabolic activity of the reticulocyte membrane. Iron 
uptake is independent of the transferrin concentration in the 
· b · d' b · 1 d · · (434)(432) incu ating me ium, eing re ate to its iron content. 
(609) (384) 
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Ready exchange between free and membrane bound transferrin has 
been shown to occur. During the period of attachment to the 
erythroblast membrane, transferrin undergoes only one change, 
the loss of its iron. In this way it acts as a true carrier . <
609) 
The size of the membrane bound transferrin pool is minute 
relative to the total body transferrin content and does not 
constitute a significant 'local pool'. The turnover time of 
membrane bound transferrin is extremely rapid. 
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The experimentally observed rapidity with which Fe labelled 
transferrin is cleared from the plasma plus the demonstration 
by external counting, y and positron camera techniques and 
autoradiography supports the concept that erythroblast iron 
uptake probably comes completely from transferri n which is 
. . (/•59) (486) (201) 
constantly bathing the maturing erythroblasts. 
(202)(21)(846)(22)(730)(79)(686)(864) Studies with bone 
marrow cultures have shown that erythroblast iron uptEke occurs 
at differing rates which depend upon the state of mati.:rity 
of the erythroblast. Iron uptake from transferrin h=s been 
demonstrated to occur in the earliest recognisable er,throblast, 
and the amount of iron uptake taken up by the maturinf, 
erythroblast seems to decrease as the cell matu-res anc:: is 
thought to cease once cellular RNA synthes i s stops, 0
89)(379) 
(486)(434)(14)(201)(202)(639)(297)(637)(609)(227)(432) 
Erythroblast iron uptake appears therefore to be dependent 
upon three factors:-
(a) cell maturity 
(b) the concentration of transferrin bound iron in 
the plasma, up to levels of 100 µgm% 
(c) the presence of transferrin. 
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Another source of erythroblast iron has been postulated on the 
basis of morphological studies. Here it is suggested that 
h bl t 
(60)(459)(839) 
reticulum cells pass on iron to eryt ro ass. 
(862) (59) It has been shown that reticulum cells are incapable 
of taking up iron from transferrin under normal circumstances 
(II-e-2), and no bone marrow 'pool' of transferrin iron, as 
(686) 
postulated by Pollycove, has been demonstrated. It would 
seem that this is not a major source of erythroblast i ::on on 
the basis of this evidence. (
452>< 258) 
Electron microscop.ic studies have shown rhopheocytosis of ferri tin 
particles by erythroblasts. There has been sone disc11ssion 
about the direction in which this procedure is going. Bessis 
et al have suggested that reticulum 'nurse' cells may be a 
major source of erythroblast iron on the basis of thei:c electron 
microscopic studies. They postulate that this iron (within 
the reticulum cells) is derived from haemoglobin catab,)lism, 
is converted within the reticulum cell to ferritin gra·1ules, 
extruded from the reticulum cell and then taken up by the 
. (59) (60) 
maturing erythroblast by rhopheocytos1s. 
III-b-6 Haemoglobin Formation. 
Once taken up by the erythroblast, the subsequent intr1cellular 
distribution of iron appears to be dependent upon the 1dequacy 
of a number of intracellular processes. For this re.1son, 
erythroblast iron uptake and haemoglobin formation are not 
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identical processes although they are closely related. Thorell, 
using ultra violet light microscopy demonstrated that haemoglobin 
was first seen, in maturing erythroblasts at a later stage than 
erythroblast iron uptake has been shown to occur. de Carvalho 
however, using identical techniques, demonstrated haemoglobin 
h 
· · l bl (486) (789) (191) (192) (190) (835) 
synt esis in ear y normo asts. 
It would seem reasonable to assume some time lag betwee,n membrane 
uptake of iron and its eventual insertion into protoporphyrin at 
a mitochondrial level to form haem. <59) ( 3o3) (896) (764) (302) (226) 
Initially, as previously described (III-b-5) the iron i s removed 
from transferrin at the membrane, passes next into the solub le 
intracellular cytoplasmic compartment where it is beliE!Ved to 
2+ 
complex as low molecular weight Fe . complexes with cytoplasmic 
constituents. These complexes are thought to serve ai: an 
intracellular iron pool for both haemoglobin and ferrit:in synthesis. 
(14) (486) 
Ferritin concentration within the erythroblast decreaSE!S as the 
cell matures. (60) This may be because it is extruded as the 
cell matures (excessive erythroblast iron u;take) or because it 
forms a true intracellular precursor store of iron for subsequent 
heme synthesis. The latter view is supported by a number of 
b 1 h h h . 
· d" db ·1 (908) (486) ( 566) (14) (448) o servers at oug tis is 1spute y Za1 • ' 
Ferritin synthesis within erythroblasts has been demomitrated in 
bone marrow cultures(
486) although the amount of iron normally 
utilised for ferritin synthesis within the erythroblas t is much 
smaller than the amount incorporated directly into haer.1. 
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Under exceptional circumstances where protoporphyrin synthesis 
is impaired and cellular iron uptake not effected (i.e. lead 




A number of factors are thought to be important in directing 
the intracellular localisation of erythroblast iron. Copper 
deficiency results in aggregation of ferritin granules within 
cytoplasmic vacuoles in the erythroblast, and a decrease in 
the amount of iron incorporated into mitochondria in the absence 
f d f . h 1 b.
 h . (3o3) o any e ect in aemog o in synt esi.s. Copper or 
caeruloplasmin seem, because of this, to be important in 
increasing intracellular utilisation of iron, whether this 
effect be by directing the iron to mitochondria or by oxidising 
2+ 3+ the Fe to Fe . Haem synthetase and ferrochelatase are 
thought to be important in promoting the incorporation of iron 
into protoporphyrin. (568b)(764)(
84) 
The intracellular synthesis of protoporphyrin w:'.11 not be 
reviewed here as I feel that it lies outside the scope of this 
thesis. Once formed in maturing erythroblasts, the haem and 
globin are retained inviolate within the red cell until its 
death. Globin is synthesised 'de novo' within the maturing 
erythroblast from precursor amino acids or short polypeptide 
chains taken up by the erythroblast during its development. 
(885)(886)(101)(37)(773) The formation of globin is dependent 
upon DNA dependent RNA synthesis at the ribosomal level. (
698b) 
(199)(458)(835)(110)(109) Haem is not added to the globin chains 
until after they have been synthesised. (
6l 3b) 
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Globin synthesis within the erythroblast appears t o precede 
haem synthesis, the two substances being synthesised indepen-
d tl 
(208)(352)(632)(635)(644) 
en y. The synthes is of haem is 
stimulated by the presence of globin and globin synthesis is 
stimulated by the presence of haem. <526b) <325) (
795) (9) (9 l 7) 
Eventually, haem combines with globin chains to · form haemoglobi n 
consisting of four globin chains plus four haem groups . 
This lies within t he soluble pr otein fraction of t he cell . 
(526b)(831)(895) 
III-b-7 Ineffective Ery thropoiesis. 
This can be defined as wasted bone marrow eryt hr opoietic activity. 
Here the bone marrow forms erythroblasts which synthes i se 
haemoglobin and mature to variable stages but due to i ntra-
medullary destruction, never enter the circulati on as viable 
red cells. In the normal individual approximat ely 10 - 15% of 
total erythropoietic activity is calculated to be inef fec tive, 
(52)(418)(725)(728)(628)(44)(724)(321)(869)(329) d . . an 1.n certain 
anaemias the proportion of total erythropoietic activity that is 
ineffective is grossly increased. Conditions i n whi ch t his 
occurs are:-
1, megaloblastic anaemias. (329)(636)(854)(232) (321) 
(724)(80)(289)(657)(504)(44)(253)(754)( 211)(383) 
(288)(258) 
2, pyridoxine deficiency anaemias< 297 a) (358) (853) 
(286)(533)(258)(852) 







. . h . (724) (321) erythropoietic porp yria 
h 11 
. (815) (370) (258) (289) (724) (854) 
ta assaemia 
(504) (657) (232) 
. (258)(106)(164) 
se:vere iron deficiency anaemias 
(687)(688)(726)(727) 
'd h , . (67)(724)(387)(386)(135) si eroac restic anaemias 
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(318)(179)(297a)(528)(533)(597)(781)(636)(183)(258) 
8 1 f 
'b . (902) (258) (232) • mye o i rosis 
In these conditions, bone marrow samples show hyperpla3tic 
erythropoiesis~i79 )<92)<528)(l82)(253)(852) a 'dyshaem.itopoietic' 
picture of 'maturation arrest 1 <67)(lS2)(286)(4B6)(BS9) and 
th bl t d t t
. (553)(499)(902)(636)(183)(258) 
ery ro as es rue ion. 
A considerable proportion of the iron delivered to the bone 
marrow will, in the presence of ineffective erythropoi~sis, 
probably not find its way into the circulating blood even though 
the amount of iron taken up by the bone marrow ~ill be increased 
because of increased total erythropoietic activity. 
III-b-8 Erythropoietin. 
(1) History. 
The existence of erythropoietin was postulated long before its 
presence was proven. Carnot and Deflandre in 1906 <
125) 
published evidence suggesting the presence of an erythropoietic 
factor in the serum of anaemic rabbits, this being confirmed 
in 1957 by Gray and Erslev. <322) With the development of 
erythropoietin assays, erythropoietin levels were found to be 
roughly proportional to the levels of the haematocrit in normal 
. d' 'd 1 (614) .... in ivi ua s. In uraemic individuals, levels were found 
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to be inappropriately low(7)(627) suggesting a renal site for 
h 
. . d . (427) (807) eryt ropoietin pro uction. Studies by a nu~ber of 
workers have shown the production by the kidney of a substance 
capable of reacting with a constituent of normal plasma to 
th , t' (482) 
(306)(244)(911) 
produce ery ropoie in. This factor has 
been called renal erythropoietic factor (R.E.F.) and is found 
in the mitochondrial fraction of the renal cortex and medulla.(912) 
It is thought that this substance is generated by microsomes and 
d ' ' h d ' <121) ' h ' ' d d store in mitoc on ria. The active eryt ropoietin pro uce 
by the enzymatic action of REF on the plasma substance can be 
neutralised by anti-erythropoietin antibody although this does 
not neutralise REF. (9l 3)(572)<762) 
(2) Production of REF is accelerated by factors known to 
increase erythropoietic activity (such as hypoxaemia, cobalt 
therapy, anaemia, testosterone administration) and depressed by 
factors decreasing erythropoietic activity (such as hyperoxia, 
1 th . ) (305
) (307) (910) 
po ycy aem1.a. The substrate in the plasma 
acted upon by the REF is produced in the l i ver. Erslev 
1 h . d h' f h . . d . (244) et a ave quest1.one tis concept o eryt ropoLetin rro uction. 
It is clear, from studies on adequately dialysed, anerhric man, 
that erythropoietin must be produced by sources other than the 
kidney. It is, however, unclear whether these sites of 
production of erythropoietin are normally present, or whether 
they develop as an adaptive response to the nephrectomised state. 
(633)(574)(587)(591)(590)(588)(627)(589)(276) 
The production of REF by the kidney appears to be a direct 
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response to hypoxia. The denervated transplanted kidney is 
capable of responding to vascular changes or rejection phenomena 
causing local hypoxia, as well as to perfusion with hypoxemic 
blood, cobalt and testosterone. (i95)(665)(59l)(834)(3)(642)(261) 
(3) Elucidation of the chemical composition of erythropoietin 
has been fraught with difficulty due to technical problems in its 
purification and instability of the purified product. It has 
however been characterised as a glycoprotein. (3ol)(53o)(650) 
(655) (787) It appears to be species specific both in biological 
activity and antigenic reactivity. <496)(498)( 759)(761! A 
number of body proteins have been demonstrated not to be 
erythropoietin (i.e. aldosterone, caeruloplasmin, angiotensin , 
renin) but may act to promote erythropoiesis by inducing 
production of erythropoietin. <85)(260)(537)(546) 
(4) Erythropoietin titres have been shown to be rough J.y 
. 1 . 1 h h . <614) . . inverse y proport1.ona to t e aematocr1. t, 1.ncreainng 
normally as the haematocrit falls. The importance of 
erythropoietin in day to day regulation of erythropoieids has 
been well demonstrated by Schooley et al, who, by neut1~alising 
circulating erythropoietin with injections of anti-eryt hropoietin 
antibody, produced anaemia and bone marrow erythroid hypoplasia. 
(761) A number of workers have shown that the primary action 
of erythropoietin is the induction of stem cell differentiation 
to early erythroblasts although it may act only upon erythroblast 
"tt d t 11 (18)(19)(241)(251)(651)(671)(830) comm1. e s em ce s. 
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In addition, under conditions of abnormal stress, erythropoietin 
may act upon differentiated recognisable erythroblasts to cause 
(a) skipping of mitoses resulting in premature release of 
innnature red cells into the circulation. (l 23)(380)( 259) 
(b) an increase in the rate of haemoglobin synthesis in 
cells capable of RNA synthesis. <487)(806)(808) This 
acceleration of terminal maturation with skipped 
mitoses and an increased rate of haemoglobin synthesis 
results in the release of macrocytes into the peripheral 
circulation. (l8)(l9) Where terminal maturat:ion is 
prolonged due to deficiency of precursor material 
(e.g. iron deficiency), Hb synthesis is decrE!ased, 
additional mitoses occur and microcytes are produced. 
(93)(510)(802)(805) 
(5) In vivo studies have shown that erythropoietin s6mulates 
the formation of RNA and DNA in erythropoietic tissue C19o) (39l) 
<65l)(736) as well as the synthesis of enzymes required for the 
synthesis of these nucleic acids. It also stimulates the 
formation of ALA synthetase, an enzyme having a rate limiting 
effect upon haem synthesis. <83)(630) 
In vitro studies have shown that erythropoietin stimulc:Ltes haem 
h . (215) (242) (243) (402) (477) . l h · · synt es1s, st1mu a t es t e incorporation 
of amino acids into the erythroblast stroma and lipid fractions 
<216) and stimulates the pentose phosphate pathway of glucose 
·1· . h 0 d 0 0 b f 1 . 0 d h · <670> ut1 1sat1on t us prov1 1ng r1 ose or nuc e1c ac1 synt esis. 
The effects of erythropoietin are inhibited by actinomycin D 
which blocks DNA dependent RNA synthesis. (7o7) 
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In conclusion, erythropoietin appears to act by a permi ssive 
effect upon DNA dependent RNA synthesis. This results in the 
production of messenger RNA, so providing the templates requi red 
for the synthesis of enzymes needed by the maturing erythr oblast 
for cell division, maturation and haemoglobin formation. In 
practical terms, it acts to maintain the circulating red cell 
mass at a level sufficient to provide optimal tissue oxygen 
requirements. 
(6) Regulation. 
Erythropoietin is excreted into the urine in amounts di rect ly 
proportional to circulating levels which in turn depend upon 
the rate of erythropoiet i n production. (
6)(l2) I ncrea:, ed 
production of erythropoietin occurs when tissue hypoxia is 
d d (124)(247)(714)(784) f
 11 . hl b (5)(4)( 8)(124) 
pro uce, o owing p e otomy, 
d . t . 
(333)(441)(495)(497)(570)(629)(64 5)(695) (304) 
an in mos anaemias, 
excepting those associated with starvation, infection, neop lasia 
or uraemia where normal or low levels may be found. Under 
normal ·circumstances an increased production of erythropoietin 
will increase red cell production, although in some anaemias 
(i.e. aplastic anaemia, pernicious anaemia, iron deficiency , 
sickle cell disease, leukaemia, sidero-achrestic anaemias) 
bone marrow response may be suboptimal. 
Decreased erythropoietin production occurs in conditions 
associated with increased tissue oxygenation - e.g. hyperoxia , 
individuals descending from high to low al t itudes or trans-
fusional polycythaemias. (8)(6) 
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There is no doubt that the ferrokinetic technique has been 
the basic research rock upon which a vast amount of the knowledge 
of iron metabolism has been built. As a research tool, the 
ferrokinetic approach has aided in a basic understanding of 
physiological and pathological iron metabolism, as well as in 
an understanding of the pathophysiology of most haematological 
states involving the red cell series. This aspect has been 
covered, in some detail, in my review of iron me t abolism. 
There remains the problem of assessing the relevance of ferro-
kinetic investigation to the clinical situat ion. In i: unnnary , 
ferrokinetic investigation of a haematological patient aims to 
achieve: 
(1) A measurement of total erythropoietic activity. 
(2) Information regarding the effectiveness of this 
erythropoietic activity 
(3) Information concerning the red cell lifespan of the 
individual being studied (when combined with chromium 
studies). 
(4) Some idea of the state of the iron stores of the 
patient being studied. 
This quantitative information is used to characterise the 
haematological status of the patient being studied, 
with reference to the erythroid series only. As a result 
of basic research, it is known that different gr oups of diseases 
affecting the red cell series can be ·characterised by a pattern 
of ferrokinetic parameters. The results obtained i n the study 
of an individual patient can be compared with those characteris-
ing different disease states, so contributing to the f unctional 
and aetiological diagnosis. 
It must be acknowledged that ferrokinetic investigation 
of a pa tient involves additional expense, time and expertise , 
and one must ask whether this is justifiable. In order to 
answer this question, one must review the di agnostic capabilities 
of other basic haematological i nvestigations whi ch a t t emp t 
to perform the same task, bearing in mind t he ease with which 
ferrokinetic investigation can be performed in a prepar ed 
laboratory. 
A. Clinical Assessment of Erythropoietic Activity. 
Every clinician is aware of the clinical features of anaemia, 
and in addition, many conditions causing anaemia can b,? readily 
recognised after careful history taking and examination of a 
patient. Very few anaemias however, present i n such a 
characteristic way that a clinician would make a solel:r clinical 
diagnosis. The amount of investigation the clinician would 
request would most likely be related to the availabili t y of 
investigative services, but certain basic investigations would 
be required. With the aid of these basic investigations, the 
presence of anaemia may be confirmed, and in many case:, , t he 
cause of anaemia will be apparent. 
investigations will be:-
The basic haematol ogical 
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(1) The haemoglobin - this will show the presence or absence 
of anaemia (Normal : Male 13.5 - 18G%, Female 11.5 - 16.4G%) 
(2) The haematocrit - this is usually more accurately measured 
than the haemoglobin, and will give one similar information. 
(Normal : Male 40 - 54, Female 36 - 47) 
These two measurements will confirm the presence of anaemia, 
but give one no idea as to the underlying mechani sm. 
(3) Other red cell values: 
(i) MCV = Hct x 10 
RCC 
(Normal 76 - 96 cµ) 
(ii) MCH = Hb lO 
RCC x 
(Normal 27 - 32 µµg) 
(iii) MCHC = Hb x lOO 
Hct 
(Normal 32 - 36%) 
(RCC = Red cell count in 
millions) 
(Hct = Haematocrit) 
(MCV = Mean corpuscular volume) 
(MCH = Mean corpuscular 
haemoglobin) 
(Hb = Haemogl obin concentration; 
(MCHC = Mean corpuscular 
haemoglobir. 
concentration) 
The accuracy of these measurements depends upon :1.ccurate 
measures of Hb, Hct and RCC. Mechanisation has not tc,tally 
removed problems associated with experimental error. The 
MCHC is probably the most accurate of these meas.irement:s, being 
uninfluenced by the red cell count. 
Examination of the blood smear. 
With the aid of (1) - (4) above, the anaemia can be 
characterised as normo, micro or macrocytic 
normo, hypo or hyperchromic. 
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In many instances, these investigations contribute all of the 
information necessary to establish a clinically useful di agnosis. 
There are cases, however, when confirmation of a suspected 
aetiological diagnosis may require more elaborate tests 
e.g. measurements of plasma iron, B12 and fola
te concentrations. 
Examination of the peripheral smear will detect the presence of 
abnormal cells which may help further in the diagnosis of the 
underlying disease state. 
Chemical investigations may produce clues to suggest the presence, 
site and severity of haemolysis (i.e. total and conjuga.ted 
bilirubin, haptoglobin, haemoglobin electrophoresis, urinary 
urobilinogen, lactate dehydrogenase, alanine aspartate 
transaminase.) 
In certain cases, an aetiological diagnosis is insufficient 
for complete patient management and some means 1.s required of 
assessing the erythroid precursor response to the disease, 
as well as its response to therapy. Similarly the severity 
of haemolysis, if present, needs to be quantitated. A 
number of investigations may be used for this purpose. These 
include the following indicators of total erythropoieti c 
activity, effective erythropoietic activity and red cel l 
survival. 
(5) Examination of bone marrow morphology. 
This is probably the most useful of basic haematological 
investigations for assessing total erythropoietic activity but, 
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for a number of reasons, it is also probably the least precise. 
A hypoplastic marrow in the presence of anaemia will obviously 
mean decreased total erythropoietic activity and a hyperplastic 
marrow will, in the presence of anaemia, mean that haemolysis 
(either extra or intra medullary) or blood loss is present. 
An estimate of bone marrow erythropoietic activity however 
depends upon an assessment of the ratio of precursor myeloid 
to erythroid cells. (The M: E ratio). This assumes that 
the sample of bone marrow studied is representat i ve of the 
bone marrow 'organ' as a whole, and that myelopoi esis is 
normal. The normal M E ratio quoted is~ 3: 1. (
661 ) 
The M: E ratio gives very little indication of normality or 
abnormality in erythropoietic activity. This is measured 
. (179)(92)(528)(182)(25 ~)(852) 
by subtle morphological features 
(67)(286)(486)(889)(553)(499)(902)(636)(183)(258) h" L b w ic1 . may e 
difficult to detect, and are not, in any case, quantit~tive. 
In addition, erythropoietic activity may be greatly increased 
with a normal M : E ratio if the bone marrow organ masf: is 
greatly increased. With the advent of radioactive methods of 
measuring bone marrow mass, this change can be readily detected. 
(21)(846)(22)(730)(79)(164)(686)(688)(864) 
(6) Faecal urbilinogen excretion. 
Measurement of total faecal urobilinogen (UBG) excretion gives 
a measurement of total pyrrole pigment catabolism. This is 
mainly derived from haemoglobin but a small amount is clerived 
from non haemoglobin sources - i.e. myoglobin, catala:;es, 
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cytochromes and peroxidases. A measure of total faecal UBG 
therefore is an indicator of total haem catabolism, reflecting 
. l h l b. h . (654) (755) (867) in most cases, tota aemog o in synt esis. 
(866)(416)(509)(774)(728)(525)(52)(418)(725)(511)(905)(628) 
Most of the bilirubin excreted by the liver is finally excreted 
as UBG, although some is reabsorbed and enters in the 
enterohepatic bile pigment circulation. Very small amounts 
of bile pigment are normally lost in the urine. Faecal 
UBG measurements should therefore give a reliable measure of 
total haem synthesis, assuming a steady state where synthesic 
and catabolic rates remain equal. As 1 gm. of Hb give3 rise 
to 35 mg. of UBG( 289) one should, in normal patients, be able 
to estimate the difference between actual UBG excretion and 
that expected from Rb catabolism as measured from total RBC 
mass and lifespan measurements, This should reflect UBG 
derived from sources other than circulating erythrocytes. 
This should, therefore, measure total and irreffective erythro-
poiesis. In practise, this method is rarely sufficiently 
accurate. The largest problem is collection of a complete 
faecal sample, even under 'metabolic ward' conditions. The 
test is useless in patients taking antibiotics a~: these alter 
the bacterial flora of the gut. <334) There is f:ome loss of 
UBG via routes other than the faeces. Finally, the test is 
cumbersome, time consuming, unpleasant to perform, and, even 
in the best hands, has been found to give an extremely wide 
range of normal results. As a measure of erythropoiesis, it 
appears to be infinitely less accurate and more unpleasant to 
perform than ferrokinetic investigation. 
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(7) The reticulocyte count. 
This parameter appears to afford an accurate indication of 
f. · 
h · · · . (385) (384) (38) (153) (2%) ef ective eryt ropoietic activity. 
The reticulocyte count, expressed as a percentage, gives a 
rough measure of effective erythropoietic activity providing 
that essential precursor material for haemoglobin synthesis is 
adequately supplied to the bone marrow. In the presence of 
anaemia, this parameter becomes less accurate as a measure of 
effective erythropoiesis when compared with other parameters, 
owing to changes in the total number of red eel ls and p·::-o-
longation of the time required for reticulum to be lost from 
reticulocytes released at an earlier stage of maturatio·:i. into 
the circulation. Corrections have been proposed by Hillman(
385) 
for these aberrations and, when these are applied, the resulting 
reticulocyte index correlates very well with other para~eters of 
effective erythropoiesis. 
corrected: 
The reticulocyte count may be 
(a) by correcting for changes in total number of red cells by 
(i) expressing the reticulocyte count as an absolute 
number per unit volume or 
(ii) by expressing the reticulocyte count in a standardised 
way relative to the haematocrit 
i.e. Corrected Reticulocyte 
Count% 
(for changes in Hct) 
Normal value is 1% 
= 
Patient's Hct Retie.Count% 
Normal Hct(l~5)x 
(Hct = haematocrit) 
(b) by using a reticulocyte index in an attempt to 
quantitate effective erythropoiesis - i.e. 
Retic~locyte Index= Corrected reticuloc te count(%) 
Normal reticulocyte count o 
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(c) by correcting the reticulocyte index for changes in 
maturation time of reticulocytes prematurely released 
into the circulation because of stress, the stress being 
proportional to the drop in haematocrit. 





This will result in a production index of effective 
erythropoiesis i.e. 
Reticulocyte Production Reticulocyte Index 
Index = 
Maturation Time 
This was found by Hillman et al(3B5) to be an excellent 
comparative method of assessing effective erythropoieti ,: activi ty. 
It does not, however, measure total erythropoietic acti·vity, 
and will not therefore measure any erythropoiesis that i. s 
ineffective. 
In concluding this introductory chapter, I feel that th,:! 
ferrokinetic technique is a quick and easy way of measuring 
total erythropoietic activity; this can be done in one day with 
minimal patient inconvenience or laboratory work, and gi ves 
quantitative results. The reticulocyte production index provides 
a good indicator of effective erythropoiesis but does not 
quantitate it in terms of amount of haemoglobin formed. The 
ferrokinetic technique is probably able to do this, and 
therefore measures effective erythropoietic activity as 
well as the reticulocyte production index. Overal l, a lot 
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of information may be obtained using the fer r okinetic technique 
that can not be obtained by other methods. This is obviously 
of interest in characterising pathophysiologi cal 1nechanisms, 
but, in the majority of anaemic patients, is not very helpful 
clinically. In situations where the haematological status 
remains unexplained after routine haematologi cal investj_gation, 
ferrokinetic investigation may be of help in elucidating the 
cause and severity of the underlying abnormal process. 
IV-1-a 
IV-1-b 
The Effect of . Iron Status on F~rrokinetic Per formance. 
It became apparent at an early stage in this study t ha t t he 
presence or absence of iron def i ciency or overload could exert 
a profound influence on ferrokinetic data obtained from any 
given patient. This is a well known observation and hc1.s been 
documented by others. 
(384) 
Hillman and Henderson, for example, 
have shown that completely 'normal' individuals have a f airly 
uniform bone marrow and ferrokinetic response to repeatE:d 
phlebotomy, this response depending largely upon the hae.mat ocrit 
and the availability of precursor material, parti :ular ly i ron. 
Since, in the long view, it was my intention to apply f E:r ro-
kinetic techniques t o the investigation of er ythroid di f:order 
that might be complicated by various degrees of iron deficiency 
or excess, I felt it necessary to devise some means of " correcting" 
the data for the diagnostically trivial effec t of varial>le iron 
status. This, it seemed, could only be done by defini ng , i n 
quantitative terms, the relationship between ferrok i ne6c 
performance on the one hand and iron status (as r ef lected in 
the plasma iron concentration) on the other, in i ndividuals 
whose bone-marrow function was, in all other respec t s, normal . 
Selection of patients for this study. 
Patients selected for this study were either normal in ever y 
haematological respect or those who appeared to have "pure" 
iron deficiency or overload with no other haematologi cai. 
abnormality. All patients with known causes for haemo:.ytic 
anaemias were excluded, as were all patients with demom:trab l e 
folate or Vitamin B12 
deficiencies. Appropriate steps were taken 
to exclude patients with hepatic, renal, infective, neoplastic 




Method of Study: 
All patients had full, routine ferrokinetic and radio-chromium 
studies as detailed in the appendix under Methods. 
Results. 
The findings in this group of patients are surmnarised in 
Table IV-1. As can be seen from the data, haemoglobin 
value; varied over a wide range (8.1 to 20.4 G%) a3 did t.he 
haematocrits (23% to 64%). 
I 
Plasma iron values and values 
for% iron saturation varied from frankly iron deficient: 
to hyperferraemic. (9 µg% 243 µg%)( 2 - 100% saturation). 
In all cases the t! for 
51cr-labelled autologous red ceJ.ls 
was normal. 
Table IV-1 Composite Ferrokinetic Findings in normal pat~ents. 























Total Iron Binding Capacity 
Percentage transferrin saturation 
t! Plasma Iron Clearance 
Plasma Iron Turnover 
Red Cell Utilisation 
51 Cr Autologous Red Cell Survival. 
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Table IV-1. ComEosi.te Ferrokinetic Findin~s in not'!Ilal Eatients~ 
Patient Rb Hct Bl.Vol Pl.Vol. P.I TIBC %Sat t&PIC PIT RBCU t/
1cr 
(G%) (%) (ml/kg)(ml/kg)(µg%) (µg%) ( in) (%) da s 
deB 15.6 43 64 45 62 286 22 60 .6245 83 25 
Web 16.2 52 54 33 88 264 33 91 .5044 93 29 
Luk 12.8 38 84 52 209 209 100 134 1.0144 49 28 
Cup 10.3 30 75 55 113 159 71 53 1.5436 53 24 
Car 12.1 38 81 49 53 :'90 59 35 .9849 83 32 
Hey 20.3 64 70 35 64 289 22 28 . 9399 87 26 
Bot 17.2 51 66 38 114 197 58 70 .8644 75 28 
Rus 11.9 36 80 52 49 210 23 64 .5121 100 27 
Kho 15.6 45 64 37 55 233 24 51 .6320 100 29 
Thy 14.7 44 91 58 105 185 57 85 .7352 84 24 
Arm 12.6 38 90 60 92 282 32 62 .9657 90 26 
Sch 11.0 36 99 69 21 280 7 34 .4131 98 36 
Bas 8.1 23 56 39 9 384 2 16 .4435 94 24 
Hoo 9.9 29 66 49 16 243 6 29 .4045 94 23 
Cha 10.9 36 65 44 19 563 3 18 .7060 96 22 
1oz 13. 2 36 79 49 9 232 3 35 • 7720 90 24 
Gog 16.8 46 81 48 196 205 95 90 1. 2561 54 26 
O'Co 13 .1 35 65 40 243 270 90 210 .7845 40 28 
Van 11. 2 34 70 40 137 343 40 86 1.0941 82 24 
Pet 16.4 42 62 39 29 302 10 51 .3489 92 27 
Mgo 16.1 46 66 39 163 164 99 133 .7069 66 26 
Tan 14.5 40 57 37 101 279 36 82 • 7184 96 27 
Wes 17.3 54 56 29 143 187 76 74 .9724 69 29 
Nqw 16.3 49 60 35 206 246 84 101 1.1202 44 29 
Mar 20.4 60 88 43 101 295 34 52 .8702 86 29 
Ans 12.0 38 74 49 32 395 . 8 30 .6938 100 33 
Wil 11.0 33 68 45 22 412 5 31 • 7613 95 27 -
Pre 17.6 47 66 43 86 302 28 34 1.4357 91 22 
Sam 16.1 44 69 44 123 287 43 61 1.2002 87 26 
Jeg 11.4 34 73 50 45 267 17 33 .9371 89 24 
Pax 13. 3 29 61 44 41 272 15 54 .5561 100 27 
Rob 9.1 28 72 59 80 249 32 42 1.4141 100 27 
Tay 16.4 54 100 60 26 366 7 17 .7696 100 30 
Sch 8.6 26 56 50 33 231 14 31 .8099 91 33 
IV-2-a 
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The Ti Plasma Iron Clearance. 
It was noticed at an early stage that patients with higher plasma 
iron concentrations took a longer time to clear radio-iron 
from their plasma than did patients with low plasma iron 
concentrations. This initial impression was studied further 
by taking this parameter, (the t!PIC), and plotting it 
against both the plasma iron concentration per 100 ml. oE 
plasma and the plasma iron concentration per 100 ml. of ·.vhole 
blood. This latter figure was obtained, as calc lated JY 
C · k<
164) ' 1 ' . 100 1 h l oo 1..e. p asma 1.ron concentration per m. woe 
blood = 100 - (0. 92 x Hct) x Plasma Iron(µg/100 ml. plas·na) 
100 
where 0.92 is a correction factor for plasma trapped 1.n the 
red cells while reading the haematocrit. 
Once plotted, these points were fitted, by the method of least 
squares, to a regression line, and the equation describi:i.g this 
line, the standard error of the estimate of the line, and its 
correlation coefficient were calculated. The results c.m be 
seen in Figure IV-1 and IV-2. 
Figure IV-1 The Plasma Iron Clearance t! (y ordinate) plotted 
against the plasma iron concentration in µg/1.00 ml. · 
plasma (x ordinate). 
tiPIC = 0.5509 x P.I. (µg/100 ml plasma) + 14.3389 
r = 0.8698 
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50 
50 100 150 200 250 
Plasma Iron Concentration (wgms/%) 
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Figure IV-2 The plasma iron clearance t~ (y ordinate) plotted 
against the plasma iron concentration in µg/100 ml. 
of whole blood (x ordinate). 
t!PIC = 0,9114 x P.I. (µg/100 ml w.b.) + 14.0171 
r = 0.8931 
SE Y/x = 17.8 
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It can be seen from these graphs that as the plasma iron 
concentration increases, whether this be measured as µgm/100 ml. 
plasma or µgm/100 ml. of whole blood, there is a proportionate 
increase in the t!PIC, as described by the regression equation, 
in different individuals. Allowing for some biological 
variation between individuals, this mathematical description of 
the variation in t!PIC as a function of iron concentration 
seems to describe normal individuals fairly well (r = 0.!3698 
and 0.8931 respectively). This observation is not new, having 
(62) (61 (863) been previously described by a number of workers. ' 
(80)(258)(735)(371) 
Other authors however have stressed the 
relationship between the t!PIC and total erythropoietic activity. 
(300)(872)(55)(848)(815)(443)(673)(635)(61)(735)(486)(900)(863) 
(284) (914) It is obvious then, that the t 1PIC depends upon both 
2 
the plasma iron concentration and the erythropoietic activity 
being more rapid where plasma iron concentrations are low and/or 
bone marrow erythropoietic activity increased, and being prolonged 
where plasma iron concentrations are increased and/or bone marrow 
erythropoietic activity decreased. The problem foerefore is 
to separate the effect of these two variables upon the t 1PIC. 
~ 
The cause of the prolongation of the t 1PIC with increasing plasma 
2 
iron concentrations in patients with the same amount of bone 
marrow activity appears to be that the bone marrow, to a major 
extent, regulates the rate of removal of iron from the plasma, 
as it is the major site of deposition of plasma iron. 
(21)(846)(22)(730)(79)(164)(686)(688)(864)(459)(486)(201)(202) 
IV-2-d 
The t!PIC will largely reflect the rate of turnover of the 
plasma iron pool which in turn will depend upon H state of 
equilibrium between erythropoietic iron demand and available 
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plasma iron supply. Should the erythropoietic demand remain 
constant, the rate of turnover of iron in the plasma, and hence 
the t!PIC, will depend on the plasma iron concentration. Should 
this decrease, the t!PIC will decrease proportionately, and the 
reverse will occur when the plasma iron concentration increases. 
That this relationship is linear is well demonstrated by our 
normal subjects. Similarly, should erythropoiet~c activity 
change and the plasma iron pool remain constant in size, the 
rate of removal of iron from the plasma and hence the t!PIC 
will be proportionate to the change in erythropoietic activity. 
Having defined, by regression equation, the relat i onship between 
plasma iron concentrations and t!PIC in subjec s with normal 
bone marrow function, this could be used to predict the normal 
t ! PIC that would be expected at any given concenti~ation of 
plasma iron. A value for the t!PIC significantly greater 
than that predicted would thus indicate depressed erythropoietic 
activity. Conversely, a value less than that predicted would 
indicate increased erythropoietic action. For convenience, 
I have chosen to combine the observed and predicted half time 
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for the clearance of Fe from the plasma as an "Erythropoiet ic 
Index" defined as the ratio of the predicted t!PIC to the 








Predicted t!PIC at Plasma Iron Cone. of patient 
Experimentally derived t!PIC of patient 
An erythropoietic index of 1 would then mean normal total 
erythropoietic activity, a ratio significantly greater t han 
1 indicating increased, and a ratio significantly less than 1 
indicating decreased total erythropoietic activity. 
A theoretical flaw exists in the development of this pa1:ameter, 
and that is the influence of non erythroid iron uptake upon 
Should non erythroid iron uptake vary in d:~fferent 
individuals independently of the variation in plasma iron 
concentration, it would be inappropriate to apply a cor::ection 
for the t!PIC based upon the assumption that there is a 
relationship. For reasons that I shall detail in the :,ection 
on non erythroid iron turnover, I believe that the influence 
of non erythroid iron uptake upon the t!PIC is constant in 
different disease states, depending only upon variation::; in 
plasma iron levels, and hence of minor impo~tance as fa~ as the 
t!PIC is concerned. (See IV-3) In consequence, I bel i eve 
that it is reasonable to insist that t 1PIC values be in-,:erpreted 
2 
only in relationship to the patient's plasma iron concentration. 
Assessment of the Validity of the Erythropoietic Index 
Parameter in assessing Total Bone Marrow Erythropoietic Activity. 
I have attempted to assess the validity of the erythropoietic 
index as a parameter of total bone marrow erythropoietic activity. 
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For this purpose I have taken two groups of patients in addition 
to my normal patients. The first group of patients was selected 
on the basis of known hypoplastic anaemia. These patients had 
been demonstrated histologically to have depress~d erytbropoiesis 
on bone marrow smears, and labelled clinically as hypoplastic 
or aplastic anaemias. The second group of patients were patients 
with hyperplastic bone marrow on histology s and anaemias 
characterised by increased total erythropoietic activity. Into 
this group I have placed patients with haemo l ytic anaemias, 
megaloblastic anaemias, sidero-achrestic anaemias and myelofibrosis. 
These conditions are known to be associated with i ncreased total 
erythropoietic activity, although a variable proportion of this 
b . ff t· (329)(636)(
854)(232)(321)(724)(80)(289)(657) may e 1.ne ec 1.ve. 
(504)(44)(253)(754)(211)(383)(288)(258)(815)(370) (832)(67)(387) 
(386)(135)(318)(179)(297a)(528)(533)(597)(781)(183)(902) 
The t!PIC is accepted by most workers as an index of total 
erythropoietic activity. (See IV-4-b) All these pacients will 
have increased total erythropoietic activity. I i: will be 
obvious that a tremendous range of erythropoietic activity will 
be present in these patients, and this will be mirrored in the 
E.I. (erythropoietic index) results. All patien;:s with 
increased erythropoietic activity should have E.I. values 
greater than 1 whereas all patients with depressed erythropoiesis 
should have E.I. values of less than 1. 
Results . 
Composite results for the normal subjects are given in 











The results for the hypoplastic group of patients are 
sunnnarised in Table IV-2 and Figure IV-3. 
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The results for the hyperplastic group of patients are 
sunnnarised in Table IV-3 and Figure IV-4. 
Composite Ferrokinetic Findings in Patients with 
Hypoplastic Bone Marrow. 
Hb Hct Bl.Vol Pl. Vol SI TIBC %Sat t!PIC 
G% % ml/kg ml/kg µg% µg% min 
11.5 32.0 60.5 41.6 100 198 51 188 
12.0 34.5 66.8 44.2 153 249 61 180 
11.2 36.0 - 230 336 68 273 
10.6 35.0 - 250 250 100 270 
9.4 27.0 56.9 42.1 160 323 49 150 
11.8 34.0 67.8 47.1 294 294 100 433 
11.4 32.0 59.2 42.2 170 174 98 311 
11.5 31.0 64.3 47.5 284 307 93 2lf9 
EI PH RBCU 
% 
.34 .3753 50 
.55 .5802 -
.52 .5635 25 
.56 .6278 25 
.68 .8017 26 
.41 .4666 9 
.35 .3857 6 











Figure IV-3 Graphical representation of t!PIC va~ues (y ordinate) 
t!PIC 
(mins) 
plotted against plasma iron concentrations in µgms/100 ml. 





200 ----~ Hean Normal ----~ + 2 SD ----~ 
100 
100 200 3()0 
Plasma Iron Concentrati on 
(µgms/%) 
The shaded area represents predicted normal t 1PIC values 
2 
(as in Figure IV-1) with 95% confidence limi t s. 
Plotted points represent the results in the hypop:l as t ic 
patients -wi th hypoplastic bone marrow. 
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Table IV-3 Composite Ferrokinetic Findings in Patients with 
HiEerElastic Bone Marrows. 
Patients Rb Hct Bl. Vol Pl. SI TIBC %Sat t 1PIC EI PIT RBCU t 1 Diagnosis 
ml/kg Vol. 2 251 
ml/kg 
Cr 
Mte 9.6 30 86 63 132 229 58 29 3.00 3.2954 22 6 Myelofibrosis 
Kot 10.3 33 77 61 234 264 89 19 7.54 8.5767 27 14 di Gugliemos 
Jae 9.0 32 83 59 146 203 72 26 3.65 3.9622 34 15 Thallassaemia 
Rob 5.2 24 - 180 189 96 46 2.47 3.0490 23 9 Myelofibrosis 
Isr 9.4 30 97 69 234 240 98 29 4.94 5.8419 - - Thallassaemia 
Bot 10.9 33 55 38 253 253 100 124 1.24 1. 4209 13 16: :Hderoachesti: 
Anaemia 
Liv 10.3 29 54 39 225 253 89 85 1.63 1.9408 15 16 L:ymphosarcoma 
Mar 9.0 27 70 54 91 264 34 22 2.93 3 .1089 28 14 ~1elofibrosis 
Ism 6.9 21 83 67 250 239 100 35 4.34 5.7629 - - T:rnllassaemia 
Sil 9.6 30 66 48 55 299 18 30 1.49 1. 3273 76 12 Ca .• Liver 
Lou 13. 7 36 65 42 85 185 46 44 1.39 1. 2920 77 18 a!red. Sphero-
cytosis 
Han 8.4 25 108 57 71 230 31 17 3.14 3.2159 58 13 Myelofibrosis 
vAa 12 .0 35 - 106 20 3.64 3.5934 - 20 A[HA 
Sto 11. 7 28 71 52 146 281 52 25 3.79 4.3356 :31 10 H!red.Sphero-
cytosis 
Bor 7.7 18 65 52 86 295 29 40 1.54 1. 7940 94 10 A[HA 
Kin 10.4 33 83 64 32 369 9 14 2.28 1.5918 -· 15 CAL 
Bro 10.4 28 73 54 104 228 46 41 1. 75 1. 8832 iO 17 ? 
Jae 8.8 25 88 64 17!• · 189 92 24 4.59 5.5825 '.:.2 11 T.rnllassaemia 
vNi 14.4 38 74 50 212 277 77 57 2.30 2.41.90 :,7 14 Lymphoma 
Sev 14.0 44 - 71 230 31 25 2.14 1.6904 E,2 17 F:>late def. 
Hoe 13.9 40 - 65 269 24 19 2.64 2.1621 (7 26: , .URA 
Jan 7.9 24 59 46 96 279 34 29 2.32 2.5794 l.6 24 B12 def. 
Rob 9.1 28 72 59 80 249 32 42 1.39 1.4141 100 11 M_yelofibrosis 
Ste 10.0 30 86 63 167 212 79 38 2.80 3.1818 -· 17 AIHA 
Wil 9.2 30 77 34 4tf 200 22 34 1.13 .9369 -· - Valve HA 
Koc 8.6 25 89 66 85 246 35 61 1.00 1.0730 29 16 AIHA 
Ber 6.3 18 56 40 377 425 89 86 2.58 3 .6578 9 9 Sideroachres-
tic Anaemia 
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Figure IV- 4 Graphical Representation of t~PIC values (y ordinate) 























The shaded area represents predicted normal t ! PIC value:, 
(as in Figure IV-1) with 95% confidence limits. 
Plotted points represent the results in the hyperplasti .:~ 




The hypoplastic group of patients all demonstrated marked 
prolongation of the t !PIC relat.ive to normal values at che same 
plasma iron concentrations. The E.I. values ranged be tween 
0.34 and 0.69 and gave a good indication of the decreas~ in 
total erythropoietic activity. 
The reverse occurred in the 'hyperplastic' group of pat i ents 
where the t 1PIC, in most cases, was markedly decreased ::elative 
2 
to predicted normal t!PIC values for the same plasma irl)n 
concentrations. Once again, the E. I. values, ranging he tween 
1.00 and 7 .54 gave a clear indication of the increase in total 
erythropoietic activity. This was not as well demonst::ated 
at low plasma iron concentrations as it was at higher pl asma 
iron concentrations. This is probably explained by th,~ 
greater avidity of the normal bone marr.ow for iron at low plasma 
iron concentrations. 
From this !:tudy, it appears justifiable to use the E, I. ' ralue 
as an index of total erythropoietic activity. The figure 
obtained appears to show, reasonably accurately, the ex1:ent of 
change of erythropoietic activity for an indivi dual compared 
with the range of normal patients, and expres ses the change in 
what appears to be a reasonably quantitative manner. 
Prolonged Plasma Iron Clearance Curves. 
A number of authors have based models for quantitating E!rythro-
poiesis from ferrokinetic data upon a study of plasma radio-iron 































(258)(164)(686)(288) By this technique, plasma is repeatedly 
sampled over a period of approximately fou ':teen days, and the 
percentage of radio-iron injected that remains in the plasma, 
bound to transferrin, is calculated. We attemgted to duplicate 
this technique in a number of patients, in an attempt to obtain 
meaningful data. Our attempts were largely unsuccesbful, and 
a number of reasons may be given for this. 
The concentration of transferrin bound radio-iron in the plasma 
is initially high, but with the passage of time, the radio-iron 
gets taken up at its various sites of deposition, and the 
concentration progressively decreases. All workers neem to 
agree that the initial clearance of radio-iron from the plasma 
is a single exponential function, but as time . progresnes the 
line becomes a curve when plotted upon semi-logarithm:~c paper. 
This is best illustrated diagrammatically as in Figun~ IV-5. 
Theoretical changes in plasma radio-iron concentration as a 
function of time. 
2 4 6 8 10 12 14 
Time (days) 
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The resultant curve can be mathematically described in terms of 
a number of exponential functions or by probability analysis and 
integro-differential equations. Initial clearance of radio-
activity from the plasma is extremely rapid. Subsequent points, 
as quoted by the various authors mentioned, are al l taken at 
times where the residual plasma radioactivity is approximately 
0.1% of the initial concentration. 
Where 4 ml. samples of plasma are being counted, one can calculate 
the amount of radioactivity that this represents. If we assume 
that the average plasma volume is 2.5 litres, for each rricrocurie 
of injected radio-iron, the amount of radioactivi t y being counted 
at t will be:-
0 
3.7 X 1010 X 4 disintegrations/second 
106 2500 
where 1 µc = 3.7 x 1010 
106 




By the time that residual radioactivity is down to 0.1% of the 
t value, the count rate will be:-o 
59.2 X 1 
103 
dps = 0.592 dps 
Normal counting efficiency for 59Fe, as quoted by Hosain et al (399) 
is+ 25%. Thus each microcurie injected would g~ve a count 
rate of:-
= 








In their experiments, the dose quoted was 0.5µc per kg. which 
represents 35µc for a 70 kg. man. This would give a count rate , 
after day one, of:-
35 X 1.405 X 10-3 cps 
or 35 X 1.405 X 10-3 cpm 
= 2.9505 X 10 cpm (+ 30 cpm) 
They counted each sample with a background count of 220 cpm. 
for a total of 10,000 counts on each sample, this being done 
in duplicate. The ratio of sample counts to background count s 
is therefore 30: 270 or 1 : 7, with a total count rate of 
250 cpm. Each sample would therefore need t o be counted for 
10,000 minutes to give a total count rate of 10,0JO, wh j.ch is 
250 
approximately 40 minutes. In practice, most samples would be 
counted at the end of the fourteen day period, when only 80% 
of the initially injected radioactivity would be present due to 
59 decay (tle = 45 days), so that this period would prol,ably be 
slightly longer with an even less favourable ratio of s ample to 
background counts . 
In a paper published by Loeringer and Berman in 1951, a method 
for calculating the intrinsic error of low counting samples was 
(522) proposed. According to them, the percentage error of a 
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fr + 1 
2 
(1-r) 
where Nt = total counts (104 in this case) 
V = percentage error of sample count s 
with 68% confidence limits 
= total count rate ( = l.OB in this case) 
background count rate 
By this calculation, V = + 18% for a .confidence limit of 68%. s 
To get a 95% confidence limit on the count rate as described, 
V will be+ 2 x 18% i.e.+ 36% or a range of 72% around the s 
experimental point. 
These statistical considerations indicate, therefore, th1t there 
are serious limitations upon the accuracy with which pla,ma 
radioactivity can be measured after the first 24 hours following 
a standard intravenous dose of 59Fe. This fact imposes 
correspondingly serious limitations upon the valid inte~>retation 
of kinetic parameters derived from the fitting of experimental 
curves to data obtained after the first day. 
If this holds when relatively high doses of 59Fe are used 
(i.e • .!_ 35µc), the results must be even more questionable when 
the dose is scaled down in ac.cordance with the practice of most 
laboratories. In our technique, we have been cou~ting radio-
1 
(164) iron over a narrower 'window' than that quoted by Cook et: a, 
in order to exclude counts due to radioactive chromium. This 
is because nearly all of our patients have had double isctope 
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studies, in order to accurately measure red cell volume and in 
an attempt to assess red cell survival. For this reason, our 
counting efficiency for radio-iron is less than that of the 
above authors, as is our count rate. We have an average back-
ground count rate of 60 cpm with a sample count rate, after 
day one, of between O and 10 cpm, Our ratio of sample to 
background counting rate is accordingly much the same as that 
quoted by other authors, but we would have to count for much 
longer periods in order to get counts of 10,000 i.e • .:!:_ 250 minutes 
per sample. This has just not been practical with our limited 
facilities and pressure on our counter. Becaus~ of this, we 
have not been able to count our plasma samples as accurately as 
we would wish to, and the resultant curves are accordingly poor. 
In discussion with Cook, we have realised that this problem is 
not peculiar to our department, and we have now discontinued the 
practice of counting plasma samples after day one. 
It is clear that the derivation of meaningful data from prolonged 
plasma iron clearance curves is difficult, and even when these 
points are corrected for a standardised plasma iron level, as 
recommended by Hozain et a1< 399) the fitting of meaningful curves 
is hazardous. This applies particularly in our experiments 
where the counting conditions were so unsatisfactory~ after day o. 
Some curves were, however, derived. In general these all 
showed deviation from a single exponential function within a 
few hours of injection. I will not dwell upon any results in 
the measurement of this parameter as I believe them to be highly 
86 
suspect, but a few curves have been demonstrated. 
(Figures IV-6, IV-7, IV-8, IV-9) m 
s 
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I must stress that in some subjects, usually pati~nts with 
severe iron deficiency, we were unable to demonstrate any 
radioactive iron in the plasma after day one. <2o7) Hy 
experimental results are set out in Tables IV-4 and IV-5. 
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I believe that it is important to scan the results from left 
to right in order to see how great the variation is in day to 
day sample counts above background. The accuracy of least 
squares fitting of an exponential function to these points is 
b • 1 d II b 11
11 f • • • • f o v1.ous y poor, an even eye a 1. tt1.ng g1 ves unsat1.~: actory 
results • 
Table IV-4 Percentage of initially injected radioactivity 
remaining in the plasma as a function of time. 
% Initially injected 
59Fe activity remaining in Plasma 
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Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Day 
1.09 o.73 o.44 o.55 o.73 
1.94 0.61 0.58 '0.53 
0.39 0.54 0.45 0.47 





0.32 0.36 0.12 0.21 0.39 0.07 0.51 0.09 
0.29 0.02 0.12 
0.46 0.55 0.10 0.12 0.19 
1.78 1.27 1.78 1.33 0.76 
0.80 0.06 0.15 0.05 
0.29 0.29 0.22 
0 0.19 0.21 
0.19 0.10 0.33 0.39 
0.07 0.15 0.06 o.oo 
0.57 0.45 0.26 
o. 70 0.55 1.13 






0 0.73 0 
0.27 0 0.53 
0 0.31 0.78 









0 . 02 0.02 
0.90 

















o. 62 o. 20 0.16 0.19 0.17 0.20 0.11 0.12 0.09 0.08 0.05 0.14 
1.32 1.31 1.44 1.41 1.58 1.03 0.63 0.76 0.58 0.77 0.52 0.50 0.47 
Wal 1.19 0.25 0.22 0.55 1.33 0.55 0.38 0.20 
Tan 0.32 0.17 0.30 0.22 0.19 0.18 
1.27 0.34 0.17 0.12 0.13 
0.80 0.04 0.05 0.11 0.01 0.05 0.04 0.05 







0.50 0.11 0.24 0.12 0.06 
0.46 0.42 0.43 0.55 0.57 0.58 0.37 0.60 0.51 0.10 
0.27 0.16 0.15 0.23 0.28 0.20 0.14 0.22 0.10 
Table IV-5 Actual counts per minute per four ml. plasma sample 
above background as a function of time. 
Counts per minute above Background/4 ml. sample. 
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Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Day 





14.5 9.75 5.90 7.30 9.75 
39.6312.38 11.88 10. 73 6.48 7.43 4.78 2.98 
0.07 0.04 0.06 0.03 0.01 0 0.03 
3.45 1.10 2.00 3.70 0.65 4.85 0.85 
4.55 0.35 1.95 4.60 4.60 3.55 
· 0.02 
3.00 
Vlo 4.63 5.54 1.01 1.17 1.92 
Bot 14.07 10.07 14.07 10.49 6.03 
0 3.70 4.16 2.42 
1.49 0.81 2.58 3.06 
0.51 1.20 0.44 0.01 6.24 0.48 1.20 0.40 
0.37 0.31 0.20 0.09 0.08 0.04 o.oo 0.02 
0.02 0.01 0.03 0.03 0.02 
0 0 0.05 0 0 0.02 0.05 

















0.02 0 0.04 0 0 
6.84 8.34 7.34 8.49 2.69 
0.01 0 0.01 
5.04 3.34 l.9L. 2.04 5.84 
Loz 8.20 14.05 15.40 15.05 16.9011.00 3.90 8.15 3.60 8.25 3.20 5.40 5.05 
Wal 16.84 3.58 3.08 7.72 B.88 7.78 5.42 2.86 
Tan 18.43 9.73 17.03 12.83 
Mat 27.13 4.98 4.48 
0 0.28 1.12 0.23 0 
6. 83 10. 33 
1.93 2.38 





4.63 0.99 2.37 1.19 0.63 0.71 0.21 0.09 2.21 
3.55 3.25 3.30 4.20 4.40 4.45 2.85 4.60 3.95 0.75 
Lou 6.60 3.95 3.75 5.55 6.95 4.95 3.40 5.45 2.55 
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Had our counting time been greater, we would perhaps have been 
able to derive curves agreeing more closely with those p·..1blished. 
In an attempt to increase the statistical accuracy of low level 
counting, I arranged with Dr. M. Peisach, at the Southern 
Universities Nuclear Institute, for the analysis of 4 ml samples 
of plasma taken from a patient with mild haemolytic anaemia 
(Skelton) using a gannna ray spectrometer with a 311 x 3" NaI(Tl) 
scintillation detector; gannna ray spectra were recorded on a 
400 channel analyser and compared with spectra obtained from 
distilled water. Under the conditions of this experiement, count 
rates as low as 2 dpm would have been observed. No counts 
were observed within the statistical validity of the method, 
( 207) 
even when samples were counted individually for up to 12 hours. 
Using the criteria that photopeak counts in excess of three 
times the standard deviation of the background count would have 
been measureable, the content of radioactivity in all samples 
submitted was calculated to be less than 4 dpm. Subsequent 
to this we applied to the South African Nuclear Institute for 
59 
permission to use larger doses of Fe (up to this time we 
had been using maximum doses of 10 µc) and receiv,?d permission 
to use up to 25 µc per patient. Although this gave us higher 
count rates, the accuracy of our late points on the plasma iron 
clearance curve was still dubious. 
Even without good data on delayed plasma iron clearance curves 
we found .::!eviation from a single exponential clear ance function 
within a few hours of injection of radio-iron labelled transferrin. 
IV-3 
IV-3-a 
The sourca:;of the changed slope appears to be mul t iple, as 
detailed by Cook (164) 
i.e. 
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(1) recycling of transferrin from extravascular 
extracellular fluids (i.e. lymphatics, ascites etc.) 
back into the plasma. 
(2) recycling of iron from ineffective erythropoiesis 
(3) return to the plasma of radio iron taken up initially 
by parenchymatous iron stores. 
It appears likely that the initial deviation in the fin:t portion 
of the plasma iron clearance curve is produced by re-ent:ry into the 
plasma of labelled transferrin from lymphatic:. and othe1: extra-
t 1 fl .d (258) (686) (399) (164) Tlte cellular, ex ravascu ar ui s. 
subsequent curve appears to be influenced by feedback o:: radio-
.. h 1 f . ff . h .. (11>4)(288) iron into t e p asma rom ine ective eryt ropoiesis. 
The subsequent single exponential fall off in plasma radioactivity 
appears to represent equilibration between plasma and s ·~orage 
iron, with gradual loss of iron from the body. 
Non Erythroid Iron Uptake. 
Theoretical considerations. 
It would, theoretically, seem reasonable to propose that non 
erythroid iron uptake does not occur in severe iron deftciency, 
since repeated phlebotomy to render a patient iron deficient 
has been shown to remove iron from body stores(3s4)(2ll)(360) 
(61)(415) (252)(156) 
In addition, patients with severe iron 
deficiency do not take up radioactivity into storage sites as 
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measured by external counting and have absent .iran ~tores as 
d b h
. 1 · l h · (252) (61) (387) (130) (698) 
assesse y 1sto og1ca tee n1ques. 
(815) (415) 
Patients with iron overloaded states however, 
show fairly marked uptake of radioactive iron from intravenously 
injected transferrin labelled with radio-iron, this upt.s.ke being 
predominantly into liver parenchymal cells. From this, one 
intuitively supposes that parenchymatous iron upt ,:ike is deter-
mined, to a certain extent, by the plasma iron co:ncentrc.tion . 
It will be low or absent where iron deficiency exists artd will 
probably increase as the plasma iron concentr ation incre,ases . 
This is represented diagrarmnatically in Figure IV·-10. 
Figure IV-10. Diagrarmnatic Representation of Postulated Paren,:ElE1atous 
Iron Uptake as a function of Plasma Iron Concentrat:ion. 
Plasma Iron Concentration 
IV-3-b 
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I have noticed, empirically, that as the plasma iron concentration 
increases, in normal patients, the percentage of injected radio-
iron incorporated into circulating red cells appears to decrease. 
This would mean, according to our postulated model of iron 
kinetics as detailed in the review section, that as the plasma 
iron concentration increases, more iron goes to sites other 
than the bone marrow, providing that the fraction of erythro-
poietic activity devoted to ineffective haemoglobin formation 
remains constant as the plasma iron concentration increases . 
The only other site to which this radio-iron can go is t he 
parenchymatous iron stores (See Figure IV-11) 
Figure IV-11 Graphical Representation of Internal Iron Kinetics 
demonstrating the possible routes of distribution of 
transferrin iron. 
P arenchyma tous 
Iron Stores 
NEIT~ 
Plasma Transferrin ~ 
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There appears to be no reason why the r,ercent.1ge of inef f ectively 
formed haemoglobin should vary with changes in plasma iron 
concentration. On this basis, I decided to adopt an empiric 
app1:oach in an attempt to quanti tate non erythroid iron uptake. 
The normal patients previously described (Table IV-1) wer e 
studied. Measurements of red blood cell utilisation (RBCU) 
were made, as detailed under methods. It was as sumed tat non 
erythroid iron uptake (NEI uptake) was represented. by the 
percentage of injected radio-iron not getting into the 
circulating red cells by day 14. (i.e. 100-RBCU%). The RBCU 
was plotted against plasma iron concentration per 100 ml. of 
plasma and against plasma iron concentration per :.OO ml. of 
whole blood calculated as previously described.(IV-2-a) 
We have postulated, (in paragraph IV-3-a), that non erythroid 
iron uptake would be zero at low plasma iron conc1:mtrati ons, 
and would increase in proportion to increase in t :1e pla£ma 
iron concentration. (Figure IV-10) Some experimerital eYidence 
exists to show that bone marrow erythropoieti c activity becomes 
limited by inadequate iron supply at plasma i ron concentrations 
. (385) (609) 
less than 70 µgms% and we have plot ted RBCU against 
plasma iron concentrations regardless of pla3ma iron level, 
and against plasma iron levels of more than 70 µgms/100 ml. 
plasma or more than 40 µgms/100 ml. whole blood in an a1:tempt 
to see whether a better fit for the data could be obtained 
using a 'cut off' point for plasma iron concentration. The 
results are summarised in Figures IV-12 - IV-15. 
Figure IV-12 RBCU plotted against plasma 'iron concentration/100 ml. 
plasma in all patients. 
Least squares regression equation. 










(100 - RBCU)% = 0.232 (PI/100 ml) - 4.422 
Equation 1. 
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RBCU plotted against plasma iron concentration/100 ml. 
plasma in patients with plasma iron concentrations 
exceeding 70 µgms %. 
Least squares regression equation: 
RBCU % = - .3654 (P.I./100 ml) + 125.2567 
r = 0.9709 
SEY/x = 4.4019 
(100 - RBCU)% = 0.3654(P.I./100ml) - 25.2567 
Equation 2. 
50 100 150 200 250 300 
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RBCU plotted against plasma iron concentration/100 ml. 
whole blood in all patients. 
Least squares regression equation: 
RBCU % = -.3633(P.I./100 ml wb) + 103.5096 
r = 0.8640 
SE Y/x = 11.22 
(100 - RBCU)% = 0.3633(P.I./100 ml. wb) - 3.5096 
Equation 3. 
-+------~-----------~------, 
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RBCU plotted against plasma iron 
concentration/100 ml. whole blood in pat ients 
with plasma iron concentrations exceeding 
40 µgms/100 ml. whole blood. 
Least squares regression equation: 
RBCU% = -0.4996(P.I./100 ml. wb) + 116.7352 
SE Ytx = 8.4857 
r = 0.8875 
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As can be seen from these graphs, the RBCU values decreased as 
plasma iron concentrations increased. This decrease was 
linearly related to the plasma iron concentration and coul d be 
fitted by a regression equation, with good correlation between 
the two parameters. This tended to support my theoretical 
postulate that as the plasma iron concentration increased, 
the amount of iron going to non erythroid sites increased 
proportionately. From the graphs, it can be seen that the best 
correlation between RBCU and plasma iron value is in Figure IV-13, 
where r = 0.9709, suggesting that non erythroid iron uptake 
probably only starts at plasma iron concentrationn of 
approximately 70 µgms%. 
By extrapolation from this data, the percentage of iron going 
to non erythroid sites can be expressed as 100 - RBCU%. When 
these points for individual patients are plotted against the 
plasma iron parameters described (IV-3-d), four equatior,.s 
describing the resultant least squares fit rcgres :3ion equation 
can be derived (See Figures IV-12 to IV - 15) . Using these 
equations numbered 1 - 4, one would be able to calculate· the 
non erythroid iron turnover, because the fraction of irc,n being 
taken up by non erythroid sites would be the same fractjon of 
the plasma iron turnover. 
be:-
Expressed mathematically this would 
where 
NEIT = (100 - RBCU)% x PIT 
NEIT = Non erythroid iron turnover 
PIT= Plasma iron turnover. 
It seems reasonable to me to express some reservations Hbout 
this empiric method of calculating NEIT values. 
IV-3-g 
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This approach obviously required accurate measurement of the 
RBCU and plasma iron. Since the scatter of my data is relatively 
small, and the correlation between RBCU and plasma iron 
concentration good, I felt justified in presuming that this 
requirement had been met. I ,,m also aware that I have 
assumed a constant rate of ineffective erythropoiesis, 
independent of plasma iron concentration. This is not a 
strictly justifiable assumption, since ineffective erythro-
. . b . . . d f. . (106) poiesis has een shown to increase in iron e ici ency. 
(164)(258)(687)(688)(727)(766) This probably explains why 
the fit for the data is best where plasma iron cut off points 
are used. I am aware that ineffective erythropoiesis and 
variations in red cell survival affect the RBCU but have no 
reason to believe that red cell lifespan was suff iciently 
abnormal in any of these patients to influence the RBCU. 
is no obvious reason, therefore, for believing that the 
There 
variation in RBCU with changes in plasma iron concentration 
was due to any factor other than change in NEIT. 
The non-erythroid iron uptake is probably relatively unaffected 
by changes in parenchymal store avidity for transferrin iron. 
My data, and that of Cook(164) would suggest that any variation 
in NEIT between individuals depends more upon var iations in 
plasma iron concentration than upon any other factor, and I 
feel t ha t the dependence of NEIT upon plasma iron concentration 
is reasonably accurately described by the regression equation 
derived from my experimental data. (Figure IV-12 to IV-15). 
IV-3-h 
Cook~ 164) using a "reflux" model, defined the relationship 
between NEIT and plasma iron concentration by the following 
equation. 
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NEIT (mg/100 ml w.b/day) = .0035 x P.I. (µg/100 ml.wb) 
r = 0.873 
As his was the only study I knew of in which any attempt had 
been made to measure NEIT, I have compared the values for NEIT 
in my patients calculated by my analytical technique with 
corresponding values obtained by substituting Cook's equation. 
The results are compared in Table IV-6. It can be seen that 
at low plasma iron values Cook's formula gives slightly higher 
values for NEIT than do my equations, the opposi t e being the 
case at higher plasma iron concentrations. 
Acting on the assumption that the preferred analytical technique 
for defining the relationship between plasma iron and NEIT 
would be that giving the highest degree of correl ation between 
these values, I examined the nature of the relati onship when 
NEIT is calculated by my method or Cook's, and expressed as 
a function of plasma iron or the iron content of whole blood. 
The resultant regression lines are shown in Figur es IV-16 and 
IV-17. 
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Table IV-6 NEIT Values Derived by Different Methods. 
Patient N.E.I.T.(mg/100 ml wb/day) Pl 
Cook French (mg/100 
1 2 3 4 ml.wb) 
deB .1312 .0622 *- .0630 * 37 
Web .1601 .0807 .0348 .0674 .0313 46 
Luk .4758 .4470 .5185 .4650 .5192 136 
Cup .2863 .3364 .2475 .4096 .3726 82 
Car .1206 .0776 '# .0887 * 34 
Hey .0921 .0980 '# .0581 • 26 
Bot • 2118 .1904 .1418 .1598 .116, 61 
Rus .1141 .0356 • .0430 • 33 
Kho .1128 .0521 • .0518 • 32 
Thy .2187 .1466 .0964 .1411 .106S 62 
Arm .2094 .1634 .0807 .1759 .1270 60 
Sc 1 .0942 • 0019 • .0066 • 14 
Bas .0248 *- ll:. *- *- 7 
Hoo .0411 *- ll:. .0030 ll:. 11 
Cha .0445 * * .0018 * 12 
Loz .0217 * * 
,., 
* 6 
Gog .3957 .5156 .5823 .4720 .499 :1 113 
OCo .5766 .4076 .4984 .4420 • 514~i 164 
vWy .3295 .2994 .2714 .3357 .331? 94 
Pet .0623 .0080 * .0103 * 18 
Mgo .3291 .2361 .2425 .2167 • 2137 99 
Tan .2234 .1366 .0831 .1414 • 1180 64 
Wes . 2519 .2796 .2625 .2200 .1868 72 
Nqw .3960 .4854 .5603 .4209 • 445i' 113 
Mar .1584 .1654 .1014 .1125 .0511 45 
Ans .0728 .0208 ll:. .0281 * 21 
Wi l .0536 .0052 * .0156 * 15 
Pre .1708 .2230 .0885 .2044 .1099 49 
Sam .2562 .2894 .2365 .2170 • 238] 73 
Jeg .1082 .0564 '# .0724 * 31 
Pax .1052 . 0283 '# .0414 • 30 
Rob • 2079 .1999 .0562 .2553 .182S 59 
Tay .0458 .0124 • .0096 • 13 
Sch • 0819 .0262 • .0455 • 25 
* The points represent zero values for NEIT, due to plasma iron 
values being markedly depressed. 
Figure IV-16 Comparison of least square fits for NEIT 
plotted against plasma iron concentration using 
different formulas to calculate NEIT (see text). 
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Cook: y = 0.0021.x + .0005 ( r = 0.9811) 
French (1) y = 0.0024x + .0521 (r = o. 9410) 
(2) y = 0.0035x ... .2354 (r = 0.9445) 
(3) y = 0.0022x .0431 (r = 0.9161) 
(4) y = 0.0029x - .1418 (r = 0.8132) 
y = NEIT (mg/100 ml wb/day) 
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Comparison of least squares fits for NEIT 
plotted against plasma iron concentration per 
100 ml. whole blood using different methods to 
calculate NEIT (see text). 
y = 0.0035 X (r = O. 873) 
y = 0.003lx - 0.0421 (r = o. S,218) 
y = 0.0050x - 0.1651 (r = o. 8901) 
y = 0.003lx - 0.0431 (r = o. 9382) 
y = 0.0046x - 0.1315 (r = 0.9203) 
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y = NEIT (mg/100 ml wb/day) 















Plasma Iron Concentration (µgm/100 ral. w.b.) 
IV-3- i 
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From simple inspection of these figures, it can be seen that values 
for the NEIT tend to be lower when calculated by my method at 
low plasma iron concentrations, and higher at high plasma iron 
concentrations. This is particularly noticeable when 'cut off ' 
· points are used. It is of interest that the slopes and equations 
derived using my method, when no 'cut off' points are used agree 
closely with those derived using Cook's equation. (i.e .. 0021, 
0.0024 and 0.0022 when x is plasma iron concentration per. 100 ml. 
of serum, and 0.0035, 0.0031 and 0.0031 when xis plasma iron 
concentration per 100 ml. of whole blood). It would se1im therefore 
that my analytical techniques yield results that are essentially 
similar to those obtained when Cook's method is used. In 
defining a functional relationship between NEIT and plasma iron 
it seems 'a priori' mo:i:-e physiological to use the concentration of 
iron to which erythroid and non erythroid iron uptake sites in 
the body would be exposed. The correlation coefficientf: obtained 
using my method were slightly better than those obtained using 
Cook's method, although both were good. 
I now had ten equations describing the relationship betwe:en NEIT 
and plasma and blood iron concentration. I then had to decide 
which of these seemed physiologically most appropriate. The only 
way in which I felt that I could do this was by comparing the 
calculated erythroid iron turnover values (i.e. PIT - NElT) 
with predicted EIT values, assuming that each patient had a 
constant proportion of ineffective erythropoiesis and a normal 
red cell lifespan. This assumption is probably not enti rely 
valid because the 51cr method of measuring red cell survival 
IV-3-j 
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used by us gives a relatively crude estimate of red cell 
survival, and, as previously described, some variation 
between individuals with regard to the percentage of their 
total erythropoietic activity that is ineffective is to be 
expected. For these reasons it was realised that these 
values would not necessarily correlate well. I, n-avertheless , 
decided to use the best statistical fit between these two 
values as an indicator of which equation best described 
non erythroid iron turnover. 
Predicted EIT was calculated assuming a red cell li EeEpan 
of one hundred days, and asstnning that 20% of total 
erythropoietic activity was ineffective. 
Predicted EIT = Hb x 3.4 x 1.2 mg/100 ml. wb/d 
L 
where Hb is the haemoglobin concentration/100 ml. w,J. 
Lis the red cell lifespan (100 days) 
3.4 represents the amount of iron, in mgms, r :!quired 
for the synthesis of one gram of he.emoglo'Jin, 
and 1.2 represents a correction factor to correct 
erythropoietic iron turnover for ineffective 
erythropoietic activity. This fi gure wa3 
derived by assuming that total erythropoie tic 
activity will be 1.2 x greater than effective 
erythropoietic activity if the amount of 
ineffective erythropoiesis is approximately 
17% of total erythropoiesis. 
Table IV-7 Comparison of indirectly calculated EIT values with 
ferrokinetically calculated EIT values using ten 
different equations to calculate NEIT (see text.) 
Ferrokinetic EIT (P.I.T. - N.E.I.T.) 
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Ind Plasma Iron/100 ml. wb. Plasma Iron/100 ml. Elasma 
EIT French French 
Patient Cook 1 2 3 4 
Cook 1 2 3 
deB .6365 .4933 .5836 .5290 .5504 .6022 .4938 .5865 .5312 .5278 
Web • 6610 • 3437 .4248 .3717 .4042 .4400 .3191 .3910 .3539 .3453 
Luk .5222 .5386 .5206 .5545 .6351 .4998 .5750 .5501 .5977 .5649 
Cup .4202 L2573 1.2988 1.2840 1. 3321 1.2996 1. 3058 1. 3577 1.3381 1.3245 
Car .4937 .8643 .9578 .9005 .9201 .9776 .8731 .9730 .9114 .9098 
Hey .8282 .8478 .9399 • 8856 .9004 .9399 .8050 .8961 .8422 .8384 
Bot • 7018 • 6526 • 7175 .6836 • 7189 • 7269 .6245 .6756 .6567 . 6429 
Rus .4855 .3974 • 4929 .4339 .4526 .5121 .4087 .5118 .4474 .4466 
Kho .6365 .5192 .6152 .5558 .5742 .6320 .5160 .6143 .5541 .5521 
Thy .5998 .5165 .5792 .5471 .5836 .5878 .5142 .5725 .5473 .5353 
Arm .5141 .7563 .8220 .7874 .8223 .8316 • 7720 .8407 . 8064 .7970 
Sch .4488 .3639 .4131 .4042 .4117 .4131 .3685 .4131 .4100 .4131 
Bas .3305 .4187 • 4435 .4435 .4435 .4435 .4241 .4435 .4435 .4435 
Hoo .4039 .3634 .4045 .4042 .4045 .4045 .3704 .4045 .4045 .4045 
Cha .4447 .6615 .7060 .7021 .7060 .7060 .6656 .7060 . 7060 .7060 
1oz .5386 .7509 • 7720 • 772.0 • 7720 . 7720 .7526 .7720 . 7720 • 7720 
Gog .6854 .8604 .8676 • 8809 .9477 .8559 .8440 . 8295 .8680 .8378 
oCo • 5345 • 2079 .1581 . 2180 .3159 .1258 .2737 .2216 • 2930 . 2534 
vWy .4570 . 7646 .7925 • 7889 .8443 .7885 .8059 .8386 • 8358 .8174 
Pet .6691 .2866 .3985 .3262 .3358 .4250 • 2875 .4066 .3282 .3314 
Mgo .6569 .3778 .4059 .4021 .4575 .4019 .3641 .3760 .3914 .3678 
Tan .5916 .4950 .5563 .5253 .5626 .5643 .5058 .5673 .5393 .5281 
Wes .7058 .7205 • 7729 .7493 .7914 • 7777 .6716 .6995 .7009 .6813 
Nqw .6650 .7242 .7313 .7447 .8116 . 7196 .6871 .6646 • 7101 .6779 
Mar • 8323 • 7118 .7936 .7459 • 7720 • 8091 .6576 • 7191 .6911 .6779 
Ans .4896 .6210 • 7296 .6599 .6714 .6938 .6261 .6938 .6665 • 6691 
Wil . 4488 • 7077 .8223 • 7477 • 7559 .7613 • 7146 • 7613 .7560 .7,606 
Pre • 7181 12649 1. 3427 1. 2982 1.3265 1. 3567 1. 2546 1. 3281 1. 2896 l. 2814 
Sam .6569 .9440 .9949 • 9724 1.0154 .9993 .9414 .9853 .9727 .9571 
Seg • 4651 • 8289 .9263 .8658 .8833 .9476 • 8421 .9371 .8812 .8812 
Pax .5426 .4509 .5493 .4880 .5050 .5561 .4695 .5561 .5090 .5098 
Rob . 3713 1. 2062 1.2724 1.2374 1.2721 1. 2822 1. 2456 1. 3239 1. 2812 1. 2742 
Tay • 6691 • 7238 .8409 .7643 • 7711 • 8693 .7145 • 7696 .7555 .7593 






































Table IV-7 compares, in tabular form, the indirectly 
calculated EIT values with EIT values derived ferrokinetically 
by subtracting the calculated NEIT (derived by 10 different 
equations as previously described) from the PIT. 
Statistical analysis of the results compared are seen in 
Table IV-8. It can be seen that the correlation between 
indirectly calculated EIT and ferrokinetically derived EIT 
values is very poor. It seemed obvious to me that while we 
were completely normalising indirectly calculated EIT values 
by assuming a constant value for red cell lifespan and 
percentage of ineffective erythropoiesis, no such norm~lisation 
of the ferrokinetic data was being attempted. I have 
previously shown (IV-2-f) that the erythropoietic index 
can be used as an indicator of variable erythropoietic 
activity. If one divides the ferrokinetically derived EIT 
value by the same patient's E.I. value, the ferrokinetic 
EIT should be normalised for variations in ineffective 
erythropoiesis and red cell lifespan, as all these patients 
were in a steady state for the duration of the experim~nt. 
Table IV-9 details a statistical comparis_on of indirectly 
calculated EIT values compared with ferrokinetically derived 
EIT values divided by the EI to normalise for variable total 
erythropoietic activity, produced by changes in red cell 
lifespan or variable proportions of ineffective erythropoiesis. 
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Table IV-8 Statistical analysis when comparing indirectly 
calculated EIT values (x axis) with ferrokinetically 
derived EIT values (y axis). 
Equation SEY /x r p 
1. Plasma Iron/100 ml. w.b. 
Cook .3013 .0221 < .45 
French (1) .3302 .0363 < • 40 
(2) .3128 .0206 < . 45 
(3) .3242 .0416 < .40 
(4) .3328 .0489 < .35 
2. Plasma Iron/100 ml. plasma 
Cook .3110 .0516 < . 35 
French (1) .3454 .0689 < .30 
(2) .3375 .0532 < .35 
(3) .3102 .0663 < . 35 
(4) .3454 .0163 < .45 
IV-3-1 
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When this is done, i.e. the ferrokinetic EIT is corrected 
for variable erythropoietic activity, the correlation between 
the indirectly calculated EIT and the ferrokinetic EIT 
improves. However, there are exceptions to this, and one 
must assume that the EI is not totally correcting or 
normalising the EIT in these individuals. For the majority 
of patients, this parameter is definitely of use, as can 
be seen from the improvement in the statistical significance 
that can be assigned to its use. The correction produced 
by using our experimental EI value is, however, far fr ,)m 
perfect. Using this approach, it would appear that my 
equations using plasma iron/100 ml. plasma as x or indc?pendent 
variable, and equations 2 or 3 for NEIT, best fit the t wo 
parameters. As can be seen, the fit is still poor. 
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Table IV-9 Statistical analysis when comparing indirectly calculated 
EIT values (x axis) with ferrokinetically derived EIT 
values divided by EI (y axis). 
Equation SEY/x r p 
1. Plasma Iron/100 ml. wb 
Cook .2537 .2029 < ,10 
French (1) .2801 .1759 < .15 
(2) .2623 • 2012 < .10 
(3) .2685 .1879 < .10 
(4) .2814 .1524 < .15 
2. Plasma Iron/100 ml. plasma 
Cook .2630 .2710 < .OS 
French (1) .2844 .2371 < .OS 
(2) .2758 .2816 < .025 
(3) .2751 .2900 < .025 
(4) .2946 .2042 < .10 
IV-3-m In view of this, I have attempted another approach to t he 
problem of deriving the best equation for calculation of 
NEIT. The equation for indirect measurement of EIT can 
be written as previously (IV-3-j). 
i.e. 
EIT (indirect)= Hb 
L 
x 3.4 x EIT 
EEIT 
where EEIT = Effective Erythropoietic Iron Turnover 
EIT/EEIT is normalised as 1.2 as previously discussed. 
L = 120 days (normal rbc lifespan). 
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Any variation in Lor EIT/EEIT will obviously have trenendous 
effects upon the indirectly calculated EIT, which will in turn 
affect any comparison of ferrokinetic and indirectly calculated 
EIT values. I have suggested that correction of ferrokinetic 
EIT values for variable erythropoiesis (which may be a resul t 
of variation in red cell lifespan or percentage ineffe,:: tive 
erythropoiesis) by an EI value should normalise the fe -rrokinetic 
value for variation in these two parameters. 
i.e. 
EIT (ferrokinetic) = Hb x 3.4 x 1.2 
EI (experimental) L 
= Hb x 3.4 (when L = 120 days) 
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I have shown that my experimentally derived EI value fails 
to do this satisfactorily. However, one can cal culate a 
theoretical EI value which will match these two values. 
i.e. 
EI = EIT (ferrokinetic) x 100 
Hb X 3.4 
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We can call this our theoretical E.I. value. I have previously 
shown that the E. I. can be expressed as the ratio of predicted 
t!PIC (at the individual plasma iron concentration) to the 
experimentally derived t!PIC value. 
i.e. 
E.I. Predicted t!PIC (at individual's P.I. concentration) 
Experimentally derived t!PIC 
By calculating a theoretical E. I. value as described, WE '. can 
also calculate a theoretical t!PIC value for each individual 
and each equation , 
i.e. 
t ! PIC theoretical = t ?IC experimental x E. I. ( theoretical) 
This can be done for all the patients in the different groups 
(i.e. the ten equations derived for calculating NEIT). The 
line giving the best correlation between plasma iron va:.ues and 
theoretical t!PIC values would represent, I believe, the 
equation best describing NEIT. The reason for my be liE~ving this 
is that all the ferrokinetic data in this group of normal patients 
that I have studied, seem~ to be primarily dependent upon changes 
in plasma iron concentration. I have previously stated (IV-3-h) 
that I feel that it is more physiological to express plasma iron 
concentration in terms of i ts concentration/100 ml. of uhole blood, 
as this probably represents the iron concentration 'seen' by the 
sites taking up iron from transferrin. In Tab le IV-9 however, 
it can be seen that P values are most highly significant: where 
plasma iron concentrations/100 ml. of plasma are considered, 
and the correlation coefficient between indirectly calculated 
EIT values and ferrokinetically derived EIT values is a i so best 
Table 
(although still poor) using these calculations. 
In Table IV-10, the results of theoretically calculated EI 
and t!PIC values as derived from ferrokinetic EIT values 
ll s 
(see above) are tabulated. When the correlation coefficients 
between the theoretical t!PIC and plasma iron concentrations 
(either as µgm% or as µgms/100 ml. wb) are calculated, it can 
be seen that the best correlation coefficient is obtained with 
equation French (3) where xis the plasma iron concentration/ 
100 ml. wb. 
IV-10 Theoretically calculated t!PIC and EI values, as 
derived from ferrokinetic EIT values compared with 
indirectly calculated EIT values (see text) using the 
various equations to calculate EIT (PIT - NEIT) 
Least squares regression equations:- (y = t !PIC) 
1. Plasma Iron/100 ml. whole blood (= X axis) 
a) Experimental y = 0.9114.x + 14.0171 (r = o. 8~) 
b) Cook y = 0.87x + 34.67 (r = o. 75) 
c) French (1) y = 0.78x + 45.10 (r = o. 6 ~) 
French (2) y = 0.89x + 37.21 (r = 0. 7,5) 
French (3) y = l.08x + 32.48 (r = 0. 8·+) 
French (4) y = o. 72x + 47.63 (r = o. 6•+) 
2. Plasma Iron/100 ml. plasma ( = x axis) 
a) Experimental y = 0.5509x + 14.3389 (r = o.8n 
b) Cook y = 0.47x + 39.18 (r = 0.70) 
c) French (1) y = 0. 46x + 46.20 (r = o. 611) 
French (2) y = 0.55x + 37.94 (r = 0. 71.) 
French (3) y = 0.58x + 35.76 (r = O. 6H) 
French (4) y = 0.42x + 49.94 (r = O. 5E:) 
TABLE IV-10 116 
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15.6 43 62 
16.2 52 88 
12.8 38 209 
10. 3 30 113 
12.1 38 53 
20.3 64 64 
17.2 51 114 
11.9 36 49 
15.6 45 55 
14. 7 44 105 
12.6 38 92 
11.0 36 21 
8.1 23 9 
9,9 29 16 
10.9 36 19 
13.2 36 9 
Plasma Iron/100 ml. whole blood Plasma Iron/100 ml. plasma 
Cook (1) (2) (3) ro Cook (1) (21 (3) (4) 
t PIC t I EI t EI t I EI t EI t EI 
! ex. clh) < th)( tA) < th) ah) < t h) < !h> c th) c !h) < th) 
t 1 EI . 
(th)(th) 
t EI t EI 















56 . 93 66 
57 .62 70 
166 1.24 160 
190 3.59 197 
74 2.10 81 
34 1.23 38 
78 1.12 86 
63 0.98 78 
50 0.98 59 
88 1.03 99 
1.10 60 1.00 62 1.04 68 1.14 56 0.93 
.77 62 o.69 67 o.73 73 o.so 53 o.58 
66 1.11 






71 o. 78 
1.20 171 1.27 196 1.46 154 1.15 177 1.32 169 1.26 184 1.37 174 1.3
0 160 1.19 
3.71 194 3.67 202 3.80 197 3.71 198 3.73 205 3.88 203 3~82 200 . 3.7
8 209 3.95 
2.33 77 2.19 78 2.24 83 2.38 74 2.12 83 2.37 78 2.22 77 2.2
1 84 2.39 
1.36 36 1. 28 31 1. 30 38 1.36 33 1.17 36 1.30 34 1.22 34 1~2
1 38 1.36 
1.23 82 1. 17 86 1.23 87 1.24 75 1.07 81 1.16 79 1.12 77 1.1
0 8( 1.20 
1.22 69 1.07 72 1.12 s1 1.21 65 1.e1 81 1.26 11 1.11 11 1.10 
81 1.27 
1.16 53 1. 05 55 1.08 61 1.19 50 0.97 59 1.16 53 1.04 53 1.0
4 61 1.19 
1.16 93 1 . 09 99 1.17 100 1.18 87 1.03 97 1.15 93 1.10 91 1.0
7 103 1. 21 
62 109 1.77 119 1,92 114 1.84 119 1.92 120 1.94 118 1.80 122 1.96 
117 1.88 115 1.86 127 2.05 
34 33 0,97 38 1.10 37 1 . 08 37 1.10 38 1.10 34 0.99 38 1.10 
37 1.10 38 1.10 38 1.10 
16 24 1.52 26 1.61 26 1. 61 26 1.61 26 1.61 25 1.54 26 1.61 




31 1.08 35 1.20 35 1. 20 35 1.20 35 1.20 32 1.10 35 1.20 35 
1.20 35 1.20 35 1.20 
32 1.78 34 1.91 34 1.89 ~4 1.91 34 1.91 32 1.80 34 1.91 34 
1.91 34 1.91 34 1.91 
59 1.67 60 1.72 60 1.72 EO 1.72 60 1.72 59 1.68 60 1.72 60 
1.72 60 1.72 60 1.72 
Gog 16.8 46 196 90 136 1.51 137 1.52 139 1.54 ll9 1.66 135 1.50
 133 1.48 131 1.45 138 1.52 132 1.47 127 1.41 
oCo 13.1 35 243 210 98 0.47 75 0,35 103 0.49 1L9 o.71 59 o.28
 129 0.61 104 0.50 138 0.66 119 0.57 80 0.38 
vWy 11.2 34 137 86 173 2.01 179 2.08 178 2.07 191 2.22 178 2.07 
182 2.12 189 2.20 189 2.19 185 2.15 192 2.2'.l 
Pet 16.4 42 29 51 26 0.51 36 0.71 30 0.59 31 0.60 39 0.76 
26 0.52 37 0.73 30 0.59 30 0.59 44 0.81 
Mgo 16.1 46 163 133 92 0.69 99 0.74 98 0.73 El o.84 98 0.73
 88 0.67 91 0.69 95 0.72 89 0.67 90 0.6B 
Tan 14.5 40 101 82 82 1.00 93 1.13 87 1.07 94 1.14 94 1.1
4 84 1.03 94 1.15 90 1.09 88 1.07 100 1.22 
Wes 17.3 54 143 74 91 1.22 97 1.31 94 1.27 100 1.35 98 1.32 
84 1.14 88 1.19 88 1.19 86 1.16 89 1.20 
Nqw 16.3 49 206 101 132 1.31 133 1.32 136 1.34 l •f8 1.46 131 1.30 
125 1.24 121 1.20 129 1.28 124 1.22 116 1.15 
Mar 
Ans 
20. 4 60 101 
12.0 38 32 
Wil 11.0 33 22 
Pre 17.6 47 86 
Sam 16.1 44 123 
Jeg · 11.4 34 45 
Pax 13.3 29 41 
Rob 9.1 28 80 
Tay 16.4 54 26 












53 1.03 60 1.14 56 1.08 58 1.11 61 1.17 49 0.95 54 1.04 52 
1.00 51 0,98 56 1.08 
46 1.52 54 1.79 49 1.62 49 1. 65 51 1.70 46 1.53 51 1.70 49 
1.63 49 1.64 51 1.70 
59 1.89 68 2.20 62 2.00 63 2.02 63 2.04 59 1.91 63 2.04 63 
2.02 63 2.03 63 2.04 
72 2.11 76 2.24 74 2.17 75 2.22 77 2.27 71 2.10 75 2.22 73 
2.16 73 2.14 78 2.29 
105 1.72 111 1.82 108 1.78 113 ·1.85 111 1.83 105 1.72 110 1.80 108
 1.78 107 1.75 112 1.84 
71 2.14 79 2.39 14 2.23 75 2.28 81 2.44 72 2.17 
54 1.00 66 1.21 58 1.08 60 1.12 66 1.23 56 1.04 
163 3.90 173 4.11 168 4.00 173 4.11 174 4.14 169 4.03 
22 1.30 26 1.51 23 1.37 24 1.38 27 1.56 22 1.28 
82 2.64 88 . 2.82 81 2.60 82 2.65 90 2.91 78 · 2.53 
0.75 0.68 0.76 0.84 0.64 0.70 
80 2.42 75 2.27 75 2.27 80 2.42 
66 1.23 61 1.13 61 1.13 66 1.23 
180 4.28 174 4.14 173 4.12 186 4.43 
23 1.38 23 1.36 23 1.36 23 1.38 
86 2.77 83 2.67 83 2.68 86 · 2.77 
0.64 o. 71 0.68 0.58 
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The most similar slope to the experimentally derived slope for 
t!PIC plotted against plasma iron concentration is from 
equation French (2) where x = plasma iron concentration/100 ml. 
plasma. 
Comparing the experimentally derived t!PIC curves with the 
theoretical curves, it can be seen that the slope of the 
regression equation is much the same, but that the line lies 
above that of the experimentally derived regression. This 
probably represents an error in patient selection on our part 
i.e. an excess of patients with iron deficiency and markedly 
raised E. I. values, perhaps reflecting sub clinical haemolysis 
or increase in ineffective erythropoiesis. 
By all the parameters that we have used in an attempt t ,) assess 
the best equation describing the NEIT function, it would appear 
that 
(a) from comparing indirectly calculated EIT values with 
ferrokinetically derived EIT values, (i.e. FIT - NiHT 
using all the formulae mentioned) divided by the 
experimental E.I. value :- the best equation seen to 
fit the data is my equation (3). 
i.e. y = 0.0022x - 0.0431 (r = O. 9161) 
where x = plasma iron concentration/100 ml. plasma 
y = NEIT (mgms/100 ml wb/day). 
In this comparison, when indirectly calculated EIT is 
plotted against ferrokinetically derived EIT, 
SE Y/x = 0.2751 
r = 0.2900 
P = < 0.025 
(b) When calculating a theoretical E. I. value by forcing 
the ferrokinetically derived EIT value to equal the 
indirectly calculated EIT (see text), and from this 
calculating a theoretical t 1PIC value which correlates 
2 
best with the plasma iron concentration the best 
equation fitting the data 1s my equaticn (3) viz. 
y =.OO:lx - 0.0431 (r = O. 9382) 
where x = plasma iron concentration/100 ml. wb. 
y = NEIT (mg/100 ml. wb/day) 
In this comparison, when plasma iron concentration is 
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plotted against the theoretically derived t 1PIC, r = 0.84. 
i 
It should be pointed out that both these equations have 
been derived from the same equation; 
i.e. (100 - RBCU)% = 0.3633 (PI/100 ml wb.) - 3.5C96 
r = 0.8640 
= 11. 22 
(c) NEIT = (100 - RBCU) x P.I.T. (mg/100 ml. wb/d) 
- 100 
The derived equations described in (a) and (b) abC>ve 
have been obtained by plotting the NEIT values calculated 
from (c) against plasma iron concentration per 1oc, ml. of 
plasma and against plasma iron concentration per 100 ml. of 
whole blood respectively, and calculati ng t he leaf;t squar es 
best fit regression equation to give equations (a) and 
(b) respectively. This data would suggest that i t does 
not really matter which parameter of plasma iron concen-
IV-3-o 
HY 
- · tration is used, both being equally valid. 
Data derived by fn'/- : method and that of Cook gives closely 
similar values. For reasons of convenience, as Cook's 
equation is already published and better known, I have used 
his method to calculate NEIT in subsequent work, believing 
that my method probably gives results of the same order of 
accuracy. It is interesting to me that my experimentally 
derived EI should fit so closely to a theo11etically derived 
EI value. I believe that my regression, experimentally 
derived, of t!PIC against plasma iron concentration, probably 
calculates too rdpid a predicted t!PIC for reasons already 
stated, and because of this prefer to use the theoretically 
derived EI value as a measure of total body erythroid activity. 
In sunnnary to this section, therefore, I propose, in future 
work in this thesis, to use the following equations for 
calculating various ferrokinetic parameters. 
(1) Predicted t!PIC = 0.87x + 34.67 (x = PI/100 ml.wb) 
(2) NEIT = O. 0035x (mg/100 ml. wb/d) ( x = PI/100 ml. wb) 
(3) EIT = PIT - NEIT (mg/100 ml. wb/d) 
(4) PIT = PI x 100 - (Hct x 0.92) (mg/100 ml. wb/d) 
100 t!PIC (experimental) 
(5) EI = Predicted t!PIC at patient's PI level. -
Experimental t!PIC 
(6) Predicted RBCU = - 0.3633x + 103.5096 % (x = PI /100 ml wb) 
Thus, all the equations measuring total erythropoietic activity 
have been derived from Cook's equation describing NEIT :; the 
equation describing predicted RBCU is derived from my own work 
(see IV-3-d). These equations will characterise normal 





The Plasma Iron Turnover 
Conventional methods of estimating the plasma iron turnover 
(PIT), utilising the formulae proposed by Huff et al(
4o4) 
have been shown to overestimate erythropoietic ~emands for 
· h b d. f d 11 1·f (405)(232)(685) iron ass own y stu ies o re ce i espan 
(684)(686)(79)(80)(289)(113)(769)(23)(218) . l t· t in norma pa ien s. 
In an attempt to remove this discrepancy, a number of 
mathematical models have been devised, based mainly upon data 
derived from study of prolonged plasma iron clearance curves. 
As I was unable to duplicate this data (IV-2-g) I have 
developed an empiric approach utilising a concep t of iron 
kinetics developed from my review of the literature 
(Table IV-9). This has been reviewed in the previous 
section. (IV-1-a to IV-3-o). 
There is general agreement that PIT reflects not only total 
(i.e. effective plus ineffective) erythropoietic activity 
but also uptake of iron by non erythroid sites. (NEIT) . 
i.e. 
PIT = NEIT + EIT 
EIT = EEIT + IEIT 
effective+ ineffective erythroid iron turnover . 
NEIT has been quantitated as described in the previous 
section (IV-3-a to IV-3-o). It was comforting to discover 
(164) 
that Cook's approach and mine produced essentially 
similar results, indicating that we were reaching the 
same conclusions with different data and different metriods. 
IV-4-c 
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The fact that the results were so similar suggests that 
the resultant equations are physiologically significant. 
As I have found NEIT to be totally dependent upon changes 
in plasma iron concentration, I do not believe that it 
significantly influences other parameters reflecting total 
erythropoietic activity, (i.e. PIT, t!PIC, EI) in different 
disease states. 
Factors influencing the PIT. 
From the form of the formula used to calculate the plasma iron 
turnover i.e. 
PIT (mg/100 ml wb/d) = PI (µg%) 
100 
X 100 - (Hct X 0.92) 
t!PIC 
it is obvious that the PIT will be influenced mathematically 
by change in plasma iron concentration, t! Plasma Iron 
Clearance and Haematocrit. We have shown (Section IV-2-a 
to IV-2-c) that the t!PIC will vary with changes in plasma 
iron concentration, the change in both being proportional. 
As a result,in normal patients, the PIT should remain within 
very small limits of a 'normal' range. Mathematically, 
as the haematocrit decreases, the PIT should increase, if 
all other factors remain constant. The influence of these 
various parameters will now be discussed in greater detail. 
IV-4-d 
IV-4-e 
Influence of changes in plasma iron levels. 
I have previously stated that:-
PIT = EIT + NEIT 
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and have shown that NEIT increases as plasma iron concentration 
increases, in a directly proportional way. Consequently, with 
no change in EIT values, should the plasma iron concentration 
increase, the plasma iron turnover will likewise increase, by 
the amount of increase in NEIT. This probably accountf: for 
the often normal PIT values in patients with aplastic anaemia, 
where plasma iron concentrations tend to be high (see section 
VI-d-5 ) and EIT values will obviously be depressed. 
phenomenon will obviously occur in all disease processes. 
Influence of changes in erythropoietic activity. 
As stated in IV-4-d, PIT= NEIT + EIT. 
This 
Changes in total erythropoietic activity will cause proportionate 
changes in the amount of iron used for haemoglobin synthesis. 
Thus, with hyperplastic erythropoiesis, EIT and PIT values will 
increase, and the reverse will occur in hypoplastic erythro-
poiesis. It seemed important to me to attempt to define 
the normal range of EIT values in normal patients. Theoretically, 
because erythroblast iron uptake has been found to be dependent 
upon plasma iron concentrations up to levels of approximately 
(434) (432) (609) (384) . . 70 - 100 µgms%, it would seem logical to 
suppose that EIT will also vary with plasma iron concentration 
in normal patients. This may be illustrated diagrannnat:ically 
as in Figure IV-18 and discussed in Section III-b-5. 
Figure IV-18: Theoretically expected changes of EIT with variation 
in plasma iron concentration. 
EIT 
Plasma Iron Concentration 
Theoretically, EIT should increase as plasma iron 
concentration increases until a critical point is reachE;d 
12.3 
at which the amount of haemoglobin being formed, insteact of 
being dependent upon the amount of iron available, will become 
dependent upon the body haemoglobin requirements. 
In order to eliminate, as far as possible, variations in EIT 
due to variable erythropoietic activity, and thus to normalise 
body erythropoietic activity, the EIT has been calculated in 
each individual and divided by his EI, and then plotted against 
his plasma iron concentration. The resultant graph is shown 
in Figure IV-19, with the results of the individuals, in 
124 
tabulated form, shown in Table IV-11. EIT and EI have 
been calculated as previously described (IV-3-o). 
Figure IV-19 EIT./EI values (y axis) plotted against plasma iron 
concentration (x axis) showing the changes in EIT 
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Table IV-11 Results of EIT/EI in Normal Patients. 
Patient PI t!exp. EI EIT EIT 
100 ml.wb EI 
deB 37 60 1.12 .4933 .4404 
Web 46 91 0.82 .3437 .4191 
Luk 136 134 1.14 .5386 .4725 
Cup 82 53 2.00 1.2573 .6287 
Car 34 35 1.85 .8643 .4672 
Hey 26 28 2.06 .8478 .4116 
Bot 61 70 1.25 .6526 .52n 
Rus 33 64 0.99 .3974 .4014 
Kho 32 51 1.23 .5192 .4221 
Thy 62 85 1.05 .5165 • 49 ]_9 
Arm 60 62 1.40 .7563 .5402 
Sch 14 34 1.38 .3639 .3637 
Bas 7 16 2.55 .4187 .1642 
Hoo 11 29 1.55 .3634 • 231t5 
Cha 12 18 2.54 ~6615 .2604 
Loz 6 35 1.14 ~7509 .6587 
Gog 113 90 1.48 .8604 .5814 
oCo 164 210 0.85 .2079 .2446 
vWy 94 86 1.36 .7646 .5622 
Pet 18 51 0.98 .2866 .2924 
Mgo 99 133 0.88 .3778 .4293 
Tan 64 82 1.10 .4950 .4500 
Wes 72 74 1.31 • 7205 .5500 
Nqw 113 101 1.32 .7242 .5486 
Mar 45 52 1.42 • 7118 .5013 
Ans 21 30 1. 76 · .6210 .3528 
Wil 15 31 1.55 • 7077 .4566 
Pre 49 34 2.27 1.2649 .5572 
Sam 73 61 1.61 .9440 .5863 
J eg 31 33 1.87 • 8289 .4433 
Pax 30 54 1.13 .4509 .3990 
Rob 59 42 2.06 1.2062 .5855 
Tay 13 17 2. 71 • 7238 .2671 
Sch 25 31 1.82 • 7720 .4242 
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As can be seen from Figure IV-19, there is a gradual increase 
of EIT as the plasma iron concentration increases, leveling 
off to a plateau at plasma iron levels of approximately 60µgms/ 
100 ml. of whole blood. With no restriction imposed upon the 
EIT by shortage of precursor iron, the normalised EIT appears 
to be..:!:. 0.5 mg/100 ml. wb/day. With limitation in precursor 
iron supply however, it can be seen that EIT will vary from 
zero to maximum normal levels. This will occur where the 
issue is not confused by variations in red cell l ifespan or 
proportions of ineffective eryth:r:opoiesis. Limitation. in 
precursor iron supply appears not to be rate limi ting i n normal 
haemoglobin production above plasma iron concentr ations of 
50 µgms/100 ml. whole blood, a figure agreeing well with the 
results found by Hillman et al(3S4) and with experimental 
f . d' . . (434)(432)(609) 1n 1ngs 1n vivo. 
Erythropoietic activity will also vary in different disease 
states, and the direction of this change will markedly 
influence the P.I.T. I have shown in section IV-2-a to 
IV-2-f, the dependence of the t!PIC upon total bone mar row 
erythropoietic activity. Thus, the t!PIC decreases, 
regardless of the plasma iron level, as erythropoietic activity 
increases, and the reverse occurs with decrease in tota l 
erythropoietic activity. From the equation used to calculate 
PIT (IV-4-c), a shortened t 1PIC will increase PIT, whi l e the 
2 
r everse w:..:..l occur with prolongation of the t!PIC. 
i.e. PIT ~ 1 
t !PIC 
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Where PIT values are elevated, the PIT will reflect 
increased total erythropoietic activity. For reasons 
stated previously however, normal PIT values may occur in 
hypoplastic bone marrow states (because of incre ased NEIT). 
Subtraction of NEIT values from the PIT to give EIT values 
will give fairly accurate representation of total body 
erythropoietic activity. 
I have attempted to test the effect of total ery thropc•ietic 
activity upon this parameter using the sam1! two group~. of 
patients used previously to test the t !PIC and i I pare.meters 
(IV-2-f). The results for t!PIC, EI, PIT and ~IT ha\'e been 
compared in patients with normal, hyperplastic or hypc,plastic 
erythropoiesis, as described in IV-1-b and IV-2·-f. The 
results are shown in Table IV-12, Figure IV-20 and Fi gure 
IV-21. The test not only tests the PIT and EIT as parame t ers 
of total erythropoietic activity, but attempts to distinguish 
which parameter best measures or reflects changes in total 
erythropoiesis. The parameters have been calculated as 






Statistical comparison of ferrokinetic parameters of 
total erythropoiesis in normal patients, patients with 
proven hyperplastic erythropoiesis and patients with 
proven hypoplastic erythropoiesis. Results taken from 
patients previously described (Table IV-1, Table IV-3 
and Table IV-2) with ferrokinetic parameters calculated 



























3.75 2.9883 2.6245 
1.81 1.8037 1.6965 






< .0005 < .0005 
from Tab l e IV-3 











































Histogram showing the differences, in ferrokinetic 
parameters, of patients with normal, hypoplastic and 
hyperp las tic erythropoiesi s . (lines represent the 














From the computed statistical values, it can be seen that all 
the parameters mentioned are excellent indicators of total 
erythropoietic activity. The EI value tends to be more 
helpful than any of the others in distinguishing more subtle 
changes in erythropoietic activity because of its more 
comparative nature in stating the degree of change of erythro-
poietic activity relative to normal values. It is also 
obvious that all of the parameters are markedly influer.ced by 
changes in total erythropoietic activity. The EIT api:ears 
to be better than the PIT in this regard, as would be expected 
once the contribution of the NEIT to the PIT has been removed. 
The utilisation of transferrin-bound radioiron by the erythroid 
bone marrow for incorporation into haemoglobin. (RBCU) 
The red blood cell utilisation (RBCU) measures the percentage 
of injected transferrin-bound radio-iron appearing in the 
circulating red cells as haemoglobin after approximately 
fourteen days. 
A number of factors will obviously influence this parameter. 
I have reviewed the uptake of iron by erythroblasts frcm 
transferrin, and the subsequent release of mature erythrocytes 
in the circulation (Chapter III). I have also shown, in 
normal patients, that the RBCU will be dependent upon plasma 
iron concentrations (IV-3-a to IV-3-f), and how t his dependence 
can be mathematically expressed. The reason for this 
phenomenon appears to be that a fairly constant proportion of 
the plasma iron turnover goes to non erythroid s i tes (IV-3), 
IV-5-c 
J..JJ.. 
~he amount increasing as plasma iron levels increase . For 
this reason, it would appear reasonable to suggest that 
similarly, a constant proportion will exist in different 
disease states. It will become obvious, however , (as will 
be discussed later) that RBCU values are not sol ely 
influenced by changes in plasma iron concentrati on. Other 
factors influencing this parameter are the relat ive rates of 
effective and ineffective erythropoiesis, the erythroid 
activity of the individual and the red cell lifespan. 
The effects of variable ineffective erythropoienis. 
It would seem reasonable, on physiological grounds, to assume 
that iron taken up by maturing erythroblasts is taken up non 
selectively - i.e. that it is taken up equally by erythroblas t s 
that will mature normally and those that will not. It is 
well known that variable proportions of erythropoiesis are 
effective in different disease states, and that, in nc,rmal 
patients, approximately 10 - 20% of total erythr opoietic 
effort is wasted. (III-b-7). The exact f i gure may v~ry 10 
different normal patients, and may change enormously in 
different disease states. If radio-iron i s non selectivel y 
taken up by maturing erythroblasts, it wil l be obviouE that 
any variation in the proportion of ineffect ive erythrc,poiesis 
will cause an opposite change in the amount of radio-iron 
being effectively utilised for haemoglobin production and 
release into the circulation. 
Mathematically, we can say that:-
EIT = EEIT + IEIT 
+ 
RBCU 
Where EIT ~ erythroid iron turnover 
EEIT = effective erythroid iron turnover 
IEIT = ineffective erythroid iron turnover 
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It will be obvious that, as IEIT increases, EEIT will decrease, 
and so will RBCU values. Assumin& for the present, that RBCU 
is unaffected by red cell lifespan, it is clear that the 
fraction of EIT used for effective erythropoiesis could be 
estimated by the ratio of RBCUe : RBCU predicted. In other 
words, if this ratio were unity, all erythroid iron turnover 
could be ascribed to iron leaving the plasma pool and being 
used for viable red cell synthesis. If the ratio were less 
than unity, this would indicate ineffective erythropoiesis. 
Expressed mathematically, we may write:-
RBCUe 
RBCUp x EIT (mg/100 ml. w.b./day) = Effective EIT (mg/lOOml. 
W, b, /day) 
and EIT - EEIT will equal IEIT, 
This mathematical expression has been used to compare 
indirectly calculated EEIT values with ferrokinetically derived 
EEIT values, in the same way as EIT/EI values were comp~red 
(see IV-3-j), in an attempt to assess the validity of bis 
assumption in normal patients. Indirect EIT values were 
derived as previously described, EIT and RBCU predicted values 
were derived using the equation given in IV-3-o! When these 
two parameters i.e. (RBCUe x EIT) and (Indirect EEIT) w,?.re 
RBCUp 
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compared with one another, a poor correlation was found 
(r = 0.0719, SEY/x = 0.3086, P = 0.30). This presumably 
reflected the effect, in this group of normal in<livi<lual.s, 
of variations in red cell survival that were not adequately 
51 detected by t! Cr red cell survival measurements. It 
may also have reflected how poorly this equation measures 
changes in effective and ineffective erythropoietic activity. 
One may, however, say that, should this ratio drop considerably 
in the absence of changes in red cell survival, the pro9ortion 
of ineffective erythropoiesis is increased or effective 
erythropoietis is decreased compared to normal patients. 
Mathematically, if we assume that EIT/EEIT remains constant 
(i.e • .:!:_ 1.2 as previously discussed in section IV-3-j) in 
normal individuals, we can solve for (l) using the equation:-
EIT x RBCUe 
RBCUp 
= Hb X 3.4 X 1.2 
([) 
(l) = Hb x 3.4 x 1.2 x RBCUp 
EIT x RBCUe 
Where (l) is red cell lifespan. 
I have shown a reasonably good correlation between RBCU and 
plasma iron levels in my· group of normal individuals and have 
shown that the relationship between these may be used to 
derive an equation for calculating NEIT. (Section IV-3). 
This equation describes a relationship very similar to that 
(164) postulated by Cook. This suggests in our normal group 
of patients, that (l) did not influence the RBCU and that the 
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ratio of EIT/EEIT remained fairly constant. The poor 
correlation between indirectly calculated EEIT and RBCUe/RBCUp 
x EIT values must have been due mainly to changes in (Z) 
which I was unable to detect adequately. In this group of 
patients, Lherefore, a calculation of (Z) by the method 
detailed above may be valid (see later under IV-5-d). 
Not only would increase in ineffective erythropoiesis cause 
a lower plateau level for the RBCU, it would also alter the 
shape of the RBCU Furve. This would occur due to recycling 
of radio-iron from the erythroblast bone marrow pool (during 
erythroblast maturation) to the reticulo-endothelial system 
(RES) as a result of early catabolism, and from there back to 
the plasma. The period of recycling is thought to be 
extremely rapid so that the delay period would depend upon 
the stage of maturation at which intramedullary erythroblast 
destruction took place. This recycled iron might contribute 
significantly to the PIT, and would undergo the same pr~cess 
of uptake by erythroblasts and release into the circulation. 
Eventually, if red cell lifespan were normal, most oft e 
label might appear in the circulation, but the time reqJired 
for this to occur might exceed the duration of the experiment. 
As a result of this phenomenon the RBCU curve would be 
'slurred' to the right, would fail to plateau early and might 
in fact not reach a plateau during the period of observation. 
This is diagrannnatically illustrated in Figure IV-21. 
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Figure IV-21 Diagrannnatic representation of the effects upon the 








(b) ineffective erythropoiesis and 
(c) extramedullary haemolysis. 
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The effect of variable red cell survival upon RBCU. 
Red cell lifespan (Z) may be shortened by a fini te reduction of 
(Z), by random destruction, or by a combir'ation of t heue two 
processes: 
(1) Where red cell survival (Z)is shortened because o= a 
finite reduction in lifespan, all the cells delivered t o the 
circulation would reach senescence before removal. Thus, 
all the cells delivered to the circulation at a particular 
time would, in the theoretical case, be removed from the 
circulation simultaneously after period (Z)in the circulation. 
This function will appear as detailed in Figure IV-22 




No. of Cells 
in 
circulation 
(%) 50 I ,I l . 
25 I 
. 
20 40 60 80 100 120 
days 
In this situation, the influence of (Z) upon RBCU would 
be negligible unless (l) happened to be shorter than the 
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duration of the experiment (i.e. 14 days). The influence 
of (Z) upon EIT would, however, be considerable. In my 
51 
patients, where the fate of Cr labelled red cel ls was 
d . d 1 f 
51 ' . . . h ld b stu ie, a pot o Cr activity against times ou e 
linear (when corrected for elution) since constant numbers 
of labelled cells would die daily. h . h' h 51 Te time at w ic Cr 
disappeared from the circulation should equal (Z). Simple 
as this may seem in theory, in practice it 1s more difficult. 
It is, however, of interest to compare (Z) values derived 
by 51cr measurements and (Z) values derived from our 
previously postulated equation, 
i.e. 
(Z) = Hb x 3.4 x 1.2 x RBCUp 
EIT x RBCUe 
1n normal patients. If we assume that, in these patients, 











These two parameters are compared in Figure IV-23 and 
Table IV-13. 
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Figure IV-23 51 Comparison of (Z) calculated by Cr data and 
by 59Fe data. (see text) 
160 Jj 
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Table IV-13 Comparison of (Z) calculated by 
51Cr 59 data and by Fe 
data. (see text). 
Ferrokinetic 51Cr(Z) EI 
Patient (Z)(days) (days) 
deB 129 89 1.12 
Web 165 127 0.82 
Luk 99 78 1.14 
Cup 27 98 2.00 
Car 58 142 1.85 
Hey 97 113 2.06 
Bot 108 124 1.25 
Rus 102 120 0.99 
Kho 104 100 1.23 
Thy . 103 104 1.05 
Arm 57 82 1.40 
Sch 114 160 1.38 
Bas 78 77 2.55 
Hoo 108 98 1.55 
Cha 64 82 2.54 
Loz 74 84 1.14 
Gog 85 114 1.48 
oCo 258 0.85 
vWy 46 105 1.36 
Pet 226 0.98 
Mgo 168 128 0.88 
Tan 92 104 1.10 
Wes 101 129 1.31 
Nqw 120 130 1.32 
Mar 109 129 1.42 
Ans 70 146 1. 76 
Wil 60 75 1.55 
Pre 49 95 2.27 
Sam 57 115 1.61 
Jeg 54 83 1.87 
Pax 103 120 1.13 
Rob 23 76 2.06 
Tay 84 80 2. 71 
Sch 43 98 1.82 
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From the figures it can be seen that in a number of patients 
correlation was excellent whereas in others it was poor. It 
would seem reasonable to suggest that 1n the latter group, 
the poor correlation was attributable to differences in 
EIT/EEIT ratios. 
(2) Where red cell lifespan is shortened because of 
random haemolysis, each newborn cell has a chance of being 
destroyed early in its lifespan. The chance of n8wborn cells 
being destroyed will depend upon the number of the3e cells 
in the circulation, and because of this, removal oE these 
cells from circulation will be an exponential function of 
time. It is obvious that this will greatly affect RBCUe 
results, both in terms of the height of the plateau and the 
shape of the curve with time. 
(i) Because of a compensatory increase 1n erythro-
poiesis, stress reticulocytes containing radio-iron might 
be released at an earlier stage and in greater numbers 
than normal with the result that the initial phase of 
the RBCU curve would be 'shifted' to the left. 
(ii) As the number of these cells in the circulation 
increased, the number removed by random destruction would 
also increase, so that the amount of circulating radio-
1 
activity would decrease with time in an exponential way. 
Thus, the later ascent of the RBCU curve would be slurred 
and the plateau would be lower. As a result of continued 
red cell destruction the plateau of the RBCU curve would 
not remain flat as it would where all t he rbc's have a 
IV-5-e 
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finite lifespan exceeding the period of the experiment, 
but would fall exponentially. 
(iii) 59Fe released by haemoglobin catabolism would 
be recycled to the plasma via the reticulo-endothelial 
system, and would result in a late rise in RBCU values. 
(3) Where a combination of random cell destruction and 
finite shortening of (Z) is present, the effect upon t he 
RBCU curve and figures would reflect the influence on~y of 
the rand'lm destruction if we assume that finite Cl) e:cceeds 
fourteen days (i.e. the duration of the experiment). 
Influence of variable effective erythropoietic activi-.:y upon 
the RBCU. 
Where EIT 1s decreased because of depressed erythroid bone 
marrow function, the amount of iron taken up by the maturing 
erythroblasts should be less, and because of this less iron label 
would appear in the circulation. Similarly, where e ffective 
erythropoietic activity is increased, the amount of iron label 
taken up by the erythroblasts should be increased, and more 
should enter the peripheral circulation. This should occur 
where no change in (Z)or EIT/EEIT values occur. 
In concluding this theoretical discussion, one can se= that 
any characterisation of the effectiveness of erythrop~iesis 
depending upon the experimentally derived RBCU values must be 
based upon an assumed or proven finite rbc lifE span w·'.1ich exceeds 
IV-5-f 
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the period of the experiment. In addition, one must consider 
the effect of the plasma iron concentration, which we have 
shown to influence experimentally derived RBCU values, and 
the amount of effective erythropoietic activity present. 
I suggest, therefore, that should any value of RBCU be used 
to assess the effectiveness of erythropoiesis, it should be 
the ratio of RBCUe/RBCUp at the plasma iron level of the 
patient being studied. Any assessment based u.pon th,~ 
RBCUe/100 must be incorrect for the reasons given, although 
b f k 
(404) (164) (253) this parameter has been used by a num er o wor ers 
including Cook, who has shown that it should be impos .,ible in 
normal individuals, even if erythropoietic activity i, totally 
effective, for all the injected iron label to enter t i1e 
circulation unless a severe iron deficiency is present (I base 
this upon his equation describing NEIT). Where the ·r atio 
of RBCUe/RBCUp is less than 1, it would seem reasonable to 
assume a decrease in (l) or EEIT. Where this ratio ~xceeds 1, 
it probably represents an increase in EEIT. 
Experimental results to show the influence of various disease 
states upon the RBCU. 
For the theoretical reasons given, any interpretation of RBCU 
curves is hampered by the variables already discussed. I have 
described a 'normal' RBCU response to changes in plasma iron 
concentration. (Figure IV-14, Section IV-3-d). It r~mains to 
describe the influence of different disease processes upon 
this parameter. I have used the same groups of pati~nts 
previously described, i.e. the hyperplastic, hypoplastic and 
normal groups of patients. The results are shown in 
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Figures IV-24 and IV-25. Comparison of the data tends to 
confirm theoretically predicted results. RBCUe values tend 
to be lower than normal at similar plasma iron concentrations 
in all disease states except for fully compensated haemolytic 
states where (Z) is probably finite. 
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patients with hyperplastic erythropoiesis and patients 
with hypoplastic erythropoiesis. 
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Figure IV-25: Comparison o~ t(max) for RBCUe values in normal 
patients, patients with hypoplastic erythropoiesis, 
and patients with hyperplastic erythropoiesis. The 
patients with hyperplastic erythropoiesis have been 
subdivided into two groups, those thought to have 
principally intramedullary haemolysis and those thought 
to have mainly extramedullary haemolysis. 
Hyperplastic Hyperplastic 
Hypoplastic Nonnal 
Intramedullar Extra Hedullar) 
• • • ••• 
•• • • • •• • • 
••• ••••••• 
• • • • •• • ••• • • • • •••• • • • • •• • • • •• • • • 
• 
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The time required for RBCU values to reach maximum height 
in normal subjects, varied between 6.0 and 12.0 days, with 
a mean of 9.2 and a standard deviation of 1.6 days. This 
time interval tended to be slightly shorter in extra-
medullary haemolytic states, longer in intra-medullary 
haemolytic states, and probably unchanged in hypoplastic 
states (see Figure IV-25 and Table IV-14). It was 
decided not to use ferrokinetic criteria in deciding 
whether patients had predominantly extra or int:ramedullary 
haemolysis, but rather to choose, as representative of 
intramedullary haemolysis, those patients with disease processes 
known to be associated with an increase in this phenomenon 
(see III-b-7). 
in Table IV-14. 
These results are sunnnarised statistically 
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Table IV-14 Comparison oft max. RBCU values between different 
groups of patients with variable erythropoietic activity. 
X 
Group t(max) 
RBCU SD p 
1. Normals 9.2 1.6 
2. Hypoplastic 7.6 2.8 < .15 
3. Hyperplastic 
a) Effective 7.2 1.6 < .0005 





The method that I have used for external counting is detailed 
in the methods appendix. Due to pressure upon equipment, 
not all patients had external counting performed, apart from 
a group of patients I studied while trying to describe bone 
marrow iron uptake. h . . b h 59 Aste patients were getting ot Fe 
51 and Cr, I attempted initially to externally count both 
isotopes. 51 To a large extent, I was unhappy with my Cr 
results, mainly because I was unable to obtain statistically 
s·atisfactory count rates in the short period of time at my 
disposal for each individual patient. With the 59Fe data 
however, the statistics were very good, and this is reflected 
in the curves obtained. My main interest in organ counting 
has been in bone marrow counting, in an attempt to describe 
the uptake of iron label by this organ. 
have been detailed in the appendix. 
The results of this 
It would be of doubtful value to attempt to draw any valid 
conclusion from my small experience with external counting. 
As has been the experience of other authors however, I 
59 have found Fe a useful label for detecting eJ:tramedullary 
haemopoiesis, splenic sequestration of red cells, and 
hypoplastic bone marrow function( 4o4)(686)(689 ) and have 
found it to be better than 51cr as an internal label for 
external counting in measuring these phenomena. 
CHAPTER V ASSESSMENT OF FEEDBACK, UTILiSING THE 
HADDINGHAM-FRENCH MODEL FOR THE 
MEASUREMENT OF INEFFECTIVE ERYTHROPOIESIS 
AND EARLY RANDOM RED CELL DESTRUCTION. 
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V-1 The theory and generation of this model are given in 
appendix B. 
A total of 101 patients were studied by this method. 
Included in this group were patients who were assessed 
as being haematologically normal, whose only haematological 
abnormality, as far as could be assessed by us, was a 
restriction of iron supply and a number of patients with 
a variety of haematological disorders. 
In an attempt to assess whether feedback, as measured by 
us, was related in any way to other ferrokinetic values 
(i.e. plasma iron concentration, t! plasma iron clearance, 
erythroid iron turnover, erythropoietic index or red cell 
utilisation values), the data for each individual patient 
for feedback was plotted against each of these valu,~s, and 
a correlation looked for. The results are presented 
graphi cally in Figures V-1 to V-5, and the compounded data 
for each patient are tabulated in Table V-1. 
Figure V-1 Graphical representation of the comparison between 
iron/100 ml. whole blood and feedback values in 
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Graphical representation of the comparison between 
ti Plasma Iron Clearance and feedback values in 
individual patients with different disease states. 
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Graphical representation of the comparison between 
erythroid iron turnover and feedback values in 
individual patients in different disease states. 
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Graphical representation of the comparison between 
Red Cell utilisation and feedback values in individual 
patients in different disease states. 
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Table V-1 Tabulated valueu for ferrokinetic parameters and feedback 
values in individual patients with varying disease states. 
*=Plasma Iron Concentration ( µgms%) 
+ = Haematocrit 
** = Erythroid Iron Turnover in mgms / 100 ml. whole blood/day. 
Patient PI* Hct + t!PIC EI EIT** RBCU f 
(mins) (%) 
Jan 44 66 83 0.00 
Fis 42 65 96 o.oo 
Ase 44 45 72 o.oo 
Lou 172 47 84 1.42 o. 8272 99 o.oo 
deB 62 43 60 1.12 0.4934 84 0.19 
Key 165 41 102 1.22 0.6478 51 o.oo 
Joh 138 37 120 0.95 0.4381 37 0.04 
Mte 132 30 29 4.06 2. 9610 22 o.oo 
Eng 100 32 188 0.51 0.1284 50 0.07 
Kot 234 33 19 9.29 8.0064 27 0.11 
McN 204 62 78 1.42 0.8168 70 0.08 
Web 88 52 91 0.82 0. 3Lf38 99 0.37 
Smi 89 37 79 1.09 0.5376 70 0.14 
Luk 209 38 134 1.14 0.5387 49 0.20 
Jae 146 37 26 4.78 3.6793 32 0.22 
Cup 113 30 53 2.00 1. 2573 82 0.32 
Car 53 38 35 1. 85 0.2997 82 0.12 
vNi 152 26 62 2.18 1.4604 41 0.04 
Hey 64 64 28 2.06 0.8478 85 o.oo 
Col 180 48 34 3.59 2. 7761 10 o.oo 
Bas 9 23 16 2.55 o. 4271 95 0.14 
Cha 19 36 18 2.54 0.6817 97 0.13 
Sil 55 30 30 2.31 1.1792 79 0.00 
Loz 9 36 34 1.17 0.1529 88 o.oo 
Gog 196 46 90 1.48 0.8605 48 0.15 
Pep 294 34 433 0.49 0.0000 9 0.00 
Lam 274 37 126 1.52 0.8018 54 0.00 
vWy 137 34 86 1.36 o. 7703 82 0.14 
Pet 29 42 51 0.98 0.2853 92 0.27 
Mag 163 46 133 0.88 0.3805 66 0.36 
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Table V-1 contd. 
Patient PI* Hct + t!PIC EI EIT** RBCU f 
(mins) (%) 
Tan 101 40 82 1.10 0.5579 96 0.15 
Ser 217 37 140 1.14 0.5229 31 0.48 
Nqw 206 49 101 1.32 0.7298 45 0.18 
Wal 95 25 28 3.51 2.3379 18 0.00 
Lou 85 36 44 1.91 1.1019 77 0.17 
Han 71 25 17 4.84 3.0823 56 0.04 
duT 284 31 249 0.85 0.1044 15 0.34 
Ans 32 38 · 30 1. 76 0.6303 100 0.03 
Wil 22 33 31 1.55 0.4343 94 0.00 
Pre 86 47 34 2.27 1.2565 90 0.33 
Bog 86 18 40 2.43 1.5250 93 o.oo 
Sam 123 44 61 1.61 0.9439 87 o.oo 
Br o 104 28 41 2.48 1.6175 69 o.oo 
Gre 133 32 88 1.32 0.7404 27 0.23 
Ri x 16 16 20 2.33 0.6484 70 0.00 
Swa 92 28 20 4. 71 3.1422 23 o.oo 
Ash 64 35 llO 0.66 0.2428 75 0.27 
J ae 174 25 24 6.30 5.1842 27 0.30 
vNi 212 38 57 2. 71 1.9578 18 o.oo 
Bow 177 40 94 1.40 0.7998 80 o.oo 
Seo 153 27 63 2.14 1. 4316 51 0.41 
Jeg 45 35 33 1.86 0.8289 92 0.03 
Pax 41 29 54 1.13 0.4567 73 o.oo 
Hoe 65 40 19 3. 71 1.9847 47 0.07 
Sav 71 44 25 2.86 1.5425 63 O. ll 
Ahr 123 39 82 1.26 0.6858 72 0.14 
Cha 51 37 57 1.12 0.4724 81 0.35 
Jan 96 24 29 3.44 2.2912 45 0.53 
Sal 70 23 71 1.17 0.5874 96 o.oo 
vNi 59 38 22 3.09 1.6259 100 0.05 
Lif 81 29 77 1.12 0.5634 65 o.oo 
Fer 46 35 33 1. 87 0.8505 21 0.00 . 
Ste 167 30 38 3.68 2. 7255 60 o.oo 
vdM 25 31 22 2.28 o. 7572 60 o.oo 
Kna 17 35 16 2.79 0.6800 60 0.30 
1.).) 
Table V-1 contd. 
Patient PI* Hct+ t!PIC EI . EIT** RBCU f 
(mins) (%) 
Tay 26 54 17 2. 71 0.7238 66 0.40 
Ngo 187 45 120 1.08 0.5296 98 0.27 
Wil 44 30 34 1.84 0.8254 93 0.00 
Sch 33 26 31 1.82 o. 7273 89 o.oo 
Ber 377 18 86 3.59 2.5739 8 0.20 
deV 196 44 84 1.62 o. 9835 25 0.19 
leG 102 57 77 1.00 0.4620 100 o. 24 
Gor 187 44 94 1.40 0.7956 82 0.53 
These figures show that there is no apparent correlation between 
feedback values, in this heterogenous group of patients: and 
any of the ferrokinetic data. The value for 'feedback' 
presumably measures some aspect of bone marrow function 
not measured by other ferrokinetic techniques. 
Having shown that the feedback values of an individual v.'as 
an independent measure of some function other than those. 
measured by conventional ferrokinetic values, an attempt 
was made to assess the use of feedback results in des-
cribing or typifying different disease states. In the 
review section, I have reviewed conditions known to be 
associated with ineffective erythropoiesis (see chapter 
III-b-7). One would expect, from our des cription of the 
model, that diseases associated with a major degree of 
ineffective erythropoiesis or with early random r ed cel l 
destruction, would be typified by high feedb ack values. 
The patients detailed in Table V-1 were accordingly 
split into their broad disease groups, and feedback values 
of the groups as a whole were analysed statistically. The 
results are shown in Table V-2. The groups described are 
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Table V-2 Feedback Results in different disease states. 
Disease Group Feedback Values 
Mean SD NO p 
1) Normal 0.11 0.22 14 
2) Normal excluding S. P. 0.08 0.12 9 < .35 
3) Haemolytic Anaemias 0.09 0.11 29 < .40 
a)Thallassaemia 0.26 0.06 2 < .05 
b) Hereditary Spherocytosis 0.17 0.17 3 < .35 
c) + A.LR.A's 0.05 0.10 5 < • 25 
d) Iron Deficiency 0.09 0.07 7 < .40 
e) Myeloproliferative 0.05 0.07 8 < .20 
4) *Aplastic 
a) 0.09 0.13 6 < .45 
b) 0.18 0.15 14 < .20 
5) ** Iron Deficiency 
a) 0.13 0.15 8 < .45 
b) 
c) 0.06 0.07 14 < .25 
d) 0.13 0.14 12 < .40 
6) Myelofibrosis 0.09 0.11 10 < .40 
7) Reticuloses 0.12 0.22 10 < .475 
8) Infection 0.11 0.14 11 < .499 
9) Inflanunation 0.08 0.09 8 < .35 
10) Cirrhosis 0.20 0.14 10 < .15 
11) ++Meg.Anaemias 0.17 0.20 7 < .30 
12) Symptomatic Prophyrics 0.14 0.13 12 < .35 
13) Neoplasms 0.20 0.22 5 < .15 
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described separately under the individual disease groups. 
Table V-2 Feedback Results in different disease states. 
+ AIHA = Auto Immune Haemolytic Anaemias 
++Meg.Anaemias= Megaloblastic Anaemias 
* Aplastics (a) = Clinically diagnosed true aplastic anaemias 
(b) = Ferrokinetically diagnosed aplastic anaemias 
or presumptive clinically diagnosed 
patients in whom the diagnosis was not 
later confirmed. 
** Iron deficiency (see Chapter VI-f-1) 
(a) = Classical Iron deficiency anaemias 
(b) = Iron deficiency unassoci ated with anaemia 
(c) = Patients with plasma iron levels 
( <70µg%) behaving ferrokinetically in 
the same way as group (a) 
(d) = Patients with low plasma iron levels 
( <70µg%) behaving suboptimally on 
ferrokinetic assessment. 
Table V-2 shows that feedback values are of no real use 
as a basis for distinguishing different diagnostic 
categories of haematological diseases. The only disease 
state with consistently elevated feedback values was 
thalassaemia, a disorder known to be associated with 
. . (815)(370) 
excessive ineffective erythropoietic activity. 
(258)(289)(724)(854)(504)(657)(232). 
It seemed, therefore, that analysis of ferrokinetic data 
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by this method might have functional rather than nosological 
value. I accordingly examined in detail the clinical records 
of each individual patient and discovered that in 48 pat i ents 
with feedback value greater than 0.05, all but 5 had some 
f actor that could be incriminated as a cause of ineffecti ve 
erythropoietic activity or early random red cell destruct ion. 
The details of these patients are set out in Table V-3. 
As can be seen, a number of the patients had conditions 
known to be associated with ineffective erythropoietic 
activity. The majority of the remaining patients admitted 
to alcohol abuse, many having cirrhosis or siderosis. 
H
. (386)(387) (135) ines and Chanarin have shown how rapidly 
ethanol impairs bone marrow folate metabolism, depresses 
effective erythroid activity, and promotes ineffective 
erythropoiesis. Twenty-three of the patients studied had 
RBCUe/RBCUp ratios of less than 0.9 (normal 1.11 + 0.27) 
of which nineteen were less than 0.85. The value of this 
ratio (Chapter IV-5-a) in attempting to analyse ineffective 
erythropoietic activity has previously been discu s sed. In 
51 
this total group of patients (48), only six had t 1 Cr red cell 
2 
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survival values of less than 22 days (normal me an - 1.SD) 
showing that haemolysis had not materially contributed to the 
overall feedback values or the depression of RBCUe values. A 
further five patient~ had hypoplastic erythropoiesis as 
assessed by EI values of less than one (i.e . normal mean - l.SD) 
making a total of eleven patients in whom the depressed RBCUe 
values can be explained by mechanisms other than ine ffe c tive 
erythropoiesis. 
It is interesting that some of the patients, despite elevated 
f eedback values, had RBCUe values above RBCUp values. Mos t 
of these patients were alcoholics who had been hospitali sed 
and put on haematinic therapy, with consequent improved "RBCUe 
values occurring later in the course of their investigations 
r eflecting a response to withdrawal of a toxic agent and marrow 
stimulation. 
The pa tients with feedback values of less than 0 .05 were also 
examined in an attempt to assess whether patients with ine ffe c tive 
erythropoiesis or random early red cell destruction were not 
being detected using this technique. Fifty-one pa t ients were 
studied. Of these, thirty-two had increased total e rythropoietic 
activity as ~ssesHed by an erythropoietic index exceeding 1.50 
(mean normal+ 1 S.D.) 
51 
Eighteen of these thirty-two patients had t 1Cr red cell 
2 
survival values of less than twenty-two days (mean normc.l 
l.S.D.). In these patients, feedback may not have been c'.etected 
because of a shift of the RBCU curve to the left (see 
discussion under section IV-5-d), and in fact three of the se 
eighteen patients had E.l. values disproportionately r aised 
relative to the degree of shortening of their red cell Hurvival 
51 
as measured by t 1 Cr signifying the probable existance of 
2 
significant I.E.I.T. 
Ten of the thirty-two patients remained who had E.l. value s 
above 1.5, whose t 1
51cr survival was normal. This E.l. could 
2 
only be explained as a consequence of increased ineffective 
erythropoiesis or increased effective erythropoiesis. Two 
of these ten patients did not have t 1
51cr measurements, but 
2 
in one of these the E.l. was only marginally elevated (1.83) 
and the haematocrit was raised (54%). The other patient was 
cirrhotic, had porto systemic encephalopathy, and in addition 
a low folate level. This patient probably had incr eased 
ineffective erythropoiesis that was not detected using this 
feedback model . 
Of the remaining eight patients only three had RBCUe/RBCUp 
ratios of less than 0.84 (mean nortnal - l.S.D.) suggesting 
that in five of the eight the increased E.l reflec ted an 
increase in ef f ective erythropoietic activity. Two of tt e se 
patients were polycythaemic and three were iron de ficien t 
on treatment with oral iron. 
In the remaining three patients the increased E.l. value in 
combination with the decreased RBCUe/RBCUp ratio probably 
signified an increase in ineffective erythropoietic activity 
that was not detected by this feedback model. The low RBCUe 
values in these three patients (18%, 21% and 8%) may have 
made interpretation of their RBCU curves more difficult. 
l~ l 
Table V-3 Individual patients and their feedback values. 
Association with disease states or toxins producing 
ineffective erythropoiesis or random early red cell 
destruction. 
Group Diagnosis f EIT RBCUe/RBCUp 
51 t 1 Cr Ethanol Other 
Normal Bot:Ethanol 0.10 
Maj:Cirrhosis 0.36 
deB : E thano 1 0.19 
Cor: S .Porph 0.33 
Hol: S .Porph 0.14 
Len: S.Porph 0.28 
Sol: S.Porph 0.06 
Thy: S.Porph 0.11 
Tan: Diabetes 0.15 
Haemolysis 
Jae: Thall 0.22 
Jae: Thall 0.30 
Lou:Her.Sf,hero 0.17 
Pre:Her.Ovalo 0.33 
Ngo: G6PD def. 0.27 
Gre: AIHA 0.23 
Saa:TB spleen 0.17 
Bas:Fe def 0.14 






Fe+ = Iron deficiency. 
























AIHA = Auto-immune haemolytic anaemia 
~ 
0.91 28 + 
0.96 + 
0.93 20 + Fe+ 
o.51 34 + 
1.35 + 
1.67 + 
0.98 28 + 
1.02 24 + 
1. 20 Nil 
0.48 15 Thall 
0.49 11 Thall 
0.93 19 Hypersple 
1.05 22 Nil 
1.53 22 + 
0.39 22 + 
1.09 25 Fe def. 
0.95 17 Fe def. 
0.98 18 + Fe def. 
o. 72 17 + Folate + 
0.35 14 + 
0.61 15 + Sidero-
blastic 
anaemia 
0.91 18 + 
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Table V-3 contd. 
Group Diagnosis f EIT RBCUe/RBCUp 51 t! Cr Ethanol Other 
Hypoplastic 
duT:Apl.Anaemia0.34 0.1044 0.50 38 + Oxymethal· 
one 
vWy:Ca Breast 0.14 0.7703 1.19 24 BM infil-
tration 
Prednisom 
Ash:CLL 0.27 0.2428 o. 85 27 + BM infil-
tration 
Hypersplet 
Web:P.vera 0.37 0.3438 1.14 29 Cytotoxic 
therapy 
Vlo:Reiter's 
Syndrome 0.16 0.3699 0.89 Nil 
Koe:Buergers 0.08 0.3057 0.84 30 + 
Pet: CVA COAD 0.27 0.2853 0.95 + 






Eng: S. Porph 0.07 0.1284 0.64 + 
Sco:Cirrhosis 0.44 1.4316 0.82 + Folatet 
Fe Def. Kna:My.Fibrosis0.30 0.6800 0.61 27 Fe def. 
Tay:Polycyth. 0.40 o. 7238 0.67 34 + Cy to toxics 
Car:jskull 0.12 0.2997 0.90 32 + Chloro-
mycetin 
Hoe:SLE 0.07 1. 9847 0.53 26 + AIHA 
Rus:Cirrhosis 6.30 0.3974 1.09 + Folate 
Cha:S.porph 0.35 0.4724 0.89 30 + Cirrhosis 
Myelo- deV: 0.19 0.9835 0.41 30 Nil 
fibrosis 
Smi 0.14 0.5376 0.85 26 Nil 
Sidero- Bot:Sidero ' 
blastic Achrestic 0.69 0.8042 0.40 Nil 
Anaemia 
Ber: II 0.20 2.5739 8.00 + 
Megalo-
Jan: Intest. blastic 
Lipoma 0.53 2.2912 0.59 24 Bl2 def. anaemia 
Others Ser:Myeloma 0.48 0.5229 0.60 27 + Cytotoxics 
'f = Fracture ,. 
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Table V-3 contd. 
Group 
Other 
Diagnosis f EIT RBCUe/RBCUp 
51 t 1 Cr Ethanol Other 
2 
LeG:Good 
pastures 0.24 0.4620 1.16 36 
vNi:Ulc. 
colitis 0.05 1.6259 1.11 15 
From Table V-3 it can be seen that, in each patient with 




reason to suspect that ineffective erythropoiesi s or random 
red cell destruction was present. In many cases this was 
not shown by other methods of analysis. 
Obviously, if we were able to predict normal RBCUe values 
on the basis of plasma iron levels and variations of 
erythropoietic activity, as discussed in appendix B, 
feedback analysis would be more quantitative. I t does seem, 
however, to give a measure of abnormal erythropoietic 
activity, in individual patients, that can be roughly 
quantitated, and used as an index of early erythroblast 
or erythrocyte destruction. This is basical ly what I have 
attempted to obtain, and I suggest that this analytica.l 
technique .is of some use in its present form. Should ~e 
be able to develop the model further, as previously stated, 
this should be not only an indicator, but also a quantitator 
of early erythroid destruction. Present methods of assessing 
ineffective erythropoietic activity are to a large extent 
unsatisfactory. This model may be of use in the quantitation 
of this phenomenon. 
CHAPTER VI AN EMPIRICAL APPROACH TO THE ANALYSIS 
OF FERROKINETIC DATA IN NORMAL PATIENTS 






The aim of this chapter is to define empirically 
the ferrokinetic performance of different disease groups. 
A total of one hundred and sixty patients have been 
studied, some of whom had more than one disorder. Those 
with multiple diagnoses have either been included only 
in that group corresponding to the major diagnoses, or 
they have been categorised under more than one disease 
process. All the ferrokinetic parameters have been 
statistically compared with those of normal individuals 
as described in Vl-b. 
Normal subjects. 
Definition: 
Subjects in this category were judged, on clinical grounds, 
to be haematologically normal. This group of pati ents is 
not identical to those referred to in Chapter III, as iron 
deficient patients were not included. Apart from ward 
patients, a number of ambulant volunteers were s t udied. 
The haematological criteria of normality used wer e those 
d 'b db . b (S
97 ) d T bl VI 1 escri e y Wintro e, an set out in a e - . 
Where all of these basic haematological parameter s were not 
available, the patient was accepted as being nonnal if the 
haemoglobin, haematocrit, white cell count and peripheral 
smear were normal. Patients with Symptomatic Porphyria 
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were included as we have previously shown that tneir fe..rrokinetic 
performance is normal. (z74 ) 
The collective results of this group of patients can be.. seen 
in Table VI-2. For purposes of analysis, it is obvious that 
there were inadequate numbers of normal female patient~ to 
draw any definite conclusions from our ferrokinetic findings 
166 
1n this group. For this reason the total group of patient s 
has been used to define statistical criteria for ferro-
kinetic normality. Only the erythropoietic index and 
the ratio of experimentally derived to predicted red cell 
utilisation figures were influenced by the plasma iron 
concentration. 
Table VI-1 V 1 
(Wintrobe 897) 
Normal Haematological a ues. 
Male Female 
1. Haemoglobin (Gm.%) 16 + 2 · 14 + 2 
2. Haematocrit (%) 47 + 5 42 + 5 
3. Mean Corpuscular Volume (c.u.) 87 + 5 87 + 7 
4. Mean Corpuscular 
Haemoglobin Concentration(%) 34 + 2 34 + 2 
5. White Cell Count (cells/mm
3) 7.8+3.0xlO 3 7.8 + 3.0 X 103 
6. Normal Peripheral smear 




1. Blood volume estimation:-
These are cxpresscJ on a volume per unit body weight basis 
(i.e. ml/kg.) That this is not an ideal way of comparing 
blood volume in different individuals is weD~known and 
167 
been · l d' 
d (16)(291)(417)(827)(712) 
the problem has extensive y iscusse. 
(676)(439)(634). 
For the purpose of a routine laboratory service however, 
the reporting of blood volumes in relation to body weight 
has the advantage of being easily understood and interpreted 
by physicians requesting the estimations, and is the most 
simple way of reporting the blood volumes comparatively. For 
these reasons I have chosen to adhere to this convention . 
My results are tabulated in Table VI-2, and, in general, 
. . (797)(696)(856) 
show reasonable agreement with published values 
(872)(55)(320)(271)(763)(272)(289)(815)(415)(74) . i.e. red cell 
volume 26.6 _:!: 5.1 ml/kg. plasma volume 40.9 + 7.0 ml/kg. 
total blood volume 67.8 + 10.3 ml/kg. 
Of interest to me was the relationship between body haematocrit, 
calculated as red cell volume x 100, and the venous haematocrit. 
total blood volume 
This value has been variously published as being 0.864 to 0.96, 




(512)(856)(253)(317)(86)(439)(534) Th' t' · b · 1 is r.a io is o vious y 
of some importance in ferrokinetic calculations, as the 
correction factor for the venous haematocrit in order to 
reduce it to body haematocrit values is introduced intc calculations 
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Jf PIT, NEIT and EIT. I have used the correction factor 
(164) 
suggested by Cook. Obviously, this correction factor 
1.s not absolute, and will vary with the method used in calculating 
the various volumes, as well as in different disease states, 
particularly the "big spleen" syndromes where red cell rich 
blood appears to be sequestered. For routine purposes it 
would seem reasonable to use a constant correction factor in 
order to eliminate errors that may be introduced when measuring 
the various volllllles. In fact, this procedure may not be 
justified, as individual values may vary fairly widely. 
In my subjects I have found that the mean ratio of body to 
venous haematocrit is 0.85 ~ 0.09, which agrees reasonably well 
with published values when plasma volume is measured by the 
59F f . h. e trans err1.n tee n1.que. 
VI-b-4 
VI-b-5 
2. Plasma Iron, Total Iron Binding Capaci ty and Percentage 
Saturation of Transferrin Values in Normal Patients. 
The results in my normal group of patients are undoubtedly 
influenced by the inclusion of patients with symp t omatic 
porphyria. These patients are known to be generally iron 
overloaded. (
344)(49 I) My mean figures in this group 




The values that I have obtained are:-
Plasma Iron Concentration:- 111.1 .:!:_ 40.7 µg% 
Total Iron Binding Capacity 277.5,::. 61.3 µg% 
Percentage Tr ansferrin Saturation 42 . 3 + 21.1% 
3. Ferrokinetic measurements. 
Ferrokinetic data from normal individuals are summarised 
in Table VI-3. 
These show a certain amount of variab i lity due to 
inter ali a, vari ation in plasma iron concentration, 
intr i ns ic bio logical variation, and technical sotrces of 
error. 
Comparison of my values with published values shows good 
agreement. (872)(521)(164)(107)(735)(80)(863)(673) 
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TABLE VI-2 COMPOSITE FERROKINETIC FINDINGS IN NORMAL PATIENTS. 
(days) NAME DIAGNOSIS Hb PCV B.PCV Bl.Vol RBC Pl. P.I. % Sat t! EI PIT NEIT EIT RBCUe RBCUe t! f P.PCV Vol, Vol, RBCUp G% % ml/kg ml/kg mg% (fuilis) % 51Cr 
Bot Transient CVA 17.2 51 0.79 64.5 26.1 38.4 114 58 70 1.24 • 8644 .2118 .6527 75 0.91 28 0.10 Bot Myoc,Infarct, 17.9 47 0.74 68.8 23.9 44.9 55 24 86 0,72 .3604 .1085 .2519 
era c.v.A 17.6 51 0.93 78.9 37.6 41.3 175 41 130 0.89 • 7145 .3251 .3894 
deV? Stress Polycyth. 18.0 52 0.85 63.7 28.0 35.7 84 21 60 1. 21 • 7138 .1506 .5631 
deV Rec.peptic ulcer 15.3 43 o. 77 64.9 21.6 li3.3 64 18 46 1. 48 • 8501 .1354 • 7148 
Isa Myoc. infarct. 16.8 45 0.80 64.0 23.0 41.0 120 - 69 1. 39 • 8517 .2051 .6466 
Mag Conval.TB Men. 16.1 46 0.90 65.6 27.1 38.5 163 90 133 0.87 .7096 .3291 .3805 66 0.96 - 0.36 Mar Epilepsy 15.9 48 0,71 60.2 20,4 39.8 60 - 124 0.51 .4518 .1954 .2564 
Moo COAD 17.6 50 0.86 60.6 26.1 34.5 80 24 79 0.91 .5468 .1512 .3956 
Nor Polycystic kidneys 16.4 47 0.87 57.2 23.5 33. 7 112 - 64 1. 40 , 9933 • 2225 • 7708 
Smi Myoc. infarct. 18.0 50 0.73 55.0 20.0 35.0 101 36 68 1.20 • 8009 , 1909 .6100 
Sep COAD 16.5 47 0.78 70.3 25.9 44.9 67 26 83 0,81 .4582 .1331 .3251 
Sch Normal 18.0 48 0.83 55.0 22.0 33.0 94 31 73 1.10· • 7143 .1825 .5318 
Vyw COAD 17.1 47 0.83 60,7 23.8 36.9 99 41 86 0.97 .6526 .1967 .4560 
Jan Conval. Fracture 15.2 44 0,98 67.5 29.3 38.2 - - 66 - - - - 83 - 35 0.00 
Fis Conval. Fracture 14.1 42 0.97 66.0 27.0 39.0 - - 65 - - - - 96 - 27 o.oo 
Ase Conval. Fracture 15.2 44 0,81 74.0 26.0 48.0 - - 45 - - - - 72 - 22 o.oo 
Lou Normal 16.5 47 0.96 72.6 32.5 t.0.1 172 58 84 1.421.1716 .8272 .3445 99 1.46 25 o.oo 
deB Normal 15.6 43 0.91 73.5 28. 8 li4. 7 62 22 60 1.12 • 6245 .4934 .1312 84 0.93 20 0.19 
Cor Symp. Porphyric 15.3 46 0.91 59.5 25.0 34.5 123 36 73 1.32 .9719 • 7236 .2483 40 0.51 34 0.33 
Hol Symp. Porphyric 15,6 44 0.95 85.8 35.8 50.0 139 54 110 0.97 .7521 .4626 .2896 100 1.35 - 0.14 
Len Symp. Porphyric 14.7 46 0.94 93.2 4o.5 52.7 264 96 130 1.2811713 .6384 .5330 80 1.67 - 0.28 
Sol Symp. Porphyric 14.7 47 0.90 56.0 23.7 32.3 88 33 130 0.60 .3842 .2094 .1748 83 0.98 28 0.06 
Sam Symp. Porphyric 16.1 44 0.84 68.9 25. 4 '•3. 5 123 43 61 1.61 1.2002 .9439 .2562 87 1.13 26 o.oo 
Thy Symp. Porphyric 18.6 51 0.94 54.0 26.0 28.0 189 63 72 1.69 13934 L0422 .3511 79 1.18 - 0.00 
Thy Symp. Porphyric 14.7 44 0.83 90.8 33.0 57.8 105 57 85 1.04 .7352 .5165 .2187 83 1.02 24 0.11 
Mal Vestib. Neuronitis 17.3 50 0.76 63.5 24.0 39.5 59 24 62 1.00 • 5147 .1115 .4032 
Hof Normal 15.6 45 0.61 76.3 21.0 55.3 151 69 98 1.14 • 9052 .3092 .5960 
Kho c.v.A. 15.6 45 74.1 26.8 37.3 55 24 51 1.22 • 6320 .1128 .5192 99 1.08 
Tan Diabetes 14.5 40 57.3 20.7 36.6 101 36 82 1.10 • 7813 • 2234 .5579 96 1.20 0.15 
Arm Normal 12.6 38 80.3 31.4 48.9 92 32 62 1. 39 • 9651 .2094 .7557 90 1.10 
MEAN 0.85 67.8 26.6 40.6 111.142. 3 80.9 1.13 .7816 .3415 .4401 83 1.1054 27~0 0.11 
S.D 0.09 10.3 5.1 7.0 40. 7 21 .1 25. 7 0. 29 • 2554 .2653 .1821 15 .2741 4.7 0.22 CVA = Cerebrovascular accident 
Myoc. Infarct= Myocardial Infarction 
COAD= Chronic obstructive airways disease 
Units for PIT, NEIT, EIT = mg/100 ml. whole blood/day. 
171 
Table VI-3 Normal Ferrokinetic Values. 
Abbreviation Mean S.D. Units 
(t~PIC t 1Plasma Iron Clearance 80.9 25.7 Minutes 
2 
(E. I.) Erythropoietic Index 1.13 0.29 
(P. I. T.) Plasma Iron Turnover 0.78 0.2 mg/100 ml. whole 
blood/day 
(NEIT) Non Erythroid Iron 
Turnover 0.34 0.27 mg/100 ml. whole 
blood/day 
(EIT) Erythroid Iron Turnover 0.44 0.18 mg/ 100 ml. whole 
blood/day 
(RBCUe) Experimental Red Cell 
Utilisation 83 15 percent of 
59Fe administered 
(RBCUe/RBCUp) Ratio Experimental to 
VI-b-6 
VI-b-7 
Pred i cted RBCU 1.11 0.27 
(a) t! Plasma Iron Clearance:- (t!PIC) 
Most authors(872)(521)(164)(107)(735)(80)(863)(673) 
give normal values for this variable ranging from sixty 
. . (872) f h d d d to ninety minutes to seventy- our to one un re an 
. . (673) sixteen minutes. 
This range of normal values presumably reflects differences 
in the iron status of the different population groups used as 
controls. The value s still correlate well with mine i.e. 80.9 + 25.7 
minutes. 
(b) The Erythropoietic Index. 
This index as discussed earlier (Chapter III) reflects the 
effects of total erythropoietic activity, independent of plasma 
:i:r~ concentration, upon the t!P .. 1.,C, I have previously shown 
it to be a fairly reliable index of total erythropoietic 
VI-b-8 
VI-b-9 
function, and the narrow limits of normality found in 
this study show how useful it's measurement in detecting 
variations in total erythropoietic activity. is. 
(C) The Plasma Iron Turnover (PIT) 
This, as previously discussed, measures the sum of 
erythroid and non-erythroid iron turnover without 
discrimination. For this reason it would appear not to 
be as useful as the erythroid iron turnover in describing 
total erythropoietic activity. My figures agree fairly 
closely with normal values published by a number of 
th (872)(107)(673)(80)(164). au ors. _ 
(d) Non Erythroid Iron Turnover (NEIT) 
Calcualtion of the NEIT has recently been introduced into 
the ferrokinetic assessment of an individual patient by 
Cook. (1 64 ) As previously described (Chapter III) we have 
derived similar equations to describe this valuation. It 
would appear that it is almost totally dependent upon 
variations in plasma iron concentration, but, as with most 
biological measurements, there is probably a fair amount 
of normal individual variation. This is probably greate)~ 
in different disease states. It also appears reasonable 
J. / L 
to postulate some deviation from linearity in the relationship 
between plasma iron concentration and NEIT at extremes of 
plasma iron concentrations. At extremely iow plasma iron 
concentrations one would, as previously discussed, expec t 
no NEIT. At very high plasma iron concentrations one would 
expect NEIT to be limited by the rate at which cellular 
mechanisms handling NEI uptake can occur. 
In the range of plasma iron concentrations normally seen, 
the effect of this variation should be minimal. I have some 
reservations however about applying this linear relationship 
to some of the disease states, particularly the aplastic 
anaemias. As a general measurement however, this function 
probably approximates reasonably closely the situation found 
in the body, and because of this, is useful in calculating 
erythroid iron turnover values. 
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VI-b-lO{e) Erythroid Iron Turnover (EIT) 
VI-b-11 
VI-b-12 
This appears to be an excellent measure of total erythropoietic 
activity with a narrow range for normal patients. My values for 
(164) normal EIT agree fairly well with those of Cook, although 
the range quoted by him is far smaller than I have f~und. This 
presumably reflects better patient selection and suggests 
that my range of normality is too large. 
{f) The Red Cell Utilisation (RBCUe) 
My values for RBCUe agree well with published values< 164)(B72 ) 
(107)(815)(443)(673)(211)(74) 'th 1· htl w1. a s 1.g y greate·r range 
than in most series. Again this presumably reflects differences 
in patient selection. I believe that the RBCU i~ in normal 
individuals , markedly dependent upon variations in plasma 
iron concentration, and believe that the ratio of observed 
RBCU values, when compared with predicted RBCU values (as 
previously described) eliminates errors due to variable plasma 
iron levels. The values found are tabulated 1.n Table VI-3. 
4. Red Cell Survival Measurement. 
As detailed under methods, I have used a least squares fit 
51 for Cr data as a function of time, plotted on semi l og paper. 
51 In this way I have calculated at! Cr red cell survival 





have stressed the variation in reported t! Cr data 
using similar methods in different laboratories. 
N h 
(470)(753)(219)(223)(222)(218)(165)(407)(203) 
umerous aut ors 
(200)(198)(513)(398)(561)(666)(667)(825)(821)(812)(813)(470) 
(7o4) <443 \ave postulated methods of correcting 5'1cr data 
for elution in order to measure mean red cell lifespan. 
My experience with these techniques has been unhappy, and 
I have decided that the simplest way to report these figures 
is to use the best semilog least squares fit for the data in 
order to calculate at~ value. While this does not give a 
direct measure of red cell lifespan, it does give one a 
comparative measure of red cell longevity, is simple to 
perform and relatively easy to interpret. I agree that this 
method is not perfect, but it at least eliminates· other 
potential sources of error from data manipulation. As 
elution seems to vary in different disea.se states as well 
as between normal individuals, it seems easier not to attempt 
too close an analysis of this relatively inaccurate data. 
The values obtained in this group of normal patients agree 
. . (470)(323)(107)(152) well with other published normal results 
(430)(710)(513)(598)(217)(753)(200)(873)(872)(443)(673)(198) 
which vary from twenty-four to forty-two days. In my .patients 
a mean value of 27 days was found, with a standard deviation 
of 4.7 days. 
Ferrokinetic Data in Patients with Haemolytic Anaemias. 
Selection of patients:-
Two different criteria were used in selecting patients for 
this study. The first group of patients were se l ected 
clinically on the basis of diagnosis being made of haemolytic 
anaemia with a disease process known to be associated with 
haemolysis. Included in this group are patients with 
VI-c-2 
VI-c-3 
thalassaemia, hereditary spherocytosis, auto-innnune 
haemolytic anaemias (AIHA's) (although this group has 
red cell survival measurements in addition to positive 
Coombes tests). 
The second group of patients was selected on the basis 
l./) 
of 51cr red cell survival data. Patients included in this 
group were those with t!
51cr red cell survival values of 
less than twenty-two days (i.e. normal mean - one standard 
deviation). In a number of these patients, conditions known 
to be associated with haemolysis were present. In some 
patients, no obvious cause of haemolysis was found by the 
clinicians looking after the patient. An attempt has been 
made to subdivide the patients into various clini~al groups. 
(See Table VI-4). 
Results 
These are summarised in Tables VI-4 to VI-12. As a group, 
these patients showed the features that one would expect 
in association with increase in total erythropoietic 
activity. However, the' findings varied between different 
disease groups, and these will be discussed under the 
individual tests. 
Plasma Iron Concentration 
In all the haemolytic patients, taken as a single group, 
plasma iron concentrations were not significantly raised 
above the values of normal patients (P = less than .35 
Table VI-5). Two groups of haemolysing patients studied 
by us did, however, have plasma iron levels significantly 
different to normal values, these being the Thalassaemic 
patients and patients with iron deficiency associated with 
haemolysis. The high plasma iron levels 1n 
patients with Thalassaemia possibly reflects 
VI-c-4 
their general state of iron overload as a result of 
multiple previous transfusions and chronically excessive 
iron absorption secondary to increased total erythropoietic 
activity. 
t! Plasma Iron Clearance Values (See Table VI-6). 
Shortening of the t 1 PIC occurred in all states associated 
2 
with haemolysis, and appeared to reflect the increase in 
total erythropoietic activity. The most marked shortening 
of t 1PIC values occurred in the group of patients with 
2 
iron defi ciency. This presumably reflects the avidity of 
their iron starved marrow for iron rather than an absolute 
increase in erythropoietic activity, as the EIT values in 
this group of patients were only slightly above normal 
values. The fact that this was present, i.e. raised EIT 
values, shows how rapid is the plasma iron turnover in 
i 
these patients, as their erythropoietic activity is known 
b 1. . d b l f . (385) to e imite y s 1ortage o precursor iron. 
The literature uniformly reports shortening of the t 1PIC 
2 
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in conditions associated with haemolysis, <258)(872)(55)(815) 
(635)(l59)(486 )(363) this shortening appearing to represent 
an increase in total erythropoietic activity in these patients. 
Shortening of the t 1PIC is , however, not specific for 
2 
haemolytic states, occurring also in conditions associated 
with relatively normal red cell survival but grossly 
· d · ff · h · · . . (288) (872) (387) (636) increase ine ective eryt ropoietic activity 
(36)(253)(55)(635)(815)(159)(62)(61)(486)(863)1 h f d th ave oun e 
t~PIC to be completely independent of plasma iron concentration 
in this group of patients (see Figure VI-l)with haemolytic 
anaemias. 
177: 











Plasma Iron Concentration 
(µgms%) 
300 
This seems to be the only group of patients in which this 
relationship is lost. This may reflect the rapid recycling 
of iron from early erythroblast or erythrocyte destruction which 
may raise the plasma iron level. (387)(
36)(683)(60) 
If the effect of ineffective erythropoiesis could be excluded, 
a relationship between these two parameters would probably be 




TABLE VI~4 Ferrokinetie findings in Patients with Raemolytie Anaemias. 
Name Rb Ret B PCV PI t!PIC EI PIT EIT RBCUe RBCUe t! f 
V PCV RBCUp 51Cr 
1. Thallassaemies. 
Ism 9.4 30 0.96 234 29 6.27 5.8419 5.2490 
Ism 6.9 21 0.90 250 35 6.00 5.7629 5.0569 -
Jae 9.0 32 0.90 146 26 4.77 4.0399 3.6793 32 0.48 15 0.22 
Jae 8.8 25 1.10 174 24 6.29 5.6532 5.1842 27 0.49 11 0.30 
2. Heriditari SEheroeitosis 
Kea 10.6 29 1.00 59 10 
Lou 13. 7 . 36 0.98 85 44 1.91 1.3009 1.1019 77 0.93 19 0.17 
Pre 17.6 47 0.73 86 34 2.26 1.4273 1.2565 90 1.05 22 0.33 
Sto 11. 7 28 0.96 146 25 5.15 4.3356 3.9562 31 0.48 10 o.oo 
3. G.6.P.D. defieienei, 
Ngo 17.2 45 o.67 187 120 1.08 .9132 .5296 98 1.53 22 0.27 
Rob 9.1 28 0.64 80 42 2.05 1.4141 1. 2062 97 1.18 17 o.oo 
4. A.LR.A's 
Swa 8.0 28 0.57 92 20 4.69 3.3812 3.1422 23 0.29 20 o.oo 
Ste 10.0 30 0.91 167 38 3.67 3.1486 2.7255 60 1.00 0.00 
Bor 7.7 18 1.10 86 40 2.42 1. 7762 1.5250 93 1.21 10 o.oo 
Gre 11. 7 32 0.91 133 88 1.32 1.0688 .7404 27 0.39 22 o. 23 
5. Fe deficiencies. 
Saa 10.l 33 0.95 69 22 3.46 2.1814 2.0160 94 1.09 25 0.17 
wi1 ·11.o 33 1.00 22 31 1.54 .4879 .4343 94 0.96 17 o.oo 
Bas 8.1 23 1. 28 9 16 2.53 • 4519 .4271 95 0.95 17 0.14 
Cha 10.9 36 0.90 19 18 2.52 .7261 .6817 97 0.98 18 0.13 
Rix 5.1 16 2.64 16 20 2.31 .6962 .6484 70 o. 71 15 0.00 
Cad 8.2 23 0.73 42 15 4.21 2.1452 2.0295 81 0.88 20 
Sev 14.0 44 0.86 71 25 2.85 1.6904 1.5425 63 o. 72 17 0.11 
vNi 11. 7 38 0.75 59 22 3.08 1. 7603 1. 6259 DO 1.11 15 0.05 
·. · .i79 
TABLE VI-4 contd. 
Name Hb Hct B PCV PI t!PIC EI PIT EIT RBCUe RBCUe t1 f 
V PCV RBCUp 2 
51Cr 
6. Mieloeroliferatives. 
vNi 9.0 26 0.68 152 62 2.18 1.8652 1.4604 41 0.66 22 0.04 
Key 12.4 41 0.79 165 X>2 1. 21 1.0075 .6478 51 0 . 77 17 0.00 
Mte 9.6 30 0.91 132 29 4.05 3.2954 2.9610 ·22 0.32 6 o.oo 
Rob 12.2 42 0.89 180 46 2.84 2.4010 2.0145 23 0.37 9 
Mar 9.0 27 0.82 91 22 4.27 3.1089 2.8695 28 0.35 14 0.20 
Han 23.0 58 o. 77 112 25 3.19 2.0895 1.9066 49 0.58 20 
Han 8.4 25 1.90 71 17 4.82 3.2737 3.0823 56 0.67 13 0.04 
Han 12.4 37 0.82 53 31 2.09 1.1277 1.0053 55 0.60 11 
Bro 10.4 28 0.90 104 41 2.48 1.8878 1.6175 69 0.91 17 o.oo 
Wil 9.2 30 1.80 44 34 1.83 .9369 .8254 93 1.01 16 0.00 
Koc 8.6 25 1.02 85 60 1.52 1.0762 .8479 29 0.36 9 
7. ThrornbocitoEaenias 
Kot 10.3 33 0.64 234 19 9.27 8.5767 8.0064 27 0.61 15 0.11 
Dav 10. 6 35 0.72 43 31 1.93 .9285 .8264 84 0.90 14 
8. Others 
Shu 9.6 30 0.90 55 30 2.30 1. 3185 1.1792 79 0.89 12 o.oo 
Jeg 11. 4 34 0.91 45 33 1.86 .9371 .8289 92 1.00 19 0.03 
Wil 7 .3 20 o. 89 43 44 1.48 .8048 .6820 54 0.59 17 
Luk 12.8 38 1.02 209 134 1.14 1.0144 .4758 49 0.91 18 0.20 
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Table VI-5 ~lasma Iron Concentrations compared between normal patients and 
patients with different haemolytic states. 
Group Plasma Iron 
N X S.D. p 
1. Normals 28 111.1 40.7 
2. All haemolytics 38 105.0 66.0 < 0.35 
3. Thalassaemias 4 201.L 49.2 < .0025 
4. Hereditary Spherocytosis 3 105.7 34.9 < . 45 
5. A.LR.A's 5 119.5 37.9 < . 35 
6. Fe Deficiencies 9 38.9 23.6 < .0005 
7. Myeloproliferative 12 108.1 45.0 < . 45 
Table VI-6 t!PIC values compared between normal patients and patients with 
different haemolytic states. 
Group t 1PIC 
2 
N X S.D. p 
1. Normals 31 80.9 25.7 
2. All haemolytics 38 39.3 27.8 < .0005 
3. Thal as saemi as 4 28.5 4.8 < .0005 
4. Hereditary spherocytosis 3 34.3 9.5 < .0005 
5. A. I.H.A' s 5 46.5 29.1 < .01 
6. Fe Deficiency 9 22.2 5.9 < .0005 
7. Myeloproliferative 12 42.6 24.5 < .0005 
Table VI-7 E.I. values co~ared between normal £atients and eatients with 
different haemolytic states. 
Group Erythropoietic Index 
N X S.D. p 
1. Normals . 28 1.13 0.29 
2. All haemolytics 38 3.13 1. 79 < .0005 
3. Thalassaemics 4 5.83 0. 72 < .0005 
4. Hereditary sphe'rocytosis 3 3. ll 1. 78 < .05 
5. A.LR.A's 4 3.03 1.47 < .01 
6. Fe deficiency 8 2.81 0.80 < .0005 
7. Myeloproliferative 11 2. 77 1. 99 < .005 
Table VI-8 P.I.T. Values compared between normal patients and eatients with 
different haemolytic states. 
Group Plasma Iron Turnover 
N X S.D. p 
1. Normals 28 0.7816 0.2554 
2. All haemolytics 38 2.2593 1. 8075 <. 0005 
3. Thalassaemics 4 5.3245 0.8599 <.0005 
4. Hereditary spherocytosis 3 2.3546 1. 7168 <.10 
5. A.LR.A's 5 2.3437 1.1063 <.0025 
6. Fe deficiency 9 0.6581 0.1941 <.10 
7. Myeloproliferative 12 2.0063 0.9197 <.0005 
Table VI-9 E. LT. values compared between normal patients and ;eatients with 
different haemolytic states. 
Group Erythroid Iron Turnover 
N X S.D. p 
1. Normal 28 0.4401 0.1821 
2. All haemolytics 38 1. 9999 1.6902 <.0005 
3. Thalassaemics 4 4.7924 0. 7463 <.0005 
4. Hereditary spherocytosis 3 2.1049 1. 6052 <.05 
5. A.LR.A's 5 2.0333 1.1013 <.0025 
6. Fe Deficiency 9 0.6079 0.1785 <,01 
7. Myeloproliferative 12 1. 7489 0.9016 <.0005 
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Table VI-10 RBCUe values compared between normal patients and patients with 
and different haemolytic states. 
Group RBCU experimenta_l 
N X S .D. p 
1. Normal 17 83 15 
2. All haemolytics 37 62.4 27.3 < .0005 
3. Thalassaemics 2 29.5 3.5 < .0005 
4. Hereditary Spherocytosis 4 64.3 25.6 < .10 
5. A.I.H.A.'s 5 50.8 32.7 < .025 
6. Fe Deficiency 9 89.4 10.1 < . 15 
7. Myeloproliferative 12 46.9 21.6 < .0005 
Table VI-11 Ratio RBCUe/RBCUp values compared in normal patients and 
and different haemolytic states. 
Group Ratio RBCU experimental I 
RBCU predicted. 
N X S.D. p 
1. Normal 14 l. ll 0.27 
2. All haemolytics 36 o. 78 0.30 <.0005 
3. Thalassaemics 2 0.49 0.00 <.0005 
4. Hereditary spherocytosis 3 0.82 0.30 <.10 
5. A. I.H.A. Is 5 o. 72 0.45 <.05 
6. Fe Deficiency 9 0.95 0.13 <.OS 
7. Myeloproliferative 12 0.60 0.24 < .0005 
Table VI-12 t 1
51cr red cell survival data compared 1.n normal patients 
2 




N X S.D. p 
1. Normal 10 27.0 4.7 
2. All haemolytics 36 16.0 4.5 < .0005 
3. Thalassaemics 2 13.0 2.8 < .0005 
4. Hereditary Spherocytosis 4 15.2 6.3 < .005 
5. A.I.H.A.'s 4 17.3 6.4 < .0125 
6. Fe Deficiency 9 17.6 3.3 < .0005 
7. Myeloproliferative 12 14.0 s.o < .0005 
12atients 
VI-c-5 The Erythropoietic Index: 
Values for this index and a comparison between normal 
patients and patients with haemolysis, are shown in 
Table VI-7. In all groups the erythropoietic index is 
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elevated, reflecting the increase in total erythropoietic 
activity. In patients with iron deficiency (2.81 ±. 0.80, 
P = <.0005)~ I would have expected this value to be 
smaller on the basis of EIT values (0.6079 + 0.1785 P = <.01) 
and the known restriction imposed on total bone marrow 
erythropoiesis by limited iron supply. The anomaly is 
perhaps partially explained by the avidity of the iron 
starved bone marrow for iron, giving a falsely elevated EI 
value. On the other hand, total erythropoietic activity and 
ineffective erythropoietic activity may be raised in iron 
d f
. . t (258) (164) (106) (687) (688) (726) (727) d h. e 1c1en states an tis 
elevated EI value may reflect this. 
In normal patients, the erythropoietic index should, in some 
way, be related to the haematocrit or to the haemoglobin level. 
It should increase as the haematocrit or haemoglobin level 
decreases in an attempt to compensate. If iron supply to the 
bone marrow remained adequate (i.e. 70µg/100 ml), as well as 
the other essential haemoglobin building blocks, the relation-
ship between EI and haematocrit should be linear. We have not 
performed a study of this relationship, as has been done by 
Hillman(385) but the attempt would be warranted in an effort 
to detail a normal EI value at various haematocrit levels. 
Any raising of EI values above this normal response would 
tend to suggest the presence of ineffective erythropoietic 
activity which could, perhaps, be reasonably quantitated by 
this method. Hillman(JSS) failed to define . this mathematical 
relationship. 
In Figures VI-2 and VI-3, two graphs are presented showing 
E.I. values plotted against haematocrit values. In the first 
grap~, normal patients as defined in section VI-b, as well as 
normal patients as defined in Chapter III are included. In 
the second graph, the results in the haemolytic group of 
patients are plotted (Figure VI-3). 
Figure VI-2 Comparison of Haematocrit and E.I. values in normal 










Figure VI-3 Comparison of Haematocrit and E.I. values in patients 









As can be seen, in a number of patients, the E.I. values at 
similar haematocrit values are much greater than in normal 
patients. This will reflect not only a shorter red cell 
survival, but also an increase in ineffective erythropoietic 
activity. It is of interest that the greatES.tE.I. values are 
found in patients with conditions known to be associated with 
increased ineffective erythropoietic activity i.e. Thallassaemia. 
Under these circumstances, the E.I. is disproportionately 
increased relative to the shortening of red cell survival. 
VI-c-6 
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Plasma Iron Turnover and Erythroid Iron Turnover measurements 
in 'patients with different haemolytic states. 
Table VI-8 and VI-9 detail the statistical comparison of 
these results with normal values. Both P.I.T. and E.I.T. 
increase in haemolytic states, although this is least marked 
in iron deficiency associated haemolysis (p < .10 for PIT, 
<.01 for EIT). It seems obvious that gross elevations of 
EIT values, disproportionate to shortening of red cell lifespan, 
must be associated with excessive ineffective erythropoiesis. 
The fairly wide standard deviations in the different disease 
states probably reflect different severity of the disease 
process in different individuals. For this reason, one 
must appreciate the limitations of empirically presented data. 
The elevated PIT and EIT characterise the haemolytic patients 
as a whole, but not the patients with iron deficiency 
associated with haemolysis. 
t 1PIC, EI, PIT and EIT have been shown to correlate with 2 
total erythropoietic activity, as long as plasma iron supply 
.. (385)(361) remains adequate for normal erythropo1es1s. Grossly 
elevated PIT values have been commented on by a number of 
authors, in association with ineffective erythropoiesis, (387) 
(36){636)(253)(815)(289)(80)(232)(852) while most authors find 
1'ncreased PIT 1 . h 1 t' d' (289)(683)(80)(232) va ues 1n aemo y 1c 1seases. 
As with a number of autbors(63l)(253) I have found all these 
values to be excellent indicators of total erythropoietic activity 
but poor indicators of effective erythropoietic activity. 
VI-c-7 Experimental red cell utilisation values, and RBCUe/RBCUp 
ratios in patients with haemolytic anaemias. 
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Statistical analysis of these measurements in the various 
haemolytic states studied by me, and a comparison with normal 
results is shown in Table VI-10 and VI-11. I have previously 
theorised about the effects of different forms of haemolysis 
upon the RBCUe values and my theoretical predictions appear 
. to be supported by the results I obtained. In patients with ; 
hereditary spherocytic anaemia, where red cell lifespan 
appears to be finitely reduced. the RBCUe/RBCUp value 1s 
0. 82 .:!:_ 0. 30 (p = < .10). In the remaining conditions where 
ineffective erythropoiesis or random early red cell 
destruction is present, RBCUe/RBCUp values are markedly 
depressed (p < .05 in all cases). It was also interesting 
to note that the RBCUe/RBCUp ratio in patients with Fe 
deficiency related haemolysis was 0.95 .:!:_ 0.13 (p < .05) being 
significantly lower than pre~icted values. This is presumably 
a reflection of ineffective erythropoietic activity a s 
well as early random red cell destruction in this group 
of patients. 
From this data it would appear unreasonably to assess 
ineffective erythropoietic activity from RBCUe values 
alone, as this value reflects the effects of a number 
of processes. If random red cell destruction has been 
excluded, however, and the finite red cell lifespan 
exceeds the duration of the experiment, the ratio of 
RBCUe/RBCUp appears to give a reasonable indication of 
the presence and severity of ineffective erythropoietic 
activity. This ratio takes into account the influence of 
VI-c-8 
plasma iron concentrations upon the RBCUe, but not the 
influence of variable erythropoiesis. 
Most authors have found RBCUe values decreased in haemolytic 
. (872)(55)(815)(289)(211)(284) . h anaemias, some stating tat 
plateau values are reached earlier in association with 
haemolysis, (872 )(2ll)(2l 2) and have found a decrease in 
RBCUe values in association with ineffective erythropoiesis. 
(387)(36)(636)(253)(386)(443)(211) Some feel that the 
RBCUe value alone is a good indicator of the severity of 
the process. <2Il)(253 ) The delay in RBCUe plateau levels 
associated with ineffective erythropoiesis has also 
previously been commented upon(2ll)(2l 2) as has the decrease 
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. RBCU 1 . h. . 1 · · (211) 1n e va ues wit increasing p asma iron concentrations. 
(187)(576)(62)(252)(284)(914)(212) It appears that RBCUe 
values are poor indicators of effective erythropoiesis 1n 
the presence of random red cell haemolysis. <212> 
In conclusion, there appears to be no way of differentiating 
the effects of ineffective erythropoiesis, effective erythro-
poiesis and random red cell destruction upon RBCUe values, 
particularly if all processes are operating simultaneously. 
t! 51cr red cell survival data in patients with haemolytic 
anaemia. 
Statistical analysis of the data and comparison with normal 
patients is seen in Table VI-12. As previously discussed, there 
are limitations imposed by us on the usefulness of this 
technique for measuring mean red cell lifespan. By this 
VI-d 
VI-d-1 
method of analysis, no differentiation of random and 
finite shortening of red cell lifespan can be made. I do not 
dispute that, with more care, this differentiation can be 
made. All our patients had shortened red cell survivals 
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51 (as measured by t! Cr data) when compared to normal patients. 
The success with which haemolysis was detected, can be 
assessed from Table VI-12. It is obvious that this data 
bears no true relationship to mean red cell lifespan, 
being only semi-quantitative; moreover, it appears that 
this method will probably only detect haemolysis once red 
cell lifespan has become significantly decreased. 
Fetrokirtetic data in Patients with Hypoplastic anaemias. 
Selection of Patients. 
Two broad groups of patients were selected for this study. 
The first group (Group A) consisted of patients who had a 
true hypoplastic anaemia, diagnosed clinically, morphologically 
and by other 1'.ac::matologj_cal criteria. A number of these 
patients were on anabolic steroids when studied, and 
two at least appeared to be in a clinical remission when 
studied. 
The second group of patients (Group B) included those 
who had ferrokinetic criteria for qualifying, or who had 
a presumptive diagnosis of hypoplastic anaemia made that 
was not confirmed on further investigation. It appears 
inevitable that some patients, who are otherwise haemato-
logically reasonably normal, will present with hypoplastic 
ferrokinetic findings. I have attempted to analyse these 
VI-d-2 
"false positives" for hypoplasis. Ferrokinetic criteria 
for inclusion in this group include EI values of 
< 0.84 (i.e. mean normal - 1 SD) or EIT values of 
< 0.2580 (mean normal - 1 SD) or PIT values of< 0.5262 
(mean normal - 1 SD). An attempt has been made to show 
cause why these patients should not be labelled as hypoplastic. 
Results. 
These are tabulated in Tables VI-16 to Table VI-24. 
Comparison of the true hypoplastic with the ferrokinetically 
hypoplastic group is shown in Table VI-25. Theoretically, 
this group of patients should show prolonged t!PIC, normal 
or low PIT, low EIT and EI, normal red cell survival and 
low RBCUe values, all reflecting depressed bone marrow 
function. 
Table VI-15 Comparison of differences of ferrokinetic data between 
true hypoplastic anaemia patients and ferrokinetically 
found hypoplastic anaemias (see text). 
True Hypoplastics (A) Ferrokinetic Hypoplastics {B) 
X SD X SD p 
Plasma 
Iron 202.4 74.4 89.4 50.2 < .0005 
t!PIC 221.8 111.5 99.4 52.6 < .0025 
EI o. 73 0.24 0.99 0.36 < .01 
PIT o. 6204 0.1535 0.5173 o. 3110 < .15 
EIT 0.1657 0.2087 0.3331 0.2462 < .05 
RBCUe 17.7 8.9 74.4 20. l < .0005 
RBCUe/ 
RBCUp 0.41 0.18 0.88 0.14 < .0005 
t!51Cr 29. 8 9.0 28.4 4.0 < .35 
-'!'able VI -16 Ferrokinetic findings on pati ents with Hypoplastic Anaemias 




All 10.6 35 250 270 0.67 0.6278 0.0345 25 0.60 
Bai( l) 9.4 27 0.96 160 150 0.93 0.8017 0.3808 26 0.43 29 0.00 
(2) 14.1 41 0.97 72 62 1.18 o.7233 o.5663 - 26 
Bur 24 - 300 24 
Coo 12.0 35 0.98 153 180 0.70 0.5802 0.2147 -
duT 11.5 31 0.84 284 249 0.85 0.8149 0.1044 15 0.50 38 0.34 
Das 11. 4 32 0.90 170 311 0.45 0.3857 0.0000 6 0.10 45 0.07 
Fra 11.2 36 230 273 0.62 0.5365 0.0251 25 o.52 19 
Lam 13.2 37 0.90 274 126 1.52 1.4344 0.8018 54 1.42 23 o.oo 
Pep 11. 8 34 0.90 294 433 o.49 o.4664 0.0000 9 0.30 40 o.oo 
vWy 11.2 34 1.10 137 86 1.35 1.0998 0.7703 82 1.19 24 0.14 
Hypoplastics 
Sol 14.7 47 0.87 88 130 0.60 o.3842 0.2094 83 0.98 28 0. 06 
Lou 18.0 52 0.75 124 193 0.47 0.2583 0.0838 -
Hol 17.6 46 0.82 123 183 o.53 o.3885 0.1402 -
Ash 8.5 35 0.99 64 110 0.66 0.3995 0.2428 75 0.85 27 0. 27 
Ver 21.2 64 0.60 101 99 0.11 o.4195 0.2141 -
Bot 17.9 47 o.74 55 86 0.12 o.3604 o.2519 -
Web 16.2 52 o.75 88 91 0.82 0.5044 0.3438 99 1.14 29 0. 37 
Vlo 12.7 41 0.94 36 50 1.08 0.4484 0.3699 85 o. 89 0. 16 
Sep 16.5 47 0.98 67 83 0.81 o.4582 o.3251 -
Koe 20.0 56 0.81 97 100 0.75 0.4703 0.3057 72 0.84 30 0. 08 
Sch 11.0 36 o.85 21 34 1.37 o.4131 o.3639 98 1.00 36 o.oo 
OCo 13. 1 35 1.12 243 210 0.85 0.7845 0.2079 40 0.91 
Pet 16.4 42 0.90 29 51 o.98 o.3475 o.2853 92 0.95 o. 27 
Ada 5.7 16 0.85 39 72 0.88 0.4619 0.3455 80 0.88 27 0 . 19 
Hoo 9.9 29 0.85 16 29 1.54 o.4045 o.3635 92 0.93 22 0.14 
Loz . 13. 2 36 1.05 9 35 1.13 0.1740 0.1529 88 0.87 o.oo 
Joh 12.9 37 0.90 138 120 o.95 o.7554 o.4381 37 o.52 25 0.04 
Eng 11.5 32 o.98 100 188 0.51 0.3753 0.1284 50 0.64 0 .07 
Seo 9.9 27 0.64 153 63 2.13 1.8340 1.4316 51 0.82 0 .44 
Mag 16.1 46 0.90 163 133 0.87 0.7096 0.3805 66 0.96 0.36 
Hal 8.0 28 o.89 32 57 0.97 0.4161 0.3329 -
Rob 16.8 50 0.80 75 90 0.77 0.4500 0.3083 -
Cra 17.6 51 0.93 175 130 0.89 0.7145 0.3894 -
Pet 19.0 60 0.74 147 113 0.81 0.5852 0.3537 -
Table VI - 17 Comparison of plasma iron concentrations in normal and 
aplastic patients. 
Group Plasma Iron 
1. Normal 
2. Aplastics (A) 




















2. Aplastics (A) 








1. Normal 28 
2. Aplastics (a) 8 
(b) 10 















erythropoietic Indices in normal and aplastic 
EI 
X SD p 
1.13 0.29 
o. 73 0.24 < .0005 -
0.88 0.36 < .05 
0. 91 0.36 < .01 
Table VI - 20 Comparison of PIT values in normal and aplastic patients. 
Group 
N 
1. Normal 28 
2. Aplastics (A) 10 













Table VI - 21 Comparison of EIT values in normal and apiastic patients. 
Group EIT 
1. Normal 
2. Aplastics (A) 

















Table VI - 22 Comparison of RBCUe values in normal and aplastic patients. 
Group RBCUe 
N X SD p 
1. Normal 17 83 15 
2. Aplastics (Al 6 18 8.9 < .0005 
3. Hypoplastics (B) 15 74 20.1 < .10 
Table VI - 23 




2. Aplastics (A) 
3. Hypoplastics (B) 
Table VI - 24 
1. Normal 
2. Aplas tics (A) 




















C . f 51 . ompan.son o t! Cr red cell survival 1.n normal 
and aplastic patients. 
N X SD p 
10 27 4.7 
9 30 9.0 < .25 
8 28 4.0 < .30 
VI-d-3 
VI-d-4 
Plasma Iron Levels (Table VI - 17) 
In the true aplastic group the average plasma iron 
concentration was significantly elevated (P < .0005) 
whereas in Group (B) patients, it was significantly 
depressed. A number of Group (B) patients had markedly 
depressed plasma iron levels on the basis of inflammation, 
infection or iron deficiency, known to be associated with 
low plasma iron concentrations as well as impaired 
erythropoiesis (see later under specific disease groups). 
The increased plasma iron levels in the patients with 
true aplastic anaemia were probably due to a large extt!nt, 
to transfusional siderosis. There may also have been a 
contribation from normal iron absorption in the presence 
of depressed erythropoietic activity. 
t 1PIC and EI values (Table VI-18 and VI -19) 
2 
The t!PIC should be prolonged in these patients becaus e 
of inactive erythropoiesis. We have previously shown in 
(Chapter III) that the initial rate constant of the 
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plasma iron clearance curve reflects mainly erythropoietic 
activity. Where erythroid iron removal is less, non-erythroid 
iron uptake should be greater than normal. I have previously 
suggested that NEIT does not differ in different disease 
states, being dependent upon plasma iron concentration 
only (VI-b-9) The rate of non-erythroid iron uptake 
should therefore, have a minimal effect upon the t 1PIC. 
2 
Under these conditions, the erythropoietic index shoul d 
be an excellent indicator of total erythropoietic act i vity 
and will be a valuable guide as to the severity of the 
hypoplasia. The t 1PIC has been found to be an excellent 
2 
guide of depressed bone marrow activity by a number of 
workers, (300)(812)(848)(735)(872)(486)(900)(863)(284)(914) 
(55) . 1 1 ' . 1 d' particu ar yin sequentia stu ies. A number of authors 
however, including myself, have shown how t!PIC values 
become prolonged with increased plasma iron values (80) 
(384)(62)(6!)(735)(863)(284) and because of this, the use 
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of the erythropoietic index as a guide to erythroid activity 
would eliminate errors from this variable as well as achieving 
a semi-quantitative assessment of total erythropoietic activity 
relative to the normal. The EI in this situation appears to 
be an excellent indicator of depressed bone marrow function 
(see Table VI - 19). In the truly aplastic patients, the? EI 
was markedly depressed (Group A in Table VI - 19) (P < • 0005). 
In the second group of patients, the t!PIC was not as 
markedly prolonged as in the first group of patients, 
probably because the plasma iron values were not elevated 
to the same degree. EI values were, however, depressed. 
As can be seen in Table VI - 16, a number of these patients 
had reasons for bone marrow depression i.e. bone marrow 
infiltration, recent excessive ethanol ingestion, 
cytotoxic therapy, inflanmatory states, malnutrition and 
chronic renal failure. A small number of patients, however, 
had no obvious cause, and these presumably reflect " a 
temporary or permanent state of bone marrow hypofunction. 
In Table VI - 19, I have underlined the patients, who by 
ferrokinetic criteria, are probably not totally hypoplastic 
although at least one ferrokinetic parameter suggests that 
they are. Where a result falls into the normal range (i.e. mean 
normal!_ SD), it is suggested that depression of any other 






Plasma Iron Turnover 0.5262 units mg/100 ml.whole blood/day 
(in absence of Fe def.) 
Erythroid Iron Turnover 0.2580 units mg/100 ml.whole blood/day 
(in absence of Fe def.) 
It is of interest that two patients referred with a bone 
marrow morphologically diagnostic of aplasia associated with 
cirrhosis had. on ferrokinetic investigation, normal or 
increased erythropoietic activity. (Johnson & Scott). 
Plasma and Erythroid Iron Turnover Values. 
In a number of aplastic patients, the PIT was within t he 
normal range (see Table VI-16). Average values were however, 
depressed in both groups (see Table VI-20). (P < .025 and < . 0025 
respectively) tending to be more depressed in the second group 
of patients where plasma iron values were lower and, hence, 
the contribution of non-erythroid iron turnover was smaller. 
In my group of patients, the PIT appeared to be of some 
use in detecting bone marrow hypoplasia, although EIT values 
were undoubtedly more accurate. (see Table VI-21) (P < .0005 and 
<,OS respectively). 
It is interesting that the Group B patients have less 
significantly depressed EIT values than the Group A patients. 
A number of authors have found normal or slightly raised 
PIT values in association with bone marrow hypoplasia . <2s9) 
(735)(80) (232) . I have expressed some reservations about 
NEIT calculations at extremes of plasma iron concentr ations 
(VI-b-9), and believe that in some of the patients i nc luded 
in the second group of patients, we have probably over-
estimated NEIT to give a low value for EIT (i.e. OCo, Cra,) 




the same has occurred with the aplastic group of 
patients, although one suspects that the contribution 
of NEIT to PIT values may be slightly greater in this 
group of patients. 
It would appear, taken overall, that the measurement 
of the EIT is a useful procedure, in association with 
EI values, for the detection of hypofunction of the 
bone marrow. 
' 
There is obviously a need for further 
investigation to define non-erythroid iron kinetics 
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at the extremes of plasma iron concentration. 
not been attempted in the present work. 
This has 
Patients with extremely low plasma iron levels may be 
unable to raise their EIT values above those in the 
hypoplastic range, but the absence of hypoplasia in 
these patients would be detected by a raised EI value. 
Should the EI value not be raised, one may postulate an 
inadequate bone marrow erythroid response in these 
patients, and some other factor should be looked for. 
RBCUe and RBCUe/RBCUp 
As can be seen from Tables VI-22 and VI-23, the patients 
who were truly hypoplastic had markedly depressed RBCUe 
values , as well as depressed RBCUe/RBCUp ratios. (Lamb and 
van Wyk have been excluded from this analysis as, by 
clinical and other criteria, they appeared to be in 
remission). It seems obvious that where less erythroid 
activity is present, less iron will be needed for haemoglobin 
formation. Less obvious to me is the fact that less label 











will be incorporated into this haemoglobin, because 
plasma iron clearance will be markedly prolonged where 
hypoplasia is present, and the percentage of the plasma 
iron turnover going to non-erythroid iron uptake has 
been postulated as being a constant fraction of the 
plasma iron turnover. The only way to explain this 
discrepancy is to postulate that NEIT is indeed greater 
1n patients with bone marrow hypoplasia, as ineffective 
erythropoiesis and random red cell destruction, which 
could lower RBCUe values, have not been shown to be 
present in this group of patients. 
To a certain extent, the EI and RBCUe/RBCUp values in 
these patients should have been similar, as ineffective 
erythropoiesis and random -..· red cell destruction were not 
present - 1.e. depression of RBCUe would reflect depression 
of EI. 
Comparison of these figures in individual hypoplastic 
patients does indeed show a fairly good correlation except 
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1n some patients on anabolic steroid therapy (see Table VI-26) . 
EI RBCUe/RBCUp 
0.67 0.60 
0.93 0.43 oxymethalone 
0.85 0.50 II 
0.45 0.10 II 
0.62 0.52 
1.52 1.42 II 
0.49 0.30 II 
1.35 1.19 prednisone 
This may reflect the presence 1n patients Bai , duf, Das, of 
a certain amount of ineffective erythropoietic activity, 
or random early red cell destruction. The EI and the RBCUe/ 
RBCUp correlate well in all patients where random red cell 
destruction or ineffective erythropoietic activity was 
absent. A comparison of this d&ta, may therefore, be of 
some use in detecting the presence of these defects. 
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My results, in the two groups of hypoplastic patients, for 
RBCUe and RBCUe/RBCUp values, appear to be markedly different. 
In the first group of patients, both were markedly depressed 
(see Table VI-22 and VI-23) - (P < .0005) whereas in the 
second group of patients (Group B) RBCUe values, while 
being depressed, were not as greatly effected (P < .10). 
This appears to reflect mainly the effect of different 
plasma iron concentrations, although the ratio of RBCUe/ 
RBCUp in the second group of patients was not as greatly 
depressed as in the first group. It may be that the 
superior RBCU of this second group of patients represented 
a temporary depressant effect of a disease process or 
toxin on the bone marrow which, while still active on the 
first day of study, became less active with treatment 
during the course of the study. This is supported by the 
generally larger RBCUe/RBCUp values, when compared to EI 
values in this group of patients (see Table VI-27). 
Table VI-27 
Patient EI RBCUe/RBCUp Toxin 
Sol 0.60 0.98 Ethanol 
Ash 0.66 0.85 CLL 
Web 0.82 0.14 P32 
Vlo 1.08 0.89 Reiters 
Koe 0.75 0.84 Buergers 
Sch 1. 37 1.00 Reiters 
OCo 0.85 0.91 Haemochrom 
Pet 0.98 0.95 Chloro 
Ada 0.88 0.88 Ethanol 
Hoo 1.54 0.93 PAS sensitivity 
Haem. cr1s1s 
Loz 1.13 0.87 Ethanol 
Cirrhosis 
Joh 0.95 0.52 Cirrhosis 
Eng 0.51 0.64 Ethanol 




In a large number · of these patients RBCUe/RBCUp values 
exceeded EI values. At low plasma iron levels, where 
RBCUp will be 100%, RBCUe cannot go above this figure, 
so that EI values of 1.0 at low plasma iron levels 
cannot possibly be matched by RBCUe/RBCUp figures of 
equal magnitude. 
Where RBCUe/RBCUp values exceed EI values, I suggest 
that temporary bone marrow suppression may have been 
present that had disappeared during the course of the 
experiment~ If correct, observation of this phenomenon 
might help in separating temporary hypoplastic states 
from permanent ones. 
Red Cell survival data in patients with hypoplastic anaemias. 
These are detailed in Table VI-24. As can be seen, neither 
f . h d 51c . 1 1 h group o patients a t! r surviva va ues tat were 
significantly different to those for normal patients. 
Ferrokirtetic Parameters in patients with Polycythaemia. 
Selection of Patients. 
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All patients included in this study had haemoglobin values 
exceeding eighteen grams/100 ml. in males, sixteen grams/100 ml. 
in females, and haematocrit values above 52% in males and above 
47% in females. These values were chosen as exceeding normal 
figures (mean+ one standard deviation). (B 97 ) 




This consisted of patients with proven polycythaemia vera 
who may have been treated or not, but were referred for 
blood volume estimations. These patients had previously 
been diagnosed as having Polycythaemia vera by conventional 
methods. This group is unfortunately rather heterogenous 
because both treated and non treated patients have been 
included. The number of non treated patients was however 
too small for adequate analysis. 
Group 2. 
These patients satisfied the haemoglobin and haematocrit 
criteria, but on blood volume · Jll8Asurements had plasma volumes 
of less than 33 ml/kg (i.e. normal mean minus one standard 
deviation). 
Group 3. 
These patients satisfied the haemoglobin and haematocrit 
criteria, and had red cell volumes exceeding 35 ml/kg 
(i.e. normal mean plus one standard .deviation). 
Group 4. 
These patients satisfied the haemoglobin and haematocrit 
criteria but, on blood volume meansurements were found to 
have volumes within the normal range (i.e. mean normal 
+ 1 standard deviation). 





These may be seen in Tables VI-28 t hrough t o Table VI-38 . 
As can be seen, most of these pat i ents had onl y one day 
studies so that RBCUe values could not be obtained. The 
few that were followed were so small in number that analys i s 
of their results is probably meaningless . Many of the 
patients referred with low plasma volumes were on diuretic 
therapy, and many of the patients had unfortunately been 
venesected prior to referral. 
Blood volume studies. 
(a) Total blood volume:-
In only one group of patients, was total blood volume 
significantly elevated (see Tab l e VI-29), thi s being 
Group (3) patients (P < .05). In most of these patients, 
the increased total blood volume was due to increase in 
red cell mass. The majority of these pati ents suffered 
from chronic obstructive airways disease (COAD), although 
one patient had cyanotic congenital heart dis ease (tetralogy 
of Fallot) and one had polycythaemia secondary to a hepatoma. 
The diagnosis of COAD was established by full pulmonary funct i on 
studies. It is of interest to me that, of the many patient s 
seen at this hospital with obstructive airways disease (often 
of an incapacitating severity), so few present with polycythaemia, 
despite markedly depressed arterial oxygen concentrations. 
One wonders whether these polycythaemic patients may not 
have either abnormally sensitive bone marrows to a normal 
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erythropoietin stimulus, or true polycythaemia vera in 
addition to COAD. They may, of course, produce excessive 
erythropoietin in response to a relatively minor drive. 
It seems of interest to study these patients further, at 
a later stage. in an attempt to assess exactly why they 
become polycythaemic,where patients with equally severe 
lung disease do not. 
(b) Red cell volumes. 
These were significantly elevated in all but the fourth group 
of patients (see Table VI-30) (P < .005, < .05, < .0005, 
< .20 respectively), who satisfied haemoglobin and haematocrit 
criteria, and yet had normal volumes. In none of these 
patients was I able to convince myself that peripheral 
haemoconcentration was present, none had splenomegaJ.y and 
the cause seems obscure. In an attempt to study this 
pr oblem further, the ratio of body to venous haematocrit 
has been studied in these patients, and compared with my 
normal results. The comparison is seen in Table VI-32. 
It can be seen that ~his ratio was significantly depressed 
in group (4) patients only, being normal or slightly 
increased in the other groups of patients. As commented 
upon in the section on normal patients, a variety of 
ratio values have been published for normal patients, 
varying from 0.86 to 0.96, with 0.92 being the most 
generally accepted figure. Groups (1), (2) and (3) 
are within acceptable limits for this value, but group (4) 
patients have a ratio of 0.76 + 0.06 which is significantly 
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lower than normal. 
I am not certain why this should be so. The most obvious 
possible cause is experimental error, the potential for 
which undoubtedly exists when blood volumes are measured 
by the techniques that I have used. It seems unlikely 
that experimental error could have been operating in 
so large a group of patients. I have studied the ratio 
in all the patients investigated (see Table VI-39), 
and only in group (4) patients was a consistent lowering 
of the ratio found. The other conclusion that may be 
drawn is that this group of patients have excessive 
peripheral haemoconcentration when compared to normal patients. 
I am not sure that I can resolve this problem witho t 
analysis of haematocrit values from central vessels. This 
has unfortunately not been done, but remains a project for 
further study. 
(c) Plasma volume measurements. 
Two groups of patients (group (2) and (4) ) had pla::;ma 
volumes that varied significantly from the normal range 
(P < .0005 and <.005 respectively). In the case of group 
(4) patients, the amount of variation was minimal, although 
present. In group (2) patients, selected because ,:,f reduced 
plasma volumes, a number of aetiological factors were 
present. A number of these patients were heavy smokers, 
and this may have interfered with antidiuretic hormone activity. 
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Some of the patients were, in addition, upon dtur~tic 
therapy for cor pulmonale or pulmonary oedema. These 
patients as a group had significantly elevated red cell 
volumes (P < .05) so that they may be masked polycythaemiavera 
patients. This possibility cannot be further studied in 
these patients as repeat estimations of therapy are difficult 
to get. It may, however, be of interest to study further 
the influence of smoking on the plasma volume. 
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TABLE VI-28 
(1) Treated and Non-Treated Proven Polycythaemiavera Patients. 
Name Rb B.PCV Hct Bl. Vol RBC Pl. Vol PI t!PIC EI PIT EIT 
V.PCV ml/kg Vol ml/kg 
ml/kg 
Gre 18.1 0.76 54 60 24.6 35.4 267 139 1.09 ,9694 .4991 
Hay 19.3 o. 77 56 54.5 23. 4 31.1 150 104 0.94 .6992 .4447 
Lyn 15.9 0.84 51 92,9 39.6 53.3 29 29 1.65 .5373 .4831 
Luc 20.3 0.83 60 73.8 36.6 37.2 40 30 1.67 .5953 .5326 
Sch 17.6 0.86 52 69.0 31.0 38.0 207 122 1.05 .8850 .5071 
Swe 19.1 0.89 59 83.5 49.9 39.6 58 23 2.50 11529 10601 
Ser 18.2 0.67 51 60.6 20.6 40.0 186 72 1.67 1.3712 10257 
San 20.4 0,81 57 68.8 31.8 37.0 236 114 1.16 .9846 .5917 
Tim 20.7 0.88 60 67.1 35.4 31.7 217 114 1.04 • 8528 .5125 ,· 
Vig 20.6 0,73 51 61. 2 22.7 38.5 40 27 1.96 .7893 • 7150 
Wic 16.2 0.73 48 68.9 24.1 44.8 86 41 1. 86 1185 7 1.0177 
Vig 18.9 1.04 53 63.5 35.0 28.5 280 115 1.38 L2476 . 7454 
Lon 19.9 o. 77 54 65.0 27.0 38.0 135 46 2, 03 14 704 1 2326 
Lon 22.8 0,91 65 81.4 48.0 33.4 198 64 1.621.2379 .9593 
Lon 22.6 0.88 67 88.1 52.0 36.1 282 52 2.47 2.0803 17017 
Row 19. 3 1.01 35 68.5 24.1 44.4 59 20 3. 46 199011. 8501 
Jaf 22.0 0,77 68 89.6 47.1 42.5 243 51 2. 23 l 7945 L 4760 
Jou 16.2 0.93 42 84.4 33.1 51.3 89 49 1.67 Lll45 .9234 
Pet 19.0 o.74 60 65.6 29.0 36.6 147 113 0.81 .5852 .3537 
Row 20.4 1.04 60 75.2 46.7 28.5 26 15 2.97 • 7765 .7358 
Web 16.2 0.75 52 54.1 21.2 32.9 88 91 0.82 .5044 .3438 
(2) Patients referred with Rb greater than 18 (male) greater than 16 
(female), PCJV greater than 52 (male) greater than 47 (female) 
Plasma volume less than 33 ml/kg (x - 1 SD) 
Name Rb B.PCV Hct Bl. Vol RBC Pl. Vol PI t!PIC EI PIT EIT 
V.PCV ml/kg Vol ml/kg 
ml/kg 
Vis 20.9 0,93 70 65.4 42.5 22.9 72 27 2.10 .9672 .8775 
Thy 18.6 0.94 51 53.3 25.5 27.8 189 72 1.69 13934 10422 
Sch 18.3 0.83 48 55.0 22.0 33.0 94 73 1.09 .7143 .5318 
deB 19.6 0.85 61 63.8 33.2 30.6 104 48 1.54 .9587 .7990 
Gal 21.2 0.95 63 81.4 48.7 32.7 190 41 2.53 19482 16686 
Pev 18.2 0.99 66 54.5 35.7 18.8 123 73 1.04 .6593 ,4917 
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Table VI-28 contd. 
(3) Patients referred with Hb greater than 18G% (male) 
-
or 16G% (female); PCV greater than 52 (male) 47 (female); 
with red cell volume greater than 35 ml/kg (x + 1 SD) 
Name Hb B.PCV Hct Bl. Vol RBC Pl. Vol PI t 1PIC EI PIT EIT 
V.PCV ml/kg Vol ml/kg 2 
. ml/kg 
Vis 20.9 0.93 70 65.4 42.5 22.9 72 27 2.10 .9672 • 8775 
Mar 20.4 0.85 60 87.5 44.4 43.1 101 52 1.42 .8786 .7204 
vdV 18.8 1.05 57 116.0 69.7 46.3 74 36 1. 81 .9669 .8437 
Gal 21. 2 0.95 63 81.4 48.7 32.7 190 41 2.53 1. 9482 l 6686 
Pev 18.2 0.99 66t.,54.5 35.7 18.8 123 73 1.05 .6593 .4917 
Mat 20.4 0.12 62 104.0 46.6 57.4 65 32 1.83 .8672 .7695 
(4) Patients referred with Hb greater than 18G% (male) 16G% (female) 
PCV greater than 52 (male) 47 (female) with normal blood v-olumes 
Name Hb B.PCV Hct Bl.Vol RBC Pl. Vol PI t!PIC EI PIT EIT 
V.PCV ml/kg Vol ml/kg 
ml/kg 
Koe 20.0 0.81 56 64.6 29.4 35.2 97 100 o.75 .4703 .3057 
Lou 22.0 0.75 65 65.6 31.9 33.7 124 193 0.40 .2583 .0838 
Smi 18.9 0.73 50 55.0 20.0 35.0 101 68 1.20 .8009 .6100 
Afr 20.4 0.82 58 65.0 31.0 34.0 123 81 1.04 .7056 .5048 
Ver 21. 2 0.59 64 63.2 23.8 39.4 101 99 o. 71 .4195 .2741 
McN 20.3 0.76 62 65.7 31.1 34.6 204 78 1. 42 1..1236 .8168 
Hey 20.3 0.11 64 70. 2 34.8 35.4 64 28 2.05 .9399 .8478 
Mar 19.2 0.78 56 67.9 29.6 38.3 59 30 1.98 -!t631 .8630 
Car 20.0 o. 72 59 72.3 30.5 41.8 215 105 1.14 .9362 .5921 
Sch 17.5 0.76 51 66.8 26.0 40.8 101 57 1.42 .9405 .7529 
Ada 17.1 o.75 50 56.8 21.3 35.5 64 38 1. 70 .9095 .7885 
deV 18.1 0.83 53 63. 7 28.0 35.7 84 60 1.20 . 7138 .5631 
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Table VI-29 Blood volumes in Normal/Polycythaemic Patients 
N X SD p 
Normal 31 67.8 10.3 
Polycythaemia (1) 21 71.2 11.5 < .15 
(2) 6 62.2 10.7 < .15 
(3) 6 84.8 23.0 < .05 
(4) 12 64.7 4.9 < .10 
Table VI-30. Red cell volum~ in Normal and Polycythaemic Patients 
N X SD p 
Normal 31 26.6 5.1 
Polycythaemia (1) 21 33.2 9.8 < .005 
(2) 6 34.6 10. 1 < .05 
(3) 6 47.9 11.6 < .0005 
(4) 12 28.1 4.5 < • 20 
Table VI-31 Plasma Volumes in Normal and Polycythaemic Patients 
N X SD p 
Normal 31 40.9 7.0 
Polycythaemia (1) 21 38.0 6.5 < .10 
(2) 6 27.6 5.7 < .0005 
(3) 6 36.9 14.8 < .30 
(4) 12 36.6 2.7 < .005 
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Table VI-32 B.PCV / V.PCV Ratios in normal and Polycythaemic 
patients. 
N X SD p 
Normal 28 0.85 0.09 
Polycythaemia (1) 21 0.84 0.11 < .40 
(2) 6 0.92 0.06 < .025 
(3) 6 0.92 0.12 < .10 
(4) 12 0.76 0.06 < .0005 
Table VI-33. Plasma Iron concentrations in normal and 
Polycythaemic patients 
N X SD p 
Normal 28 111.1 40.7 
Polycythaemia (1) 21 145.9 88.9 < .10 
(2) 6 128.7 49.9 < • 25 
(3) 6 104.2 47.4 < • 40 
(4) 12 111.4 50.6 < .495 
Table VI-34. tiPIC values in .nonnal and Polycythaemic 
:!.'atients 
N X SD p 
Normal 31 80.9 25.7 
Polycythaemia (1) 21 68.1 40. l < .15 
(2) 6 55.7 19.8 < .01 
(3) 6 43.5 16.8 < .0005 
(4) 12 78.1 44.9 < .45 
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Table VI-35 Erythropoietic Index in Normal and Polycythaemic 
Patients 
N X SD p 
Normal 28 1.13 o. 29 
Polycythaemia (1) 21 1. 72 o. 71 < .0005 
(2) 6 1.67 0.58 < .025 
(3) 6 1. 79 o.52 < .0025 
(4) 12 1.25 0.50 < • 475 
Table VI-36 Plasma Iron Turnover values in normal and 
polycythaemic patients 
N X SD p 
Normal 28 0.7816 0.2554 
Polycythaemia (1) 21 1.0869 0.4574 < .005 
(2) 6 1.1069 0.4870 < .10 
(3) 6 1.0479 0.4552 < .10 
(4) 12 0.7651 o. 2611 < . 45 
Table VI-37 Erythroid Iron Turnover values in normal and 
Policxthaemic Patients 
N X SD p 
Normal 28 0.4401 0.1821 
Polycythaemia (1) 21 0.8434 0.4330 < .0005 
(2) 6 0.9018 0.4299 < .01 
(3) 6 0.8952 0.4026 < .01 
(4) 12 0.5836 0.2528 < .05 
Table VI-38 Comparison of the statistical difference of ferrokinetic 
parameters in different types of polycythaemia compared 











P values (i.e. probability of significance of the 
difference) have been entered. 
(2) (3) (4) as defined in text (VI-e-1) 
GROUP 
(2) (3) (4) 
< .05 < .10 < .025 
< .40 < .005 < .05 
< .0005 < .45 < .20 
< .025 < .10 < .01 
< .30 < .10 < .10 
< • 20 < .025 < .30 
< • 45 < .40 < .025 
< .475 < .45 < .01 
































·Comparison of body PCV /venous PCV ratios 1.n 
different disease groups. 
N X SD p 
28 0.85 0.09 
8 0.94 0.08 < 
24 0.86 0.12 < 
11 0.93 0.16 < 
3 0.87 0.15 <: 
31 0.97 0.35 •: 
17 0.93 0.28 < 
15 1.03 0.38 <: 
11 1.01 0.37 <'. 
13 0.87 0.14 <: 
9 o. 89 0.21 <: 
11 0.86 0.11 <: 
8 0.87 0.07 <: 
12 0.88 0.10 <'. 
9 0.87 0.14 <: 
3 0.94 0.06 <: 
21 0.84 0.11 <: 
6 0.92 0.06 <: 
6 0.92 0.12 <. 
12 0.76 0.06 <. 
4 0.96 0.09 < 
4 0.92 0.13 < 
Haemolytic Anaemia 5 0.87 0.22 <' 
Fe deficiency 
and haemolysis 9 0.90 0.19 <. 





























Plasma Iron Values 
These are statistically presented in Table VI-33. In 
none of the groups was plasma iron concentration significantly 
different to normal values. A number of individual patients 
were iron deficient as a result of repeated venesection, but 
this was not mirrored in the overall results of the groups 
as a whole. 
t!PIC and EI values (see Tables VI-34 and VI-35) 
The t ! PIC was significantly elevated in groups (2) and (3), 
reflecting their increase in erythropoietic activity to 
maintain a larger than normal circulating red cell mass. 
EI values were significantly elevated in groups (1), (2) 
and (3) where red cell mass was also significantly el evated. 
This shows the value of this parameter in detecting ~ncreased 
erythropoietic activity. Of interest are the norma:l 
t 1PIC and EI values in group (4) patients, tending to 
~ 
support the thesis that their red cell volumes were not 
elevated, and that their peripheral haematocrit repr1!sented 
a difference in distribution in red cell rich blood. 
PIT and EIT values. (see Tables VI-36 and VI-37) 
PIT values were significantly elevated only in group (1) 
patients, this probably reflecting their slightly greater 
plasma iron values. EIT values, however, show signj_ficant 
elevation in groups (1), (2) and (3), where erythropoietic 
activity must be increased to maintain an increased red 




values for this parameter, s.uggesting that blood volume 
estimations were experimentally sound. 
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Thus, all the indices previously postulated as indicating 
increased total erythropoietic activity have shown good 
correlation in practice, with situations where red cell 
mass is increased and erythropoiesis must be increased. 
The best of these indices undoubtedly appears to be the 
erythropoietic index. 
Ferrokinetic Parameters in Patients with Iron Deficiency, 
and in disease processes associated with l ow pl asma iron 
levels. 
Patient selection. 
Four groups of patients have been selected for discussion in 
this section. 
Group (1) Classical Iron Deficiency Anaemias:-
The criteria for inclusion of patients into thiE group 
are:-
a) Haemoglobin less than 12 G% 
b) Microcytosis and hypochromia on peripheral smear 
examination. 
c) Plasma iron concentrations of less than 30µgm%, 
with total iron binding capacities exceeding 300µgm%. 
A number of these patients had associated diseaHe 
processes which were thought not to have interfE!red 
with their ferrokinetic performance. 
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Group (2) Iron deficiency by the above criteria ' 
unassociated with anaemia. A nuniber of these patients 
were obtained, :Particularly amongst patients with 
polycythaemia treated by venesection. 
Group (3) Patients with low plasma iron levels (<70µgm%) 
behaving ferrokinetically in the same way as patients 
with classical iron deficiency anaemia. These patients 
have been included under a separate group, as they 
often had low TIBC values or a disease process that may 
have interfered with their ferrokinetic performance. 
Group (4) Patients with low plasma iron levels wit~ 
suboptimal ferrokinetic performance. In this ,5roup, 
as in group (3), a plasma iron level of <70µg% ·;.ras 
selected, as Hillman has shown this level of plasma 
iron to be necessary for normal erythroid function. (
3B4) 
The ferrokinetic value chosen in order to decide whether 
a patient was ferrokinetically suboptimal or not was an 
erythropoietic index of less than 1.45. Where the 
erythropoietic index exceeded 1. 45, the patient was put into 
the appropriately responding group. This f i gure was 
chosen arbitrarily, but was decided upon because it 
represented the upper limit of normal EI values. Patients 
with iron deficiency have, under normal circumstances, 
bone marrows that are avid for iron, and these patients 
would therefore, have rapid t!PIC value~ more rapid than 






These may be seen in Table VI-40 through to Table VI-49, 
A level of plasma iron of less than 30µg% has been chosen 
for my group (1) patients as this level, in association 
with a TIBC level of >300 g%, virtually establishes the 
diagnosis of classical iron deficiency anaemia. 
Plasma Iron Levels. (See Table VI-41) 
The values in the different groups was, not surprisingly, 
significantly depressed. Many of the group (3) patients, 
in fact, had classical iron deficiency and wer e only 
excluded from groups (1) or (2) because their plasma iron 
levels were >30 but <70µg%, In patients of groups (3) 
or (4), the low plasma iron levels were usually associated 
with blood loss. In a number of patients, t his could not 
be demonstrated and, in eleven patients, the causative 
agent appeared to be inflammation or infection . Six 
patients had low plasma iron levels in association with 
neoplasms. 
t!PIC and EI values (Tables VI-42 and VI-43) 
As can be seen from the relevant tables (VI-42 and VI-43), 
t!PIC was significantly depressed below normal in a l l patients . 
To some extent, this reflected the decrease in plasma iron 
concentration, as the EI values were, in groups (2) and (4), 
not as significantly depressed. Moreover, group ( L,) patients, 
had EI values within the normal r~nge, in sharp contrast 
to the patients in the other groups. The greatly elevated 
EI values in the responsive iron deficient situation may 
be related to a number of factors. 
(i) the extreme avidity of the bone marrow for iron. 
(ii) an increase in total erythropoietic activity to 
compensate for 
a) increased ineffective erythropoietic activity. 
(258)(164)(106)(687)(688)(766)(727) 
b) decreased or shortened red cell survival. 
(198)(246)(292)(411)(687)(833) 
c) the presence of anaemia with presmnable 
increase of erythropoietin production. 
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The t!PIC in the patients with iron deficiency was even 
more rapid than that of patients with haemolytic anaemias 
(see Table VI-6), although in most cases EI values were 
not as greatly elevated (Table VI-7) . The extremely 
rapid t !PIC values probably indicated the influence of 
low plasma iron l evels as well as of increased eryth.ropoietic 
activity. The variation due t o changes in plasma iron 
level are r emoved by using the erythropoietic index, which 
appears to refl ect i ncreased total erythropoietic activity 
in these patients. Almost certainly, t hese patients were 
not producing nearly as much haemoglobin as t he EI values 
suggest, because they remained anaemic until i ron t herapy 
was given. A major portion of their erythropoietic 
activity must, therefore, have been ineffective. 
Group (4) patients were specifically chosen because they 
stood out as a separate group when EI values were examined. 
In this group were seven patients suffering from acute 
VI-f-5 
infective processes and, in two of these, ethanol was a 
major cause for their acute infection (aspiration lung 
Zl~ 
abscesses). Two of the patients had chronic renal failure, 
two had blood dyscrasias with bone marrow involvement, 
and two of the patients were unconscious, on catheter 
drainage of the bladder, and were demonstrated to have 
urinary tract infections. In the remaining patients, 
the only associated factor that I could find that may 
have been associated with depressed bone marro'il function 
was ethanol ingestion which was usually associated wi th a 
poor diet. 
A clear message emerges from this study. If, on ferrokinetic 
investigation, a patient is found who has plasma iron levels 
of <70µg%, and has an EI value of <1. 45, another associated 
disease process causing bone marrow suppression must be 
actively looked for and excluded. These findings confirm 
much of the previously described ferrokinetic findings i n 
l.
• ran d f · · t b · t (62) (61) (284) (675) (385) e 1.c1.en su Jee s. 
PIT and EIT .. values (see Tables VI-44 and VI-45) 
Theoretically, because of restricted bone marrow iro·1 supply, 
one would expect PIT and EIT values to be depressed. The 
values obtained were, however, normal or increased i n all 
groups except group (4), whilst PIT values tended to be 
normal (P <.45, < .20, < .005). EIT values tended to be 
raised (P <.005, < .025, < .0025) in groups (1) to (3) 
respectively. Values for PIT and EIT were significantly 
depressed in group (4) (P < .0005,< .10). This generalisation 
VI-f-6 
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certainly does not apply to all individual patients within 
the various groups. and where plasma iron levels were 
excessively low, thi s was mirrored by ' hypoplastic' PIT 
and EIT values. Had iron been freely available to these 
patients , it is almost certain that PIT and EIT values 
would have been far higher, as described by Hillman . (385) 
This finding of normal or increased PIT values in iron 
defi ciency has been previously reported by a number of 
workers, <679><232><258) although at least one worker has 
f d 11 d d 1 . h . d . . ( 80) oun genera y epresse va ues 1.n t 1.s con J_tion. 
Presumably ineffective erythropoietic activity accounts 
for a ~arj.or fraction of EIT and PIT as many of these patients 
remain anaemic. 
RBCUe and RBCUe / RBCUp values . (Tables VI-46 and VI-47) 
A number of workers have shown t hat ineffective erythropoietic 
activity is greater than normal in i ron deficient states. 
(258)(164)(106)(687)(688) (726)(727) 
This would explain 
my findings in patients wi th iron deficiency, where the ratio 
RBCUe/RBCUp is significantly depressed 1.n all groups. Most 
authors state that RBCUe values should be 100% in conditions 
· t d · th · d f · · (211) (576) (62) (212) (164) (258) associ.a e wi iron e 1.c1.ency. 
We have not found this to be the case, and this presumably 
reflects the early removal of iron label from the red cells 
by either random haemolysis or ineffective erythropoiesis. 
It is interesting that of all the groups, group (4) patients 




presumably reflects the withdrawal of a temporarily 
depressant factor from the patient while in hospital and 
on treatment, as previously discussed with the second group 
of hypoplastic patients. 
t
1
51cr Red Cell Survival Values. (see Table VI-48) 
I have found, as previously discussed (VI-c), significant 
shortening of red cell survival in patients with severe 
iron deficiency. This may represent the effects of blood 
loss, but independent shortening of red cell lifespan in 
this situation has been found by a number of workers, (l
9B) 
(246)(292)(411)(833)(687) th d f t b · th ht t b e e ec eing oug .o e 
an intrinsic cellular abnormality. Group (4) patients, 
whose low plasma iron levels were associated with depressant 
disease processes, had normal red cell survival, as 
51 
measured by t! Cr data. 
Comparison of the results in the different iron def i cient 
groups. 
The results of the different groups have been compared 
with group (1) used as a standard. The comparison is 
presented in Table VI-49. As can be seen, group (2) 
patients behave identically to group (1) patients. 
Group (3) patients, because higher plasma iron level s have 
been accepted, behave identically to group (1) patients 
except under circumstances where increase in plasma iron 
level will increase the value of an individual ferrokinetic 
parameter (PI, t!PIC, PIT, EIT). Group (4) patient s are 
totally different in their ferrokinetic behaviour to 
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group (1) patients, this difference reflecting their 
selection on the basis of depressed bone marrow function. 
Table VI-40 Ferrokinetic findings in patients with low serum Iron values. 
(1) .. 































Classical Iron Deficiency (lib <12, PI <35, TIBC >300, %Sa t <10) 
Iron Deficiency as above unassociated with anaemia 
Low Plasma Iron ( <70) with EI > 1.45 
Low Plasma Iron ( <70) with EI< 1.45 






























































































2.74 • 7204 
2. 97 • 7765 
1.65 .5373 

















































































Table VI-40 contd. 




(3) Cad 23 1.01 42 15 4.21 2.1452 2.0295 81 .88 20
 
Jeg 34 0.91 45 33 1.86 .9371 .8289 92 1.00 19 .0
3 
Bei 25 0.67 39 40 1.51 .7508 .6456 
Wil 20 2.27 43 44 1.48 .8048 .6820 54 o· .. 59 17 
Han 37 • 87 53 31 2.09 1.1277 1.0053 55 .60 11 
vNi 38 .75 59 22 3.08 1. 7603 1.6259 100 1.11 15 .05 
Row 35 1.01 59 20 3.46 1.9901 r. 8501 
Fer 35 • 85 46 33 1.86 .9596 .8505 21 ;23 38 .oo 
vdM 31 • 83 25 22 2.27 .8197 .7572 60 .62 21 .00 
Wil 30 1.88 44 34 1.83 .9369 .8254 93 1.01 16 .00 
Sch . 26 .94 33 31 1.81 .8151 • 7273 89 .95 33 .00 
vdM 32 .83 70 25 3.09 2.0160 1. 8431 87 1.0L. 28 .20 
Mab 62 • 72 65 32 1.83 .8672 .7695 
Hoe 40 1.34 65 19 3.69 2.1285 1.9$47 47 • .S3 26 .07 
Ada 50 .75 64 38 1. 70 .9095 .7885 
deV 43 • 77 64 46 1.48 .8501 • 7148 
(4) Vlo 41 .94 36 50 1.08 .4484 • 36.99 85 • 89 .16 
Rus 36 .96 49 64 .98 .5l21 .3974 100 1.09 .30 
Mau 31 .94 44 52 1.19 .6048 .4948 100 J..09 .oo 
Kho 45 .93 55 51 1.22 .6320 .5192 100 1.09 
Ada 16 • 85 39 72 .88 .4619 .3455 80 • 88 27 .oo 
Loz 36 1.05 9 35 1.13 .1740 .1529 88 .87 .oo 
Ash 35 .99 64 110 .66 .3955 .2428 75 • 85 27 . 27 
Pax 29 .94 41 54 1.12 .5619 .4567 73 .78 27 .00 
Mal 50 .75 59 62 1.00 .5147 .4032 
Cha 37 • 71 51 57 1.12 .5902 .4724 81 • 89 35 .35 
Bot 47 .74 55 86 • 72 .3604 .2519 
deB 43 .69 62 60 1.12 .6245 .4934 84 .93 20 .19 
Sep 47 .78 67 83 • 81 .4582 .3251 
Sal 23 1.94 70 71 1.16 • 7806 .5874 96 1.16 24 .00 
Hal 28 .89 32 57 • 97 .4161 .3329 
Pet 42 .90 29 51 .98 .3475 .2853 92 .95 .27 
Sch 36 • 85 21 34 1.37 .4131 .3639 98 1.00 36 .oo 
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Table VI-41 Plasma Iron Values in normal and -Ir0.n Deficiency Patient s . 
GROUP Plasma Iron 
N X CJ p 
Normal 28 111.1 40.7 
Fe deficiency 
(1) 12 24.3 10.8 < .0005 
. (2) 3 27.0 1. 7 < .0005 
(3) 28 48.5 16.0 < .0005 
(4) 17 46.0 17.0 < .0005 
Table VI-42 t!PIC values in normal and Iron deficient patients 
GROUP t!PIC 
N X CJ p 
Normal 31 80.9 25.7 
Fe deficiency 
(1) 12 21.9 6.3 < .0005 
(2) 3 20.3 7.6 < .0005 
(3) 28 28.9 7.6 < .0005 
(4) 17 61. 7 18.7 < .0025 
Table VI-43 Erythropoietic Indices in normal and Iron deficient patients 
GROUP Erythropoietic Index 
N X CJ p 
Normal 28 1.13 0.29 
Fe deficiency 
(1) 12 2.39 0.65 < .0005 
(2) 3 2.44 0.10 < .0025 
(3) 28 2.27 o.79 < .0005 
(4) 17 1.03 0.18 < .10 
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Table VI-44 Plasma Iron Turnover values in Normal and Iron deficient 
.patients 
GROUP Plasma Iron Turnover 
N X a p 
Normal 28 .7816 .2554 
Fe deficient 
(1) 12 .8107 .3656 < .45 
(2) 3 .6945 .1362 < • 20 
(3) 28 1.1232 .5713 < .005 
(4) 17 .4880 .1398 < .0005 
Table VI-45 Erythroid Iron Turnover values in normal and Iron 
Deficiency patients 
GROUP Erythroid Iron Turnover 
N X a p 
Normal 28 .4401 .1821 
Fe deficiency 
(1) 12 .7507 .3476 < .0005 
(2) 3 .6476 .1426 < .025 
(3) 28 1.0164 .5459 < .0025 
(4) 17 .3820 .1135 < .10 
Table VI-46 Red cell utilisation in normal and iron deficient patients 
GROUP RBCUe 
N X a p 
Normals 17 83 15 
Fe deficiency 
(1) 9 85.1 14.2 < . 40 
(2) 
(3) 18 75.6 20.9 < .15 
(4) 13 88.6 9.7 < .15 
'l.27 
Table VI-47 Ratio RBCUe/RBCUp values in normal and !ran deficient patients 
GROUP RBCUe/RBCUp 
N X a p 
Normal 14 1.11 0.27 
Fe deficiency 
(1) 9 • 87 0.15 < .01 
(2) 
(3) 18 .83 0.23 < .0025 
(4) 13 .96 0.11 < .05 
Table VI-48 
51 




N :x; a p 
Normal 10 27 4.7 
Fe deficiency 
(1) 8 20.1 7.1 < .025 
(2) 
(3) 16 22.6 9.3 < .10 












Comparison of differences in various parameters, 
of different groups of Fe deficient patients 
(results expressed in terms of significance 
of the differences) , compared with group ( 1) 
patients (i.e classical Fe. deficiency anaemia) 
GROUP 
(2) (3) (4) 
< .25 < .0005 < .0005 
< .40 < .0025 < .0005 
< .475 < .30 < .0005 
< • 20 < .025 < .0005 
< • 25 < .05 < .0025 
< .10 < .30 
< .30 < .10 





Ferrokinetic studies in Patients with Neoplastic Disease . 
Patients were selected for this study who were shown 
histologically to have some form of neoplasm, either 
benign or malignant. In this group of patients, a number 
of disease processes were often operative so that this 
study does not characterise ferrokinetic performance 
due to neoplastic processes alone. A number of the 
patients studied were on anti-metabolites or receivi ng 
radiotherapy, and a number had associated folate def iciency . 
The results in this group of patients may be seen in 
Table VI-50, In this group of patients, plasma iron, 
51 
t!PIC, and t! Cr values did not show any significant 
deviation from normal results. EI, PIT and EIT vaJ.ues 
tended to be raised, whereas RBCUe and RBCUe/RBCUp values 
were significantly depressed. From these results, it 
would appear that erythropoietic activity in these patients 
was increased, al though much of this increase appea,~ed to 
be ineffective. This may have been due to the effects of 
'conditioned folate deficiency 'by a growing tumour o:~ a 
result of cytotoxic therapy. 
As described in the literature, the anaemia associa~ed with 
neoplastic disease is usually associated with decreased 
erythropoietic activity and increased red cell dest:~uction, 
(47) (39) (149) (151) (150) (197) (733) (583) (414) (413) a :: inding 
LJU 
not found in this group of patients. In addition, . 
impaired release of catabolised haemoglobin iron from 
reticulo-endothelial sites has been postulated, (
36 l)(46o) 
with plasma iron levels being reduced. (
33o) Other 
factors may aggravate the anaemia i.e. blood loss, bone 
marrow infiltration, conditioned deficiency of Vitamin B12 
f 1 h 1 
. d . . h (392) (269) 
or o ate, aemo ysis an microangiopat y. 
(677) (514) 
lJl 
Ferrokinetic values, and their sta~i stica l difference 
Table VI-50 
from normal in patients with Neoplastic Diseases. 
Name Neoplasms Hct B.PCV PI t 1PIC EI PIT EIT RBCUe RBCUe t51Cr f 
V.PCV 2 RBCUp i 
a) Benign 
deV Phaeo 43 0.77 64 46 1.48 .8501 • 7148 




Lipomatosis 24 0.90 96 29 3.43 2.5530 2.2912 45 0,59 24 0.53 
b) 
Malignant 
Mab Hepatoma 62 0.87 65 32 1. 83 • 8672 .7695 
Sil Hepatoma 30 0.90 55 30 . 2.30 1.3185 1.1792 79 0.89 12 o.oo 
Sen Myeloma 37 0,90 217 140 1.14 1.0238 .5229 31 0.60 27 0.48 
Tay Hyper- 54 o.74 26 17 2.69 .7696 • 7238 66 0.67 43 0 .40 
nephroma 
Folate + 




vRo Adeno 32 1.18 193 148 1.03 • 9201 .4435 
Ca.+R/T 
vWy Ca~breast 34 0.69 137 86 1.35 1.0998 • 7703 82 1.19 24 0.14 
+ R/T 
Ret Ca.caecum 54 0.95 331 158 1.14 1.0542 .4712 
+5-FU+R/T 
Pau Ca.Oesoph.45 o. 78 114 60 1.54 1.1134 .8796 
Normal X 111.1 80.9 1.13 .7816 .4401 B3 1.11 27 
CJ 40.7 25.7 0.29 .2554 .1821 15 0.27 4.7 
N 28 31 28 28 28 17 14 10 
Benign X 68.0 34.3 2.34 1.4702 1.3050 
CJ 26. 2 10.1 1.00 .9410 .8596 
N 3 
p <.475 
Mal i gnant 
X 129.2 77 .o 1. 70 .9985 • 7241 63.6 0.79 25.4 
CJ 102.4 57.9 0.60 .1722 .2291 20.4 0.25 11.3 
N 9 9 9 9 9 6 6 6 






-Ferrokinetic studies in patients with lnf~ctious .diseases. 
All patients included in this study were studi ed whi It' 
on appropriate chemotherapy for their infective process. 
The results that I have obtained in this group of patients 
are detailed in Table VI-51. Characteristic of the group 
was:-
No significant difference from normal in PI, t: !PIC, PIT, 
51 RBCUe or t! Cr. 
A significant increase in EI (P < .05)and EIT (P < .05). 
A significant decrease in RBCUe/RBCUp (P < .05) 
Once again, there appears to be increased ery t:hropoietic 
activity, with a major portion of this being i neffective 
as evidenced by a decreased RBCUe/RBCUp ratio in the 
51 presence of normal t! Cr red cell survival. Two of the 
patients included in this study had evidence of folate 
deficiency, one patient had an associated auto-immu~e 
haemolytic anaemia, and seven of the pati ents were known 
to be altoholics. These complicating;factors undoubtedly 
influenced the results, so that I cannot claim to have 
demonstrated any ferrokinetic pattern characteristi c of 
infection alone. 
Plasma iron levels tend to be decreased i n the prese,nce of 
. f t" (129)(130)(673)(698)(796)(273)(735)( 252) d . in ec ion, espite 
adequate body iron stores. <29) Impaired red cell 
23'3 
production appears to be the main c·ause of the anaemia 
. d . h . f . (113) (273) associate wit in ection. This may, in part, 
be due to impaired reticule-endothelial release of 
catabolised haemoglobin iron, due either to increased 
reticule-endothelial avidity for iron or impaired release 
mechanisms. (ll3)< 273) The bone marrow, as emerges from 
my results, appears to be capable of normal utilisation 
of transferrin iron. A moderate haemolytic element has 
also been described in the anaemia of infection, (lOO) 
this usually being of minor significance although it may 
assume major importance. (433)(110)(579)(148)(742)(538) 
Limitation of erythroid activity may be conditioned by 
lowered plasma iron levels, but there also appears to be 
. d d . f h . . (129) ina equate pro uction o eryt ropoietin. Haurani 
et al have also shown that gastrointestinal absorption of 


























Ferrokinetic values, and their statistical difference from 
normal in patients with Infectious Diseases. 
Hct B.PCV PI t!PIC EI PIT EIT RBCUe RBCUe t! V.PCV RBCUp 51 
23 • 98 38 17 3.55 1. 7623 1. 6574 86 0.92 
58 • 82 123 81 1.04 .7056 .5048 
38 1.05 53 35 1.84 .4204 .2997 82 0.90 32 
59 • 72 215 105 1.14 .9362 .5921 
29 • 85 16 29 1.54 .4045 .3635 92 0.93 22 
37 138 120 0.95 .7554 .4381 37 0.52 25 
29 .90 139 90 1.37 1.1324 • 7757 
36 1.05 9 35 1.13 .1740 .1529 88 o. 87 
46 .90 163 133 0.87 . 7096 .3805 66 o. 96 
45 .70 187 120 1.08 .9132 .5296 98 1.53 22 
29 .94 41 54 1.12 .5619 .4567 73 o. 78 27 
36 .96 49 64 0.98 .5121 .3974 100 1.09 12 
28 .57 92 20 4.69 3.3812 3.1422 23 o. 29 21 
30 .91 167 38 3.67 3.1486 2.7255 60 1.00 -
111.1 80.9 1.13 .7816 .4401 83 1.11 27 
40.7 25.7 0.29 .2554 .1821 15 0.27 4.7 
28 31 28 28 28 17 14 10 
102.1 67.2 1. 78 1.1084 • 8869 73.2 0.89 23 
68.1 40.5 1.24 .9910 .9395 24 .9 0.31 6.2 
14 14 14 14 14 11 11 7 


















Ferrokinetic Perfonnance in patients with inflammatory 
and/or auto-immune disturbances. 
235 
The patients selected for this study all had non-inf ectious 
(as far as could be established) inflannnatory or immune 
disturbances. Patients with auto-irrnnune haemolyti c 
anaemias were, however, specifically excluded from this 
study. 
The results obtained on study of these patients, may be 
seen in Table VI-52. Values showing minimal deviation 
51 from normal are the PIT, EIT, RBCUe, RBCUe/RBCUp, t! Cr 
(P for all> 0.05). Plasma iron was significantly 
depressed (P < .05), and t!PIC values were s i gnificantly 
shorter than nonnal (P < .0125). EI values were 
moderately but significantly raised (p< .05) . These 
results suggest a suboptimal bone marrow response to a 
low plasma iron level. 
A review of the literature shows that depression of plasma 
iron levels is common in association with inf lannnation, 
(111)(439)(440)(643)(873)(810)(734)(221)(273) althcugh 
body iron stores appear to be adequate. The defect 
appears to be reticulo-endothelial retention of catabolised 
haemoglobin iron. (363)(656) Defective gastr o-intEstinal 
iron absorption has been described in association "ith 
. fl t" (722)(810)(849)(73) in amma· ion. Measurements of red 
236 
cell survival are usually normal. <65)(221)(5!2)(716)(873) 
The anaemia seems to be one due to relative rather than 
absolute bone marrow suppression, perhaps aggravated by 
reduced plasma iron supply. 
237 
Table VI-52 Ferrokinetic values, and then sta.tistical diff erence from normtil, 
in patients with inf!.mmnatory and auto-inm,une diseases. 
Inflannnations Hct B.PCV PI t!PIC EI PIT EIT RBCUe RBCUe t! f 




itis 40 .86 177 94 1. 40 1.1913 .7998 80 1.27 24 .00 
Hoe SLE 40 1.34 65 19 3.69 2.1285 1.9847 47 .53 26 .07 
Koe Buergers 56 • 81 97 100 .75 .4703 .3057 72 .84 30 .08 
leG Good 
pastures 57 .57 102 77 • 99 .6325 .4620 100 1.16 36 .24 
Sch Reiters 36 • 85 21 34 1.37 .4131 .3639 98 1.00 36 .oo 
Vlo Reiters 41 .94 36 50 1.08 .4484 .3699 85 . f,9 - .16 
vNi Ulcerative 
Colitis 38 .75 59 22 3.08 1. 7603 1.6259 100 1.11 15 .05 
Arm Rheumatoid 33 .96 10 22 1.84 .3165 .2922 81 .HO - .00 
Arthritis 
Fe.def. 
II II 38 • 92 92 62 1.39 .9651 .7557 90 1. 10 -
Normal X 111.1 80.9 1.13 .7816 .4401 83 1.11 27 
CJ 40.7 25.7 o. 29 .2554 .1821 15 • ').7 4.7 
N 28 31 28 28 28 17 14 10 
Inflanunation 
X 75.1 53.3 1. 73 .9251 .7733 83.7 • 97 27.8 
CJ 48.5 31.6 1.00 .6491 .6198 16.9 .23 8.0 
N 9 9 9 9 9 9 9 6 







Ferrokinetic studies 1n patients with cirrhosis. 
Patients selected for this group were thos e whose clinical 
sunnnaries contained mention of histologically diagnosed 
cirrhosis, or abnormal liver function studies with a 
clinical diagnosis of cirrhosis having been made. 
My findings in this group of patients are detailed in 
Table VI-53. 51 PI, t!PIC, RBCUe and t! Cr red cell 
survival did not deviate significantly from normal. 
EI, PIT and EIT values were all significantly increased 
(P <.025, < .05, < .01 respectively) while the ratio 
RBCUe/RBCUp was mildly depressed (P < .0005). These 
findings suggest the presence of a mild degree of ir.effec t i ve 
erythropoiesis in this group of patients , related probably 
to disturbed folate levels and excessive ethanol 
consumption. Two patients had evidence of haemoly~is, 
one having a severe iron deficiency anaemia and the other 
being a patient with porto-systemic encephalopathy. In 
both patients, blood loss was probably a contributory 
factor. 
The anaemia associated with liver disease appears to have 
certain common characteristics independent of the nature 
of the disease process affecting the liver. Other 
abnormalities frequently co-exist, particularly blood loss, 
iron deficiency, folate deficiency and acquired haenolytic 
d . (194)(374)(403)(429)(431)(466)(471)(478)(582)(516) 1sease. 
(738)(772)(785)(868) 
The bone marrow is frequently 
VI-j-5 
hyperplastic with macronormoblastic features. <56)(437)(582) 
(648) 
Although liver B12 levels are usually decreased, 
(377) (69 9) serum levels are frequently elevated above normal, 
(711)(799)(31)(506)(349)(823)(505) d l f B ue to re ease o 12 
from damaged hepatocytes. Liver folate concentration is 
also decreased( 3l)(5o6) and folate can easily be displaced 
from the liver. (l44) In most reports, plasma iron levels 
are reported as normal or mildly elevated except in the 
f 1 . . 1 (672) 1 1 presence o an acute iver insu t. TIBC eve s are 
often depressed, and% saturation levels increased. 
Increased gastrointestinal iron absorption, often in the 
presence of excessive body iron stores, has been demonstrated 
by a number of workers. (l57)(l94)(89 l) The plasma volume 
of these patients tends to be increased(164)(229)( 343)(5l7) 
especially in the presence of portal hypertension , and this 
may give rise' to a 'dilutional' anaemia. Erythropoietic 
activity is usually increased. A number of workers have 
. (15) (133) demonstrated a decrease in red cell survival, 
(137b)(250)(343)(429)(442)(451)(466)(680) the defect being 
extracorpuscular. A number of different causes for this 
extracorpuscular defect have been described, a lthough 
corpuscular defects have also been described as in Zieve's 
S d (148)(915)(461)(619)(35b)(70)(880)(166)(204)(308) yn rome. 
(554)(780)(790)(412) The abnormalities at an extra-
corpuscular level that have been described include G6PD 





and haemolysis caused by .viral hepatitis. In some 
patients, haemolysis appears to be the dominant haematological 
defect. 
Reported ferrokinetic studies tend to show increased total 
erythropoietic activity with increase in both effective 
and ineffective components. (l45)(l57)(466)(289)(343) The 
increase is thought, however, to be suboptimal 
The anaemia of liver disease is frequently complicat=d by 
the presence of other variables i.e. blood loss, malnutrition, 
iron deficiency, folate deficiency, vitamin deficiency, 
infection, alcohol etc. Alcohol seems to play a major 
role in the anaemia of liver disease, usually by interference 
with folate metabolism (decreased folate intake, decreased 
folate absorption, increased folate requirements, decreased 
hepatic avidity for folate and depletion of liver enzymes 
required for folate metabolism plus increased urinary 
t . ) (91)(194)(374)(386)(438)(465)(471)(788)(348) excre ion. 
(127b)(580)(711) These factors may all combine to produce 
severe folate deficiency with megaloblastic bone marrow 
changes and concomitant changes in ferrokinet i c performance. 
Alcohol also appears to exert a direct toxic effect upon 
th .. (438)(571)(228)(386)(401)(818)(49)(865) ery ropoiesis, 
Anaemia associated with liver disease presents a complex 
pathogenetic problem, and my findings probably reflect the 
effects of folate deficiency rather than any other factor. 
Table, , VI-53 Ferrokineti c values, and then statistical difference 
from normal, in patients with cirrhosis. 
Cirrhosis t ! 
Name Hct B.PCV PI t !PI,C EI PIT EIT RBCUe RBCUe 51 f 
V.PCV RBCUp Cr 
All 23 .98 38 17 3.55 1.7623 1.6574 86 .92 .00 
Ada 16 • 85 39 72 .88 .4619 .3455 80 .88 27 .19 
Cha 36 '.90 19 18 2.52 • 7261 .6817 97 .98 18 .13 
Cha 37 • 71 51 57 1.12 .5902 .4724 81 .89 35 • 35 
Cra 51 .93 175 130 • 89 . 7145 .3984 
Gre 32 .91 133 88 1.32 1.0688 .7404 27 . 39 23 • 23 
J oh 37 .90 138 120 .95 .7554 .4381 37 . 52 25 .04 
Rus 36 .96 49 64 .98 .5121 .3974 100 1. 09 12 .30 
Seo 27 .60 153 63 2.13 1.8340 1. 4316 5 1 .82 22 .44 
Sev 44 .90 71 25 2.85 1. 6904 1. 5425 63 . 72 17 .11 
vdM 32 .83 70 25 3.09 2. 0160 1. 8431 8:1 1.01 28 .20 
Normal X 111.1 80.9 1.13 .7816 .4401 83 1.11 27 
a 40.7 25.7 0.29 .2554 .1821 1i-. ) .27 4.7 
N 28 31 28 28 28 17 14 10 
Cirrhosis X 85.1 61. 7 1.84 1.1029 • 90lf4 70 .9 . f,2 23 
a 54.2 39.4 1.01 .5988 .5865 2.5 .2 • L.2 6.8 
N 11 11 11 11 11 10 10 9 




Ferrokinetic parameters in chronic renal disease. 
Only three patients with renal disease severe enough to 
warrant repeated dialysis were studied. In these patients 
the results are sununarised in Table VI-54. As a group 
these patients had EI and EIT values that were not 
significantly different from normal values, but had 
significantly depressed PI, t!PIC (reflecting the depressed 
PI level) and PIT values (again reflecting low PI values). 
In the two pati~nts in which RBCUe values were obtai·c1.ed, 
these were both maximum and within the normal RBCUe/RBCUp 
range. Red cell survival was normal in the one patient 
in which it was measured. All of the patients were anaemic, 
indicating that bone marrow erythroid activity, while normal 
in absolute terms, was depressed in relation to the 
haematocrit levels. 
Reviewing the literature, it would appear that a number of 
factors are operative in the anaemia of renal failure. 
Inappropriately low levels of erythropoietin have been found, (7) 
and a haemolytic element to the anaemia has been described. (800) 
(20) Some degree of marrow failure is invariably present, 
the degree of depression usually being related to the amount 
. (95) (732) of urea retention present and the degree of 
glomerular filtration rate depression. Bleeding disorders 
. . (131)(230)(523) also contribute to the anaemia. Variable 
PI levels are reported, although TIBC levels are usually 
(523) 
depressed. Iron absorption appears to be norrr.al. 
(862) (7) (221) 
Red cell survival studies have usually 
L4J 
d f h 1 . < 45 7) u~83)"( 233) demonstrate some ·degree o aemo ys1.s, 
(137b)(l96)(443)(523)(701)(771)(800)(851) h' b . t 1.s e1.ng 
related to the severity of the renal failure and thought to 
be due to extracorpuscular abnormalities. Studies 
of red cells have demonstrated a number of abnormalities 
in red cell metabolism. (196)(410)(516)(613)(815)(855)(879) 
(892) (293) (294) Bone marrow erythroid activity is 
suppressed, this being due to impaired or decreased 
f h 
.. (7)(102)(103)(282)(281) production o eryt ropo1.et1.n, 
(545) (626) 
although relative bone marrow hyporesponsiveness 
to erythropoietin has been described. <89)(485)(549)(845) 
Ferrokinetic studies show depressed PIT values( 7)(lo3)( 221) 
(826)(483)(484)(536)(770)(443)(457)(523)(545) ( 701) and 
depressed RBCUe values. This latter abnormality has 
not been demonstrated in my patients, but it should be 
noted that they were on repeated dialysis treatment which 
has been shown by a number of authors to improve ferrokinetic 
f (58)(128)(221)(984)(545) per ormance. On the other hand 
dialysis has been shown to remove folate and iron from 
the body, producing deficiencies of both of t ese essential 
substrates. (353)( 221) 
L.44 
Table VI-54 · Ferrokinetic values_, arid then statistical difference ftctrn 
nonnal, in patients with chronic renal failure. 
Chronic Renal Disease 
t 
Name Hct B.PCV PI t!PIC EI PIT EIT RBCUe RBCUe st f 
V.PCV RBCUp Cr 
Hel 28 .89 32 57 • 97 .4161 .3329 
LeG 37 1.00 102 77 1.21 .6325 .4620 100 1.16 36 • 24 
Mau 31 .94 44 52 1.19 .6048 .4948 100 1.09 .oo 
Normal X 111.1 80.9 1.13 .1816 • 4401 83 1.11 27 
<J 40.7 25.7 0.29 .2554 .1821 15 • 27 4.7 
N 28 31 28 28 28 17 14 10 
Chronic Renal 
Disease 
X 59.3 62 1.12 .5511 .4299 
<J 37.4 13.2 0.13 .1178 .0856 
N 3 3 3 3 3 






Ferrokinetic observations in Megaloblastic Anaemias. 
All patients in this group had megaloblastic bone marrow 
change. They all had low serum B12 or folate levels or 
showed haematological response to these agents. In 
addition, all showed macrocytosis on examination of the 
peripheral blood. Many of the patients were started on 
specific therapy shortly after initiation of their ferro-
kinetic investigations. The results of study on this 
group of patients are shown in Table VI-55. 
As can be seen from the results, grossly increased 
erythropoietic activity was present in the group as a whole, 
as manifested by shortened t!PIC values (P < .0005), 
increased erythropoietic indices (P < .0005), increased 
plasma iron turnover and erythroid iron turnover (P < .0005 
for both). This increased erythropoietic activity appears 
to be largely ineffective as judged by depressed RBC:Ue 
and RBCUe/RBCUp values (P < .05 and< .005 respectively). 
Red cell survival in the group as a whole was also 
significantly shortened (P < .025). As a group, m~, patients 
demonstrated significantly depressed PI values (P < .01). 
The coincidence of iron deficiency with megaloblast i c anaemia 
(64)(117)(180)(290) has frequently been observed although 
the reverse has also been noticed. (ll9)(lS0)(573) Bone 
marrow morphology has demonstrated increased total 
erythropoiesis, and increased bone marrow volume ha:, likewise 
VI-Z- 4 
b t . d (178
)(519)(709)(449)(596) 
een no ice. · Morphological 
features of maturation arrest, nuclear cytoplasmic 
dissociation, megaloblastic erythropoiesis, as well as 
myelocyte and megakaryocyte abnormalities have been 
described. The abnormality of erythroid maturation has 
(889) . 
been confirmed by bone marrow culture, which has 
showed an inability of megaloblasts to complete DNA 
synthesis and enter mitosis during maturation. All 
changes respond rapidly to treatment with the deficient 
. (184)(383) factor 1.e. B12 or folate. 
Many workers have shown the presence of ineffective 
erythropoiesis and haemolysis in megaloblastic anaemias. 
(524)(526)(350)(754)(258) A combined intrinsic and 
extrinsic haemolytic defect is present that responds 
rapidly to treatment with the deficient factor (i.e. B12 
or folate). Iron absorption in untreated megaloblastic 
anaemias is normal or increased<
72) and PI levels are 
usually increased in association with an increase in body 
iron stores. In the untreated state ferroki netic 
investigation shows markedly increased erythropoietic 
activity (decreased t!PIC, increased PIT) that is largely 
ineffective (decreased RBCUe), these parameters usually 
returning to normal with treatment. <253)(383) (622) All 
these changes occur in both B12 and folate defi
ciency. 
(373) (375) (376) 
'-'+ I 
Table VI-55 Ferrokinetic findings in patients with Megaloblastic 
Erythropoiesi~ and comparison of these results with those" 
of normal Qatients. 
Megaloblastic Anaemias 
Name Hct B.PCV 
V.PCV 
All 23 .98 
Cad 23 .73 
Cup 30 .90 
Jan 24 • 90 
Mte 30 .91 
Sev 44 .90 
vdM 32 .83 









PI t!PIC EI PIT EIT RBCUe RBCUe t1 
RBCUp 2 51 
Cr 
38 17 3.55 1. 7623 1.6574 86 .92 
42 15 4.21 2.1452 2.0295 81 .88 20 
113 53 1.99 1.5436 1.2573 82 1.11 22 
96 29 3.43 2.5530 2.2912 45 • 59 24 
132 29 4.05 3.2954 2.9610 22 .32 6 
71 25 2.85 1.6904 1.5425 63 • 72 17 
70 25 3.09 2.0160 1.8431 87 1.01 28 
25 22 2.27 .8197 • 7572 60 .62 21 
111.1 80.9 1.13 .7816 .4401 83 1.11 27 
40.7 25.7 0.29 .2554 .1821 15 .27 4.7 
28 31 28 28 28 17 14 10 
73.4 26.9 3.18 1.9782 1.7924 65.8 .77 19.7 
38.0 11. 7 .79 .7324 .6667 23.1 .26 6.9 
8 8 8 8 8 8 8 7 














Ferrokinetic studies in patients with symptomatic porphyria. 
I h . d. · l d . (844) (491) n tis isease process, iron over oa is common, 
1 h 1 b . l . . bl (768)(206) d l . a coo a use is a most invar1a e an ana ys1s 
of the liquor consumed by these patients has shown it to 
h h . h . (744) ave a 1g iron content. I have investigated a 
number of patients proven to have this condition, the 
results of this study being shown in Table VI-56. This 
information has been previously published. C274) 
The patients were studied under metabolic ward conditions, 
and most had been without ethanol for four or five days 
prior to study. As a group, these patients showed normal 
red cell survival values, but had significantl y raised 
PI (P < .025), elevated t!PIC (P < .20) with normal 
EI values (P < .1) suggesting that the elevated t !PIC 
values were due to their greater PI concentrat ions. For 
the same reason PIT was significantly elevated (P < .01) 
although this was confined to only a few patients in the 
group who also tended to have elevated EI values. These 
individuals may have had folate deficiency conditioned by 
ethanolic excess, as described in cirrhotic patients 
(see VI-j). RBCUe values were depressed, but once again 
this appeared to reflect the effect of increased PI values, 
as RBCUe/RBCUp was not significantly different from normal 
values. 
In effect, these patients, studied while not drinking ethanol, 
had normal haematological and ferrokinetic performance. 
.£.'-t::> 
Ferrokinetic findings in patients with symptomati c porphyri a 
Table VI-56 and comparison of these results with those of normal patients 
Symptomatic Porphyries 
Nrune Hct B.PCV PI t!PIC EI PIT EIT RBCUe RBCUe t 1 f V.PCV RBCUp 2 51 
Cr 
Cha 37 • 71 51 57 1.12 .5902 .4724 81 • 81 35 .35 
Cor 46 .91 123 73 1.32 .9719 • 7236 40 .51 34 .33 
Eng 32 .98 100 188 .51 .3753 .1284 50 .64 .07 
Hol 44 .95 139 llO .97 .7521 .4626 100 1.35 .14 
Lou 45 186 53 2.44 2.0450 1.6635 
Luk 38 1.02 209 134 1.14 1.0144 .5387 49 .91 18 .20 
Len 46 • 94 264 130 1.28 1.1713 .6384 HO 1. 67 .28 
Sol 47 .90 88 130 .60 .3842 .2094 83 .98 28 .06 
Srun 44 .84 123 61 1.61 1.2002 .9439 87 1.13 26 .00 
Thy 51 .94 189 72 1.69 1.3934 1.0422 79 1.18 .00 
Thy 44 . 83 105 85 1.04 .7352 .5165 83 1. 02 23 .11 
vNi 26 .68 152 62 2.18 1.8652 1.4604 41 . 66 23 .04 
vNi 38 • 84 212 57 2.71 2.4404 1.9578 18 . 34 14 .00 
Normal x 111.1 80.9 1.13 .7816 .4401 83 1.11 27 
(1 40.7 25.7 o. 29 .2554 .1821 15 .27 4.7 
N 28 31 28 28 28 17 14 10 
Symptomatic 
Porphyries 
X 149.3 93.2 1.43 1.1491 .8275 65.9 0.93 25.1 
(1 59.8 41.6 o.67 .6403 .5622 25.1 0.37 7.3 
N 13 13 13 13 13 12 12 8 





Ferrokinetic observations ·in. patients with myelofibrosis. 
Patients selected for this study were those diagnosed as 
having agnogenic myelofibrosis by the clinician looking 
after them, usually in consultation with the haematology 
service of the hospital. The results of study in this 
group of patients are sunnnarised in Table VI-57. As can 
be seen, PI levels were normal, but the remaining parameters 
all differed significantly from normal. Erythropoietic 
activity tended to be greatly increased with shortened 
t!PIC values (P < .0005), greatly elevated EI valueH 
(P < .0005) and greatly elevated values for PIT and EIT 
(P < .0005 for each). RBCUe and RBCUe/RBCUp were greatly 
depressed (P <,0005 for both), while red cell survi val 
was significantly shortened. 
The anaemia of myelofibrosis, as seen in these patients, 
appears to represent a defect in effective erythropoiesis 
rather than, as the name implies, inadequate total 
erythropoiesis. The apparently excessive erythropoietic 
activity appeared to be largely ineffective, although 
a haemolytic element, probably on the basis of hypersplenism, 
was probably also operative. Other workers have reported 
ferrokinetic evidence of increased erythropoi etic activity, 
(631a) (863) d h 1 . (631a) (130b) d . ff . an aemo ysis an i ne ective 
h . . . . (902) l eryt ropoietic activity. Our resu ts appear to 
agree with these observations, presenting a fairly typical 
ferrokinetic picture when the clinical and ot her haematological 
features are considered. 
L.J l. 
-Ferrokinetic findings in patients with myeldfibrosis and 
Table VI-57 
comparison of these results with thoeeof normal patients. 
Myelofibrosis 
Name Hct B.PCV PI t!PIC El PIT EIT RBCUc llBCUc t ! r 
V.PCV RBCUp 51 
Cr 
deV 44 o.73 196 84 1.62 1. 3931 .9835 25 0.41 30 0.19 
Fer 35 0.85 46 33 1.86 .9596 .8505 21 0.23 38 0.00 
Gol 44 0.99 180 34 3.75 3. 1511 2. 7761 10 0.15 27 0.00 
Han 1961 58 o. 77 112 25 3.19 2.0895 1.9066 49 0.58 20 
Han 1970 25 1.90 71 17 4.82 3.2737 3.0823 56 0.67 13 0.04 
Han 1970 17 1.21 128 24 5.35 4.5949 4.2170 
Han 1971 27 0.90 150 29 4.57 3.8347 3.4401 
Han 1971 37 0.82· 53 31 2.09 1.1277 1.0053 55 0.60 11 
(AML) 
Hun 36 0.96 169 63 2.11 1. 7941 1.3985 22 0.35 
Kna 35 0.89 17 16 2. 77 • 7204 .6800 60 0.61 27 0 .30 
Lif 29 1.16 81 77 1.12 • 7713 .5634 65 0.79 27 0.00 
Mte 30 0.91 132 29 4.05 3.2954 2. 9610 22 0.32 6 o.oo 
Mar 27 0.82 91 22 4.27 3.1089 2.8695 28 0.35 14 o. 20 
Rou 67 7 16 
Smi 37 0.67 89 79 1.08 .7431 .5376 70 0.85 26 0.11. 
Wil 30 1.88 44 34 1.83 .9369 .8254 93 1.01 16 0.00 
Normal x 111.1 80.9 1.13 0.7816 0.4401 83 1.11 27 
(J 40.7 25.7 0.29 0.2554 0.1821 15 0 . 27 4.7 
N 28 31 28 28 28 17 11+ 10 
Myelofibrosis 
X 103. 8 41.5 2.97 2.1196 1. 8731 44.3 0.53 20.8 
(J 57.6 23.7 1.42 1.3055 1. 2317 24.7 0.26 9.1 
N 16 16 15 15 15 14 13 13 




During the course of my work, I had occasion to study 
one patient repeatedly. He had previously haJ fe rro-
kinetic studies while in Johannesburg, and the progression 
of his disease is of interest 1n that it showed the 
classical progression of polycythaemia to myelofibrosis 
terminating in acute monomyeloblastic anaemia. This patient, 
a Mr. Han, first consulted a doctor in 1961 when he was 
found to have a haemoglobin of 23.5G% and a white cell 
count of 18600. In 1962, a bone marrow aspiration \Tas 
performed with difficulty, but the morphology of this was 
reportedly normal. Bone biopsy was subsequently performed 
and showed fibrous hypocellular bone marrow tissue. Ferro-
kinetics studies (see Table VI-57) showed increased total 
erythropoiesis, largely ineffective, with considerable 
splenic myeloid metaplasia. Myelofibrosis was diagnosed, 
and over the next seven years he remained reasonably well, 
on no treatment, with a leuko-erythroblastic peripheral 
blood picture. 
In 1970 he consulted a doctor again because of a palpable 
abdominal mass. Splenomegaly and mild hepatomegaly were 
found on examination. Bone marrow aspiration failed and 
his second lot of ferrokinetic investigations were performed. 
This showed considerable pooling of red cells in the spleen, 
with a B.PCV/V. PCV ratio of nearly 2. Total erythropoiesis 
was markedly increased, this being largely ineffect i ve, 
and external counting again showed splenic erythropoiesis. 




In an attempt to shrink the spleen, the patient was 
started on myeleran therapy, but this was stopped because 
of significant depression of the haematocrit and lack 
of effect on the spleen. Repeated ferrokinetics at 
this stage, still showed active erythropoiesis but the 
blood volume had decreased considerably and splenic 
pooling was no longer present. It was concluded that 
haemolysis was a dominant feature, and the patient was 
started on prednisone, oxymethalone, pyridoxine and folate, 
as well as being transfused. On the prednisone, he 
developed diabetes, the dose of prednisone was decreased, 
and as a consequence of this, his haematocrit dropped 
sharply. The prednisone was once again increased, the 
diabetes being controlled with oral therapy. He was 
then referred to Prof. Bothwell for his opinion concerning 
the advisability of splenectomy. This was recommended on 
the grounds of increasing transfusion requirements, and 
was performed in May of 1971. Ferrokinetics at this stage 
still showed grossly elevated erythropoiesis. 
The spleen was removed and weighed 4.3 kg. 
showed marked splenic myeloid metaplasia. 
Histology 
The post 
operative period was complicated by thrombocytopaenia 
and anaemia, requiring platelet packs and whole blood 
transfusion, but after one month the patient was di 5charged 
on methenolone, small doses of prednisone, folate and 
pyridoxine. The haemoglobin and haematocrit were well 
maintained for approximately two weeks, when the 
patient was again admitted with a massive gastro-intestinal 
bleed that was shown to come from two large benign gastric 




period, repeat ferrokinetic study showed a similar 
pattern to previous tests. At this stage, AML was 
diagnosed on bone marrow examination and the patient 
died shortly thereafter. 
This patient's ferrokinetic features are consistent 
with the diagnosis of myelofibrosis, no deficiency 
of precursor material being demonstrated at any stage. 
This is in contrast to patient Smi., whose ferrokinetic 
performance was nearly normal, as were those of Li£. 
Progress of the disease, as seen in these pat i ents, 
254 
appears to be associated with progressively increasing 
ineffective erythropoiesis as emphasised in the literature. 
Ferrokinetic studies in patients with Reticulo-endothelial 
tumours (Reticuloses). 
·This group included patients with leukaemia and lympho-
sarcoma. The diagnosis in all patients was made 
histologically. 
in Table VI-58. 
The ferrokinetic findings are presented 
As a group, these patients showed 
significantly increased total erythropoietic activity, 
(increased EI, decreased t!PIC, increased PIT, increased EIT) 
that was largely ineffective (decreased RBCUe, decreased 
RBCUe/RBCUp). Red cell lifespan was also markedly 
depressed. Most of the patients were, at the time of 
study, receiving cytotoxic therapy, and many appeared to 
be folate deficient as judged by elevated MCV values. 
This may have contributed to their ferrokinetic 
performance. 
erythropoiesis. 
One patient had markedly depressed 
255 
Decreased red cell survival, ineffective erythropoiesis, 
and variable total erythropoietic activity have all been 
d . . . . h h . l (55) (27b) (631) reporte in association wit t e reticu oses. 
Ferrokinetic findings in patients with Reticuloses or 
Table VI-58 Leukaemia and comparison of these results with those of 
llQt:lllsll 1u1:ti~nt~ s 
Reticuloses 
Name Hct B.PCV PI t!PIC El PIT EIT RBCUe RBCUe t! f 
V.PCV RBCUp 51 
Cr 
Ash 35 0.99 64 110 0.66 .3955 .2428 75 0.85 27 0.27 
Bro 28 0.94 104 41 2.48 1.8878 1.6175 69 0.91 17 0.00 
Key 41 o. 79 165 102 1.21 1.0075 .6478 51 o. 77 17 o.oo 
Kin 33 0.87 32 14 3.84 1.6386 1.5606 
Mah 14 20 20 
Rob 42 1.49 180 46 2.84 2.4010 2.0145 23 o. 37 9 
Sal 23 1.94 70 71 1.16 • 7806 .5874 96 1.16 24 0.00 
Siz 29 0.91 225 85 2.09 1.9408 1.3634 8 0.18 - 0.00 
vNi 26 0.68 152 62 2.18 1.8652 1.4604 41 o. 66 23 0.04 
vNi 38 0.84 212 57 2. 71 2.4404 1. 9578 18 0.34 24 0.00 
Wal 25 0.84 95 28 3.50 2.5940 2.3379 18 o. 23 28 0.00 
Han 37 0.82 53 31 2.09 1.1277 1.0053 55 0.60 11 
Normal x 111.1 80.9 1.13 .7816 .4401 83 1.11 27 
a 40.7 25.7 0.29 .2554 .1821 15 0.27 4.7 
N 28 31 28 28 28 17 14 10 
Reticuloses 
X 122.9 55. 6 2. 25 1.6436 1.3450 43.1 0.61 20 
a 66.9 31.5 0.98 0.7268 .6584 28.5 0.32 6.8 
N 15 15 11 15 15 14 10 9 




Ferrokinetic studies in Sidero-Achrestic Anaemias. 
No attempt has been made to study this disease in depth, 
as only two patients were studied. The subject has been 
excellently reviewed in a recent issue of the British 
Journal of Haematology, (597b) where mention is made of 
grossly elevated erythropoietic activity, the majority 
of this being ineffective. This was confirmed in my 
patients. The interest in my one patient lies in her 
response to iron removal by intramuscular desferrioxamine, 
after all other therapy appeared not to have helped her. 
The ferrokinetic findings, before and after desferrioxamine 
are shown in Table VI-58. This patient first presented 
in 1960 with bilateral axillary hydro-adenitis that was 
treated with 600r of local irradiation. In 1961, she 
presented with vague abdominal pain, general symptorr.s and 
fever. She was extensively investigated for her obscure 
pyrexia, investigations including laparotomy. The only 
positive finding was an anaemia (Hb 9.5G%, PCV 30), a 
raised PI with raised B
12 
and folate levels; peript.eral 
smear showed two cell populations, one microcytic 
hypochromic, the other normochromic and anisocytotic. 
Bone marrow showed erythroid hyperplasia with megaloblastic 
features as well as features of dyshaemopoiesis, ringed 
sideroblasts and increased bone marrow iron stores. 
Ferrokinetics at this stage showed increased, largely 
ineffective, erythropoiesis. A definitive diagnosis of 
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sidero-achrestic anaemia was made, for which no obvious 
cause was present. She was treated with pyridoxine and 
ascorbic acid with no response until her ferrokinetic 
investigation in 1970. On the basis of the reported 
mitachondrial toxicity of excessive mitachondrial iron 
. (318)(59)(170b)(597b) . deposits and the suggestion that 
chelating agents may be of use, as well as the report by 
Crosby showing response to vigorous phlebotomy, it was 
decided to attempt to deplete her iron stores with 
intramuscular injection of desferroxamine (500 mg. 
daily). Over the course of one month her haemoglobin 
rose by 1.5G%, and two months later it had r i sen to 
11.5G%. During this period her PI fell from 253µg% 
to 71µg%. The improvement in her ferrokinetic performance 
is detailed in Table VI-58. She has apparently relapsed 
since stopping desferrioxamine therapy. 
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1970 Bot(l) 33 
1971 Bot(2) 34 
Ber 18 
anaemias and comparison .of. these results with those 
of normal patients. 
t 
B.PCV PI t!PIC EI PIT EIT RBCUe RBCUe ; 1 V.PCV RBCUp Cr 
38 2.8700 48 26 
253 124 1.51 1.4209 .8042 16 0.40 
75 30 6.13 1. 7180 1.5376 64 
377 86 3.99 3.6749 2.5739 8 
f 









Informed consent was obtained from all ·patients ·studied." 
This necessitated a brief description of the nature of 
radioactivity and the experimental protocol to the patient.· 
Two patients refused study. 
between 8.30 and 10.30 a.m. 
LABELLING TECHNIQUES 
All experiments started 
a) A total of 35 ml. of blood was taken from the patient 
at the start of the experiment. Of this, 5.0 ml. was 
placed into a polycarbonate tube containing 2 mg. of powdered 
ethylene diamine tetra acetic acid (EDTA) for haematological 
study, 10 ml. was placed into an iron free tube for serum 
iron determinations and 20 ml. was put into a sterile! 
Mcconkey bottle containing 5 ml. of acid citrate dextrose 
solution (ACD). 
b) 59Fe was obtained as a sterile solution of ferr: c 
citrate in isotonic saline from Amersham, U.K. This 
solution contained 100 mg/ml. of sodium citrate and 
6 mg/ml of sodium chloride. The specific activity of 
the iron varied between 5 and 10 microcuries per microgram 
of iron. The amount of iron used for labelling approximately 
15 ml. of plasma varied between one and two micrograns. 
) 51 b ' d d' h ' ' ' c Cr was o taine as so ium c romate in isotonic 
saline from Amersham, U.K. This had a specific activity 
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of 125 to 250 ·microcuries per micro.gram ·of chromium. 
The amount of radioactive chromate used for iabelling 
varied between one and two micrograms, the recommended limit 
being 10 micrograms/ml. of packed red cells. (l) 
d) The doses of isotope used were usually 10 microcuries 
f 
59 d 100 . . f 51 Th d o Fe an microcuries o Cr. ese oses are 
recommended by the South African Atomic Energy Board, 
and deliver a total or whole body radiation dosage of 
approximately 500 milli Rads to the patient, (Z) this 
being well within the maximum recommended dose of 
5 rads/year. In children the dose given was decreased 
in proportion to body weight. 
e) In a few patients known to have high serum iron 
concentrations with high transferrin iron saturation , 
Australia-antigen-free donor plasma was l abelled anc 
injected. 
f) Blood was prepared for labelling as follows:-
The 20 ml. of patient's blood plus 5 ml. of ACD was gently 
inverted two or three times to insure adequate mixir.g. 
The Mcconkey Bottle was then centrifuged for 10 minDtes 
at 5000 revolutions per minute (rpm). The supernatant 
plasma was aspirated and transferred to a second sterile 
Mcconkey bottle. The remaining red cells were resuspended 
in a volume of sterile isotonic saline equal to the volume 
of aspirated plasma. 
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g) To the plasma, 10 microcuries of 
59Fe as ferric 
citrate was added. The mixture was gently rotated and 
0 
then incubated for 30 minutes at 37 C. After this 
period all but 1.5 ml. of the labelled plasma was drawn 
up into a sterile disposable syringe, the syringe plus 
plasma was then weighed prior to injection. 
h) An 59Fe standard solution was then prepared. The 
Mcconkey bottle plus residual labelled plasma was fiTst 
weighed. One ml. of the labelled plasma was then 
pipetted out of the Mcconkey bottle and transferred to 
a clean 100 ml. volumetric flask. This was then made 
up to 100 ml. with distilled water. The flask was 
stoppered. The Mcconkey bottle and any residual plasma 
was weighed, the difference in weights prior to and after 
the removal of 1.0 ml. of plasma being the weight of 1.0 ml 
of the labelled plasma. 
i) 100 microcuries of 5
1cr as sodium , chromate was .::dded 
to the resuspended red cells in the original Mcconkey 
bottle. The mixture was gently agitated for apprm:imately 
one minute and was then incubated at room temperatur e 
for 30 minutes. At the end of this period, the mixture 
was centrifuged at 5000 rpm. for five minutes, the :mpernatant 
solution was aspirated, and fresh sterile normal sal ine 
was added. This washing procedure was repeated twice. 
The washed labelled red cells were then resuspended in 
an approximately equal volume of sterile normal saline. 
All but 1.5 ml of the red cell mixture was then drawn up 
into a sterile disposable syringe. The syringe 
containing labelled red cells was · then weighed:. 
j) A· 51cr standard solution was . prepar·ed ·in t he same 
way as the 59Fe standard solution (A-1-h).· 
k) 
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Four 4.0 ml. and four 2.0 ml. samples of Fe 
standard were pipetted into clean uncontaminat~d . 
disposable counting tubes for later use as a counting 
standard. The same procedure was carried out on the 
51 Cr standard. The remaining standard solution was 
stoppered for use as standards for external counting . 
A-2 HAEMATOLOGICAL MEASUREMENTS. 
These were performed as detailed by Dacie. (3) 
a) Haemoglobin concentration was measured by the 
cyarunethaemoglobin method, and gave a reproducibility 
of+ 0.5 G%. 
b) Haematocrit volumes were measured by the micro-
haematocrit method using a Clay Adams mi crohaematocrit 
centrifuge and spinning samples for 5 minutes each . 
The haematocrit was read off in a Clay Adams micro-
haematocrit reader. The reproducibility of this method 
was+ 0.5 volumes%. 
c) White cell count, platelet count, mean cell volLme 
and mean cell haemoglobin concentration were measured 
as described by Dacie. (3) The peripheral smear was 
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examined by trained haematology technicians who reported 
upon red cell morphology, white cell morphology and 
differential white cell counts. 
e) Other haematological parameters were assessed in 
these patients by the clinician referring the patient fo r 
isotope investigation. At the end of my period of 
laboratory work, the hospital records qf all patients 
studied were obtained and summarised for subsequent 
analysis. 
A-3 INJECTION OF PATIENTS AND SAMPLE COLLECTION 
a) Injection of labelled plasma and red cells:-
Prior to injection of the labelled solutions, the we ight 
of the syringe and contents was recorded. A tourniquet 
was then applied to the patient's arm, a suitable large 
vein was identified, and venepuncture perforrr,.ed. 
Once the needle was adequately placed in the vein, t he 
syringe containing the labelled red cells was emptied, 
followed by the syringe containing the labelled plasma. 
The time of injecting the plasma was recorded immediately. 
The two empty syringes were then weighed, the weights 
recorded and the syringes discarded. 
b) Sample collection: 
Whole blood samples were taken at fifteen minute intervals 
for the first hour. These, and subsequent samples were 
injected into clean test tubes containing five drops 
of heparin made up to a concentration of 5000 units 
per ml. with normal saline. The tubes were stoppered, 
mixed and identified with the patient's name, the time 
at which the sample had been collected, and the date. 
Samples were taken by repeated venepuncture, 10 ml. 
being taken on each occasion. In patients who were 
being studied for prolonged plasma iron clearance, 
repeated samples were taken as follows: 
(i) Every 15 minutes for the first hour 
(ii) Every 30 minutes for the next two hour :,. 
(iii) Every 60 minutes for the next six hours. 
(iv) At six hourly intervals for the next 
24 hours 
(v) Twice daily for the next three clays 
(vi) Daily thereafter until the end of the 
14th day. 
In patients not having prolonged plasma iron clearance 
studies, Slllilples were taken daily for the first week, 
and on alternate days for the second week of the 
experiment. 
A-4 PREPARATION OF SAMPLES FOR COUNTING 
a) The first four samples were handled as follows : 
(i) 2.0 ml of whole blood was pipetted into 
clean new disposable counting tubes. 
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(ii) the remaining blood was centrifuged 
(iii) 2.0 ml. of supernatant plasma was 
pipe tted into clean new disposable 
counting tubes. Where enough plasma 
was available, this was performed in 
duplicate. 
(iv) the remaining red cells were washed 
in normal saline and stored until the 
end of the experiment. 
All samples were stoppered. 
b) Subsequent samples were handled as follows:-
(i) the sample was centrifuged 
(ii) 4 ml. of supernatant plasma was pipetted 
into clean disposable counting tubes 
which were then stoppered. 
(iii) the remaining red cells were washed iu 
normal saline and retained as packed 
cells until the end of the experiment . 
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c) At the termination of the experiment, the patient 
had usually been venesected of between 140 and 200 ml. of 
blood, 10 ml. samples being taken with each venepuncture. 
d) At the end of the experiment, haemoglobin solut ions 
were prepared from the packed red cells. This was done 
by adding distilled water to the packed cells, stoppering 
the tubes and mixing until all the cells had been l :7sed. 
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The solutions prepared were made up to an approximate 
volume of 10 ml. Each sample was then analysed fo r 
its haemoglobin concen tra tion using the cyanmctlwcmog I ob.in 
method. Two ml. of each haemoglobin solution was t hen 
pipetted into clean disposable counting tubes, this usually 
being done in duplicate. 
e) At the time of counting, each patient had the following 
samples counted: 
4 X 4.0 ml 59Fe standard solutions 
4 X 4.0 ml 51Cr standard solutions 
4 X 2.0 ml 59Fe standard solutions 
4 X 2.0 ml Slcr standard solutions 
4 X 2.0 ml whole blood solutions 
4 x 2.0 ml plasma solutions 
(this may have been done in dupl i cate) . 
Subsequent daily 4.0 ml plasma solutions anct 
2.0 ml. haemoglobin solutions (usually in 
duplicate) - usually twelve days samples being 
counted (24 to 36 tubes) i.e. a total of be t ween 
48 and 60 samples for each patient. 
f) Background count rates were obtained on plain cl ean 
disposable counting tubes which were inserted at ev1!ry 
tenth space to insure that change of background count 
rate did not occur during the time of the experiment . 
A-5 SAMPLE COUNTING TECHNIQUES 
a) Counting Equipment and Settings: 
A dual channel, 100 sample capacity, Packard Automatic 
Gannna Spectrometer with a lead shielded three inch 
sodium iodide crystal, was used for sample counting. 
To this was attached an automatic printer which printed 
out, on each sample, the sample number, duration of 
counting, and the counts recorded during the counting 
interval in each channel. 
The counter was housed in a "counting room" where no 
radioactivity other than that contained in the samples 
being counted was allowed. The isotope spectra for 
59 51 Fe and Cr were plotted on a spectrum scanner and 
settings for counting these two isotopes were planned 
h 
51 d. · · d 1 · h sot at no Cr ra ioactivity was etectab e int e upper 
59 
channel while the upper photopeak of Fe was measured 
in this channel. 
The "upper window" used for counting 
59Fe was 490 to 750 kev. 
In this window setting, 
The "window" setting for 
51 . . d bl Cr activity was not etecta e. 
51cr was 200 to 380 kev. At 
h . · d b h 
51 d 59 d" · tis setting, counts ue to ot Cr an Fera ioactive 
decay were detectable. 
.2.70 
b) $ample Counting: 
Each patient's samples were counted 1.n a·. simple "run" at 
the termination of his study. For reasons of conveni ence 
and because of pressure upon the machine for counting time, 
each sample was counted for a maximum of forty minutes. 
During this period 10,000 counts were usually recorded, 
giving a standard deviation of+ 1% using the equation 
SD= 100 
INT 
where SD= standard deviation 
N = count rate in cpm. 
T = time of counting 
as suggested by Veall and Vetter. (6) Background count 
rates were 60 cpm in the lower channel and 40 cpm in the 
upper window. 
) S . f 51 d 59 . h 1 c eparation o Cr an Fe counts in eac samp e. 
59Fe and 51cr standards were counted in each run. The 
background count was subtracted from the sample count 
in each channel. Because of the window settings, no 
51 d. · · d d . h . d Cr ra ioactivity was etecte int e upper win ow 
setting, whereas the lower channel counts recorded were 
usually a mixture of 51cr and 59Fe counts. It was possible 
to calculate the number of 59Fe counts in the lower channel 
by a knowledge of the ratio of 59Fe standard counts i n the 
upper and lower channels. In a mixed sample, the 59Fe 
counts (n) in the lower channel would be: 
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n = 59Fe Standard counts in lower window x Sample counts 
upper window 
59Fe Standard counts in upper window 
Counts due to 51cr in the lower channel could then be 
calculated as the difference between total recorded 
counts in the lower channel and counts in the lower 
channel due to 59Fe as calculated above. 
A-6 CALCULATION OF TOTAL BLOOD VOLUME 
This was calculated by the isotope dilution pr inciple 
· 51 h · (51 ) 1 b 11 d d 1 using C rom1.um Cr a e e re ce ls. The total 
amount of radioactivity injected, in counts per minute 
51 (Cpm(. ")), as Cr labelled red cells was calculated 
l.nJ 
as follows: 
51cr Cpm = W 
· (inj) 1 x Cpm(s) x dilution factor(s) 
w2 
in 
= the weight of labelled red cells injected 
(Gms) 
w2 = the weight of 1.0 ml of labelled red cells (Gms) 
Cpm(s) = the radioactivity contained i n 
2.0 ml. of the standard solution 
of diluted red cells (Cpm). 
Dilution factor (s) = the volume in which 1.0 ml. 
of the labelled cel ls had 
been diluted in the 
preparation of the standard 
solution. 
The total blood volume (TBV (51Cr) ) was then calcul ated 
as follows: 
51 




51 . I• • • • . I where Cpm(bl) -= the amount of Cr rau1.oac t1.v1.ty conla1ncu 
in a 2.0 ml. sample of whole blood. 
The same volume of blood and standard was counted, 
obviating any need to correct for volume. The Cpm(bl) 
b . d f h 
51 d. . . (C ) value was o ta1.ne rom t e mean Cr ra 1.oact1.v1.ty pm 
contained in four samples of whole blood taken at fi f teen 
minute intervals after injection of the 51cr labellerl 
red cells. 
The patient was weighed (kg), and the blood volume was 
divided by the patients weight to give a recording of 
blood volume in ml/kg. 
A- 7 CALCULATION OF PLASMA VOLUME 
This was performed using 59Fe labelled transferrin as the 
isotope marker, and the isotope dilution principle as 
outlined in A-6. 
Four blood samples were taken from the patient at fifteen 
59 minute intervals after the injection of the Fe labelled 
transferrin in plasma (59Fe plasma). 
Two ml. samples of plasma were prepared from each sa~ple 
of whole blood as described in A-4. These s amples were 
then counted, where possible in duplicate. The radioactivity 
of each sample (Cpm) was plotted as a function of time on 
semilogarithmic paper with time being the independent 
variable. A regression equation describing the best 
semilogarithmic least squares fit for these values was 
then calculated, and the correlation coefficient (r) of 
this line was determined. Where (r) values were less 
than 0.95 it was assumed that either free (unbound) 
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59Fe had been injected or that equilibration of labelled 
transferrin between the plasma and an extravascular 
transferrin pool had occurred. This data was, therefore, 
discarded in calculating plasma volumes. In this group 
of patients (less than 5% of all patients tested) plasma 
volume was indirectly calculated from the TBV(51Cr) as 
follows: 
where PV (51Cr) = Indirectly calculated plasma volume 
Hct = Patient's haematocrit (volumes%) 
0.92 = A correction factor to bring the peripheral 
Hct. to the value of the body haematocri t 
i.e. Body Hct = Venous Hct x 0.92 
This correction factor of 0.92 is recormnended by Cook(S) 
and used in all his ferrokinetic equations. As a L:irge 
proportion of my work has been based upon his calcula tions, 
it seems prudent to use the same correction factor. 
Where the correlation coefficient exceeded 0.95 (more 
than 95% of patients studied), plasma volume was cal culated 
59 using the Fe plasma method. 
The theoretical value of radioactivity per uni t volume 
present at the time of injection (t) was calculated 
0 
from the regression equation. 
then calculated as follows: 
PV (59Fe) (ml/kg) 
59 
= Cpm(. ") Fe 1nJ 
Cpm(pl) 
The plasma volume was 
X 1 
Wt. 
Where PV(59Fe) (ml/kg) = total plasma volume in ml. 
59 l f 59 d " . · Cpm(. ") Fe= tota amount o Fera 1oact1v1ty 1nJ 
injected (Cpm) 
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Cpm(pl) = the amount of 
59Fe radioac t ivity present 
in a 2.0 ml. sample of plasma at (t ). 
0 
Wt = Patient's weight in kgs. 
59 Cpm(. ") Fe was calculated as follows : 1nJ 
59 




= weight of 59Fe labelled plasma injected (Gm) 
w2 = weight of 1.0 ml of labelled plasma (Gm) 
Cpm(s) = the amount of radioactivity (Cpm) in a 
2.0 ml sample of the 59Fe standard solution. 
d.f. = the volume in which 1.0 ml. of labelled plasma 
had been diluted in preparing the standard. 
A-8 CALCULATION OF RED CELL VOLUME 
This was calculated as the difference between the total 
blood volume and the plasma volume. 
A-9 CALCULATION OF TRUE BODY HAEMATOCRIT. 
This was calculated as follows:-
Hct(B) (%) = Red cell volume (ml) x 100 
Total blood volume (ml) 
A-10 CALCULATION OF CORRECTION FACTOR TO CORRECT VENOUS 
HAEMATOCRIT TO BODY HAEMATOCRIT VALUES. 
This was calculated as the ratio of body haematocrit 
to venous haematocrit 
i.e. Correction factor Body haematocrit 
Venous haematocrit 
A-11 CALCULATION OF THE t} PLASMA IRON CLEARANCE ( t} PIC) 
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This was calculated from the regression equation described 
in A-7 which described the best least squares fit between 
the logarithmic values of plasma radioactivity/unit volume 
of plasma, and time. 
t!PIC was calculated as follows: · 
= Log 2 
e 
Slope of regression line 
t!PIC values were expressed in minutes. 
A-12 CALCULATION OF PLASMA IRON TURNOVER (PIT) 
This was calculated by the method of Bothwell( 7). This 
method excludes the potential error of inaccurate plasma 
'L./6 
volume estimations, and has the added advantage that 
data from patients with differing plasma volumes or weights 
can be compared. Results from different laboratories may 
also be compared. The method of calculation is as follows: 
PIT = ~ x [100 - (Hct x 0.92)]mg/100 ml.whole 
t!PIC 100 blood/day 
Where PI= Plasma Iron Concentration in µg% 
Hct = Haematocrit 
0.92 = A correction factor to convert venous 
haematocrit values to body haematocrit values. 
A-13 CALCULATION OF NON ERYTHROID IRON TURNOVER (NEIT) 
This was calculated by the method of Cook. (B) 
i.e. 
NEIT = 0.0035 x PI x [100 - (Hct x 0.92)]mg/100 ml. whole 
100 blood/day 
A-14 CALCULATION OF ERYTHROID IRON TURNOVER (EIT) 
This was calculated as the difference between the PIT 
and the NEIT. 
A-15 CALCULATION OF THE ERYTHROPOIETIC INDEX 
The rationale and development of this index has been 
detailed in my thesis (IV-3-o). The erythropoietic 
index (EI) is the ratio of predicted normal t 1PIC values 
2 
at the same serum iron concentration as the patient to 
the patient's actual t!PIC. 
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i.e. 
EI= predicted t!PIC 
Experimental t !PIC 
The predicted t!
1
PIC is calculated by the following 
equation: 
t!PIC (Pred) = (0.87 x PI x PCT) + 34.67 
where PCT= plasmatocrit = 100 - (Hct x 0.92) 
100 
A-16 CALCULATION OF RED BLOOD CELL UTILISATION (RBCUe) 
This value measures the percentage of injected 
59Fe 
radioactivity getting into the haemoglobin of circulating 
red cells. It was important, to me, because of the model 
that I have generated, to attempt an accurate measurement 
of this value. My method of calculating RBCU values is 
as follows: 
RBCU (%) = 59Fe Cpm (rbc's) x 100 
59Fe Cpm (inj) (1) 
59 59 where Fe Cpm in rbc's is the amount of Fe radioactivity 
in circulating red cells. 
has been derived as follows: 
This value 59
 Fe Cpm. (rbc 's) 
At the end of each patient's experiment, the packed red 
cells were resuspended in distilled water. These packed 
cells had previously been separated from the plasma , 
washed in saline and stored at 4°c. Each days samples 
were accurately labelled. Resuspending the cells i n 
distilled water resulted in cell lysis and liberation 
of free haemoglobin. On each sample thus prepared, 
a haemoglobin estimation was performed as previously 
described. (A.1.b) Two ml. aliquots of haemoglobin 
solution were then pipetted into counting tubes, and 
counted. From this, the specific activity of the 
haemoglobin could be calculated. 
= Cpm(s) 
Hb. cone. (s) (2) 
where Hb = haemoglobin 
Hb. cone. (s) = haemoglobin concentration/100 ml. 
in sample being counted 
= 1 59 d" • . d tota Fera 1.oact1.v1.ty counte 
in the sample. 
The total amount of circulating haemoglobin (Hb . ) c1.rc 
could be calculated as follows: 
Hb.( . ) c1.rc 
= Hb (pt) 
100 
x TBV (51Cr) (3) 
where Hb(pt) = the haemoglobin concentration of the 
patient during the period of observation 
(Gm/100 ml. whole blood) 
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Th 1 f . 1 . d 11 
59 d" · · e tota amount o c1.rcu at1.ng re ce Fera 1.oact1.v1.ty 
could then be calculated as: 
A-17 
279 
Cpm(rbc 's) = Cpm(s) Hb X .{ • ) c1rc 
Hb • Cone. ( s) 
from (3) 
= Cpm(s) x Hb (pt) x TBV (51Cr) 
Hb. cone. (s) 100 
= Cpm(s) 
X Rb (pt) x TBV (51Cr) 
Hb(s) 
= Cpm(s) x Hb (pt) x TBV(51Cr) 
Hb(s) 
59Fe Cpm( .. ) is calculated as previously described (A-7) 
1nJ 
where all the samples and the standard are counted on the 
same "run". R.BCU can then be calculated as detailed 
in A-16 (1). 
Using this method to calculate R.BCU, I have managed to 
obtain very rep_roducible values on same day samples 
counted in duplicate, and very little day to day variation 
in R.BCU values once the plateau phase of the R.BCU curve 
has been reached(.:!:, 2%). 
CALCULATION OF PREDICTED NORMAL RBCU (R.BCUp) 
This calculation has been derived as stated in the t ext 
of my thesis. (IV-3-o) and is calculated by the equation 
RBCU predicted(%) = 103.5096 - (.3633 x PI x PCT) 
(4) 
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A-18 CALCULATION OF t!
51
cHROMIUM RED CELL SURVIVAL (t!
51
cr) 
For reasons stated in the text (VI-£-7), I have elected 
51 to calculate t! Cr rather than to correct this data so 
as to arrive at a value for mean cell survival. This 
decision was taken before the recommendations of the 
standardisation committee were made known, and the majority 
of patients were likewise studied before this committee's 
recommendations appeared in print. 
The two ml. samples of haemolysed red cells used for 
counting 59Fe haemoglobin specific activity were used 
1 1 51 .f. · . h h db to ca cu ate Cr speci ic activity. Te met o y 
wh • h h 
51 .f . . . 1 b. ic t e Cr speci ic activity of the haemog o in 
solution was calculated was: 
51 .f. . . 5 Cr Speci ic Activity = Cpm( lCr) _ _,:_..::;.;;;~-----of sample 
H b ( s) 
where Hb(s) = the haemoglobin concentration of the sample. 
51cr Haemoglobin specific activity was plotted against 
time on semilogarithmic paper. A semilogarithmic least 
squares regression line was calculated and a regression 
equation obtained. The t! 51cr was calculated using 
this regression equation i.e. 
t 1




This was performed on a number of patients. An attempt 
was made to obtain "true organ counts" daily. True 
organ counts in this context may be defined as the counts 
59 
over an organ due solely to Fe sequestered in that organ, 
to the exclusion of counts due to 
59Fe coming from the 
organ caused by perfusion of the organ by labelled blood 
or plasma. 
(i) Counting technique: 
Patients having external counting performed upon themselves 
were injected while lying upon a stretcher under th€: 
crystal_ of a scanner (Picker Nuclear Dual Probe Magna 
Scanner). This machine had a five inch sodium iodide 
crystal, and was connected to a Picker Nuclear Digi t al 
counter (scaler/timer). The crystal was mounted over 
the patient at the site where counting was to be pedormed. 
Four sites were counted routinely - viz - over the sacrum, 
the spleen, the liver and the heart. These spots were 
marked with ink and counted repeatedly on serial days 
of the experiment. Points chosen . to count these organs, 
when palpable enlargement was not present, were chosen 
anatomically. The heart count was obtained over the 
fourth left intercostal space, approximately one inch to 
the left of centre. The spleen count was obtained over 
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the line joining the ninth costal cartilage and the mid 
axillary line. The liver count rate was obtained over 
the line joining the ninth costal cartilage and anterior 
axillary line on the patient's right side. The sacral 
counts were obtained over the point joining the posterior 
iliac crests, in the midline. These points were marked 
and accurately localised using a light mounted in the 
head of the counting crystal. The height at which the 
crystal was situated above the patient was recorded on 
the first day of counting, and this height was used 
throughout the period of observation. 
A focusing co11imeter with a five inch focal point was used 
for counting. Settings for counting were determined on 
the basis that the patient had both 
51cr and 59Fe activity 
in his body. Initially, two window settings were used, 
the higher window being selected so as to exclude any 
counts above background when a 
51cr standard was bei ng 
counted. This window was set at 400 to 1000 Kev. The 
lower window was set to include 
59Fe and 
51cr counts, the 
setting being 200 to 380 kev. 
51 
The counts due to Cr 
59 
and Fe were determined using the method detailed in 
A-5-(iii). It was found that count rates due to 
51cr 
were disappointingly low using this method, and the data 
obtained was highly suspect. Eventually it was decided 
d . d h" 51 59 to iscar tis Cr data and to count Fe alone. 
counts were always high and the accuracy of the count rate 
was+ 1%. These counts were very reproducible and good 
59 
curves were obtained using Fe d.ata alone. 
(ii) Calculation of organ counts. 
A series of calculations was required to correct the 
gross count rate obtained on different days to a count 
rate corrected for variations in machine efficiency 
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and for change in count rates due to isotope decay. Thi s 
59 
correction was performed by counting a standard Fe 
solution daily. The steps in the correction procedure 
may be detailed as follows: 
a) count patient and obtain gross count rate on day(t) 
b) subtract background count rate on day(t) from this 
c) 
value. Gross count rate - BG count rate 
= Organ count on day(t) 
(hereafter called Ot) 
Count standard 59Fe solution on day. 
0 
Subtract background count rate on day O. 
(hereafter called S) 
0 
d) Count standard 
59Fe solution on day (t). 
Subtract background count rate on day (t). 
59 This gives the Fe standard count rate on day (t) 
(hereafter called St). 
e) Gross organ count rate on day(t) may then be 
corrected for isotope decay and for day to day 
variations in machine counting efficiency by 
the equation: 
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Corrected O(t) = 
The counts of each organ,corrected in this way, could 
then be plotted as a function of time. This yields 
a line showing the gross day to day variation in organ 
counts. These counts may be corrected to show changes 
in specific organ counts as follows: 
If I assume that at t(o)' the time of injection of i sotope , 
all the counts obtained over an organ ar e due to perfus ion 
of that organ by blood or plasma containing isotope, the 
count rate due to uptake of that isotope by the organ 
itself will be zero. 
The ratio of organ counts to counts obtained over the 
heart will, at t, reflect the ratio of blood perfus i ng 
0 
the organ to blood perfusing the heart. 








0 = Zero 
where O = organ counts at t 
0 0 
H = heart counts at t 
0 0 
If we assume that all counts obtained over the heart are 
due to blood perfusing this area, then count rates over 
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where B(t) = counts over organ due to perfusing blood 
at time (t) 
H(t) = counts over heart at time (t) 
This value can then be subtracted from the corrected 
organ counts at time (t) to give a measure of "true" 
organ counts at time (t), i.e. counts in the _organ 
due to active or passive isotope uptake 
i.e. 
TO(t) = o(t) - B(t) 
= o(t) -[ o(o) x H(t)l 
H(o) 
where TO(t) = true organ counts at time ( t). 
This value (TO(t) ) may then be plotted as a function of 
time, resulting in a graph that will represent the uptake 
or loss of isotope by the organ as a function of time, 
independent of counts due to blood perfusing it. 
This procedure has been followed in order to obtain 
"true organ counts" , over liver, spleen and sacral marrow. 
In some patients it was not possible to obtain counts 
at \o). This obviously influenced the ratio (Oo/Ho) 
i.00 
considerably, particularly in organs such as the inarrow 
59 where Fe uptake occurs very rapidly. It was reasoned 
59 that all Fe sequestered in the erythroid marrow wou ld be 
released by day 14, i.e. the period at which the experiment 
in each individual was terminated. As a result, I 
decided that, for the marrow, the ratio of o14/H14 would 
probably more accurately reflect the ratio of marrow to 
heart blood perfusion, where 014 and H14 are the corrected 
organ counts on the 14th day of the experiment, respective ly, 
In the other organs, i.e. the liver and spleen, I have 
assumed iron uptake not to be as rapid, and have used the 
Oo/Ho ratio. In all patients, it was possib l e to perform 
the initial count within thirty minutes of inj ection . 
Using this corrected method of obtaining organ specific 
count rates, it was possible to obtain more specific data 
about the distribution of isotope within the body. The 
values were plotted as a function of time. A positive 
slope of the graph means active uptake of isotope by the 
organ, a negative slope meaning active loss of isotope 
from the organ. In the liver area, posi tive slopes 
usually meant iron storage, and usually occurred in 
individuals with high serum iron concentrations. Biphasic 
curves over the liver almost invariably occurred where 
hepatic myeloid metaplasia was present. Positive s J.opes 
over the spleen occurred in splenic stasis syndromns and 
where splenic red cell destruction was present. Bi phas i c 
slopes over the spleen were taken as evidence of sp l enic 
myeloid metaplasia. No effort was made to quantitate 
these curves, the count rates being dependent upon i njected 
A-20 
doses of radioactivity and body ma-ss. However, the 
shape of the curves often gave valuable information, 
particularly with regard to hypersplenism and myeloid 
metaplasia, and were vastly superior to data obtained 
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. h 51 h . wit C rom1.um. These curves also showed more effectively, 
the presence of iron storage, myeloid metaplasia and 
splenic sequestration. 
WHOLE BODY COUNTING 
Unfortunately, the whole body counter used by the 
Department of Diagnostic Isotope services at Groote Schuur 
Hospital, arrived towards the end of my period in the 
department. The model used was a Nuclear Ent erprises 
Whole Body Counter based upon the shadow shiel d principle. 
The machine initially had a single 3" sodium i odide 
crystal, and was linked to a Nuclear Enterprises scaler 
and rate meter. In the context of this thes i s, I used 
the machine only to study loss of radioactive 
59Fe from 
the body during the course of the experiment. Thi s 
averaged 3%, reflecting sampling from the pati ent. 
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APPENDIX B 
DEVELOPMENT OF A MODEL FOR DESCRIBING 
BODY ERYTHROPOIESIS 
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DEVELOPMENT OF A MODEL FOR DESCRIBING BODY' ERYTHROPO!ESIS 
INTRODUCTION 
The development of this model depended almost entirely 
upon the ingenuity of Mr. Paul Haddingham, a graduate 
of the University of Cape Town, who was, at the time, 
working in the Department of Chemical Engineering at 
the University. No apology is made for utilising his 
skill, as it seemed important to me to attempt the 
development of a model to describe the function of the 
bone marrow as an organ intermediary between the plasma 
and red cell compartments, in an attempt to mathematically 
unite these compartments. 
been done. 
MODEL DESCRIPTION 
To a large extent, this has 
Erythropoietic activity can be conveniently reduced to 
four physiologically defined concurrent processes for 
purposes of modelling iron kinetics. 
1-a Uptake of transferrin bound iron from the plasma by 
maturing erythroblasts. 
1-b . Maturation of erythroblasts. 
1-c Release of matured erythroblasts into the circulation 
as erythrocytes. 
1-d Destruction of red cells or erythroblas t s at the 
termination of their lifespan. 
291 
Each of these physiological processes can be mathemat ically 
described so that an overall model of erythropoietic 
activity can be generated. Iron kinetics can be described 
1n terms of four compartments (see Figure I). 
2-a Plasma containing labile, transferrin bound iron. 
2-b Bone marrow - the site of erythroblast maturation and 
haemoglobinisation. 
2-c The circulating red cell. 
2-d Parenchymal iron stores. 
Figure I. Model diagram of the different compartments 
in the body concerned with iron kinetics, 
showing the typical changes, in time, of 






For the purposes of this model, the reticule-endothelial 
system (RES) is seen as a rapidly turning over iron pool, 
acting as a transfer station between 
(1) catabolised haem from bone marrow and red cells and 
(2) the plasma • 
. The model developed describes the short term relationships 
between these compartments, and tends to ignore long term 
feedback of iron from red cells dying outside the period 
of the experiment. The model does, however, account for 
any feedback of iron that may occur from this source during 
the experimental period (which is two weeks). The amount 
of feedback of iron from these combined sites (i.e. intra-
medullary and early extramedullary haem catabolism) is 
quantitated in an attempt to describe the erythropoietic 
process. 
Physiology of radioactive iron kinetics. 
The .aspect of the model has been largely covered in the 
review section of this thesis. 
The plasma compartment:-
After injection of 59Fe labelled transferrin into this pool, 
radioactivity is cleared in a way that may be described by 
a number of exponential decays. The f i rst exponential 
decay tends to zero within twenty four hours of injection. 
59Fe 1.·s taken b b h h · h bl d up y ot t e maturing eryt ro ast an 




a first order process indicated by the first exponential 
of the plasma iron clearance curve. The other exponentials 
of the plasma iron clearance curve appear to arise as a 
result of feedback of label from other sites into the 
plasma, i.e. lymphatics, ineffective erythropoiesis, 
. t (164) storage si es. The rate constants of the first order 
processes to the bone marrow and stores can be determined 
from the initial exponential of the plasma iron clearance 
curve. This will be mathematically shown (4-1). 
The bone marrow compartment: 
In the bone marrow (BM) there are erythroblasts at all 
stages of maturation. The iron uptake of au individual 
erythtoblast has been shown to be dependent upon the state 
of maturation of the erythroblast (section I I I-b-5 of 
review). One can attempt to define a function, the 
probability of iron uptake by the maturing er ythroblast, 
in relation to its maturity. Red cell production involves 
mitotic division of a single erythroblast precursor. The 
initial erythroblast precursor, plus its mitotic derivatives, 
can be looked upon as a single 'unit' in the bone marrow. 
The iron uptake by this unit will be the sum of the iron 
uptake of its members. As a generalisation, all t he 
bone marrow units, under stable conditions, will have the 
same amount of iron uptake. One can attempt to define 
the probability of iron uptake by this unit as a function 
of time, and, based upon this probability curve, a 
mathematical model describing BM haemoglobin production 
may be derived. 
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There is a lot of evidence to suggest that the maturation 
period of erythroblasts is approximately 6.5 days (see 
section III-b-3 of review section) and that this maturation 
period remains fairly constant in different disease states. 
We have attempted to define, by external counting methods, 
an accurate measure of this maturation period. 
Nineteen patients thought to have relatively normal 
erythropoiesis were used in this study. Shortly after 
injection of 59Fe labelled transferrin, they were externally 
counted over the sacral bone marrow, as detailed under 
methods. Bone marrow curves were calculated for each 
patient, the results being compared and analysed statistically. 
Count rates were normalised as a percentage of the maximal 
count rate obtained. The results can be seen in Table 1 
and Figure II. By extending the initial slope of .. . he bone 
marrow clearance curve to the x axis, we obtained an average 
erythroblast maturation period of 6.7 .:!:. 0.7 days in these 
nineteen patients. The remaining area under the curve 
59 was thought to represent uptake by erythroblasts of Fe 
from feedback sites. For convenience, we have assumed 
an erythroblast maturation period of 6.5 days for purposes 
of this model as this agrees well with our data and that 
calculated by other workers (see section III-b-3). This 
curve, in effect, defines the delay between injection of 
labelled transferrin into the plasma, and its clearance 
from the bone marrow, and characterises the amount of 
clearance of label from the bone marrow with the passage 
of time. 
Figure II Composite Bone Marrow Clearance Curve following injection 
of radioactive Iron bound to plasma transferrin. Results 
of a study of nineteen patients sumnarised statistically 
(mean .!. 1 SD) • 


















































Experimental Results in Nineteen Patients.Standardised 
Sacral Bone Marrow Curves (see text). 
Day 
1 2 3 4 5 
100 92 74 60 25 
100 81 
100 
100 94 78 63 50 


















93 62 39 22 
86 86 53 44 
74 65 56 34 
95 82 68 
91 66 48 35 
96 50 30 17 
96 65 38 23 
89 64 46 24 
85 53 44 32 
75 55 42 28 
90 75 57 46 
100 88 60 45 
89 84 58 33 
69 52 35 22 
89 69 50 32 
8.8 12.5 11.1 10 
17 17 16 16 
6 7 8 
18 12 9 
38 24 19 
3 - 0 
14 9 6 
24 18 19 
41 34 26 
26 18 13 
7 4 3 
9 2 0 
12 9 3 
28 26 23 
21 14 13 
40 36 31 
35 28 19 
19 11 14 
10 6 3 
21 17 12 
12.2 10.7 9.8 
16 15 17 
9 10 11 12 13 
4 10 0 0 0 
0 0 0 0 0 
0 0 0 0 0 
11 9 5 3 0 
0 0 0 0 0 
5 4 3 2 0 
9 6 1 0 0 
19 13 3 0 0 
7 3 0 
10 6 3 0 0 
0 0 2 0 0 
0 0 0 0 0 
0 0 0 0 0 
20 17 14 0 0 
11 8 4 3 0 
25 21 16 3 
13 8 5 0 0 
13 13 6 4 0 
0 0 0 0 0 
8 6 4 1 0 
7.9 6.7 4.5 0.3 0 .6 
18 17 19 17 17 
3-c The Circulating Red Cell Compartment. 
Mature labelled red cells are released from the bone 
marrow into the general circulation. The percentage 
of injected dose released as a function of time, is 
described by the RBCU curve. This in turn depends 
upon the amount of iron label taken up by the maturing 
erythroblasts, and the state of maturation of those 
erythroblasts. Thus, iron label released between t 
0 
and t 24 hours will
 reflect the amount of iron label 
taken up by the most mature erythroblasts (i.e. between 
5.5 and 6.5 days old). The amount of iron released 
between t 24 and t 48 h
ours will reflect the amount of 
iron taken up by erythroblasts 4.5 - 5.5 days old, and 
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so on. Only terminally will the RBCU curve be influenced 
by feedback iron, as erythroblasts not originally present 
when the initial bolus of radioactive iron was injected, 
become labelled by recycled label. 
As previously discussed, the RBCU curve will also be 
influenced by variable erythropoietic activity (both 
effective and ineffective) as well as changes in red 
cell survival (whether finite in which case Z must be 
< 14 days, or random) (see Section IV-5). In pra,:tise, 
the two factors most influencing the RBCU curve will be 
ineffective erythropoiesis and random red cell destruction. 
Both of these processes will tend to slur the RBCU curve, 
as well as cause a decrease in its maximum value. 
4 
4-1 
Extramedullary haemolysis will, however, shift the curve 
to the left, whereas ineffective erythropoiesis will shift 
it to the right. From the point of view of feedback iron 
label from these sources, earlier feedback will occur 
with ineffective erythropoiesis. 
Mathematical Derivations: 
Iron transport from plasma to bone marrow and parenchymal 
iron stores. 
As described in section 3-a, iron uptake by BM and parenchymal 




where NBM, Ns and Np are the amounts (in Cpm) of 
radio iron in the bone marrow, parenchymal iron 
stores and plasma respectively. 
= 
(2) 
k1 and k2 are the rate constants for transport of i ron 
from the plasma to the BM and parenchymal iron stores 
respectively. 




= (klNp + k2 Np ) 
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b 
. . .- (kl+k2) t By su st1.tut1.ng w- into equation (1) and solving 
by integration 
= constant of integration 
where k1 + k2 
= Al = the decay constant of the first 
exponential of the PIC curve. 
-+ 00 = k 
1 
After approximately eight days, the iron in the hone 
marrow has passed out completely into the circulating 
red cells, and the resultant RBCU curve forms a plateau, 
which is not usually effected by the slow process of 
red cell destruction unless random destruction is present. 
From Figure I, the amount of radio iron circulating at 
this time represents the RBCU [ Iu Cpm] • 









can be calculated from · a knowledge of Al 
and I using equation (3). From this, the rate of input 
u 
of radioactive iron into the BM can be calculated 
i.e. rate of input = = d NBM 
dt 
Bone marrow compartment and RBCU curve 
A number of assumptions have been made in preparing a 
model to describe the bone marrow. 
a) New cells are born at a constant rate in the BM. 
This assumption is reasonable under steady state 
conditions, but need not be under non steady state 
conditions, i.e. where production exceeds destruction 
or the reverse. 
b) The maturing erythroblasts in the BM have an average 
maturation period of 6.5 days, and that each BM unit 
(as defined in 3-b) behaves in the same way in regard 
to iron uptake as a function of maturation. 
c) The probability of iron uptake by an erythroblast 
unit during maturation is assumed to be a parabolic 
function which varies according to the stage of 
maturation of the erythroblast. Autoradiography 
studies (see section 3-b-5 of review) have shown 
iron uptake to be maximal in the primitive erythroblast 
and to decline to zero as the cell matures. As a 
result of mitosis however, the number of cells 
::soz 
.de.rived from the same erythroblast precursor increases 
so that the amount of iron taken up by these cells, as 
a function of time, is probably maximal during the mid 
stage pf their development. This function, i.e. amount 
of iron uptake as a function of time, is assumed to be 
parabolic. 
d) The initial slope of the plasma iron clearance curve 
represents the rate at which labelled iron is 
incorporated into maturing erythroblasts. 
e) All compartments, described in Figure I, are assumed to 
be "lumped" so that space dependent effects are 
assumed to be negligible. This assumption is 
demanded by the complexity of the physiological 
system. 
From assumption (d) for the early part of iron uptake 
after radio iron injection, the first exponential of the 
plasma iron clearance curve represents the rate of 
incorporation of iron into maturing erythroblasts (see 
section 3-a) • The total amount of radioactivity (z in Cpm) 
taken up at time (t) by the erythroblasts can be defined 
as:-
) (4) 
where k1 is the rate constant of BM iron uptake (as 
described in section 4-1) 
C
0 
is the amount of iron label initially injected in Cpm. 
tis time in days. 
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derived from the same erythroblast precursor increases 
so that the amount of iron taken up by these cells, as 
a function of time, is probably maximal during the mid 
stage of their development. This function, i.e. amount 
of iron uptake as a function of time, is assumed to be . 
parabolic. 
d) The initial slope of the plasma iron clearance curve 
represents the rate at which labelled iron is 
incorporated into maturing erythroblasts. 
e) All compartments, described in Figure I, are assumed to 
be "lumped" so that space dependent effects are 
assumed to be negligible. This assumption is 
demanded by the complexity of the physiological 
system. 
From assumption (d) for the early part of iron uptake 
after radio iron injection, the first exponential of the 
plasma iron clearance curve represents the rate of 
incorporation of iron into maturing erythroblasts (see 
section 3-a). The total amount of radioactivity (x in Cpm) 
taken up at time (t) by the erythroblasts can be defined 
as:-
.. ) (4) 
where k1 is the rate constant of BM iron uptake (as 
described in section 4-1) 
C
0 
is the amount of iron label initially injected in Cpm. 
tis time in days. 
JUJ 
The rate of radio iron _uptake[ Ru(t)] by the ery_throblasts 
at time (t) is given by differentiating equation (4). 
. . R (t)/t = dx/t 
dt~ 




The amount of radio iron taken up by the (i-th) group of 
maturing units born (t) days earlier (x. Cpm) is, using 
1 
assumptions (a) to (d), given by the product of the amount 
of labile radio iron in the plasma, (x) and the probability 
(Pr) that this group of units will take up the available 
radio iron at their stage of maturation (Pr.). 
1 
x. = Pr.x 
1 
dx. = ox. 
1 1 
oPr 
• dPr + ox .. dx 
1 
~ 











to compute the rate of output 
BM in Cpm/day at time (t)' all 





(t~ of label 
the groups of units 
t3, i .•• t ' ••• tn 
units of time earlier which are taking up radio iron must 
be considered. Thus, at time t = t, (the time of 
0 
injection of radio iron) the output is given by equation (6) 
as:-
At time 





t = t 2, Ro2(t) = dz2 
dt 
At time t = t., 
1 
Ro.(t) = dz. = 
1 1 
dt 
- ·r dPr " o n + Pr .d:t n o 
dt 
= [x .d.Pr 1 o n-
dt 





+ Pr 1 .dx ] n- o 
dt 
+ Pr 2• dx ] n- o 
dt 
+ Pr l .dx] n- o 
dt 
+ Pr





xj • dPr• . . P ( . . ) .l-.] n-i+J + r n-i+J u:!J_ 
dt dt 
Here, Pr is the probability of iron uptake at the stage n 
of rull maturation in the BM when the mature red cell is 




the only ones contributing to radio iron output at 
t = t • 
0 
These cells 'see' the initial labile radio iron 
concentration x. 
0 
At time t = t 1 , a fraction 
after t
0
, cells which had this 
fraction of time t 1 - t 0 
left to mature will be released 
and will ·have been exposed to concentrations of labile 
radio iron x when the probability is Pr 1 ( at time o n-
t = t
0
) and x1 when the probability is Prn. 
This process is generalised into the sunnnation formula 
(formula (7) ) • 
Assuming that the functions Pr(t) and x(t) are continuous 
and differentiable, the summation of equation (7) may be 
expressed as:-
Ro(t) = dz/ = 
dt/t 
t 
J(x(T)dPr[L -(t-T ~ + Pr [ L-(t-T)] dx(T)] dT dt dt 
0 
••• (8) 
Where Tis the dunnny variable of integration and Lis 
the erythroblast maturation period .which appears to be 
6.5 days as previously indicated. 




This equation expresses the rate of red cell output of 
radio iron (Cpm) from the BM in terms of the plasma iron 
clearance constants and the probability of iron uptake 
distribution at time (t) after the initial injection of 
radio iron. A further assumption, implicit in equation 
(9), is that mature cells are released from the BM only 
once they have reached full maturity. This may not 
always occur in stress situations where earlier release 
of "stress" reticulocytes has been shown to occur. 
These cells will, however, still require 6.5 days from 
the time of birth of their original erythroblast precursor 
until they reach ultimate maturity. 
Prpbability Distribution. 
From assumption (c) in 4-2-(1), the probability distribution 
curve is parabolic. 
0 <or= t < or = L 
Pr(t) = O, t < 0 
Pr(t) • O, t > L 
• ••••• (10) 
Since (L) is known - (6.5 days) i.e. BM maturation period 
Pr/ O t= Pr/t=L = 0 = 
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J Pr(t) dt = 1 
0 
The quadratic constants a
0
, a1 and a2 are readily 
evaluated in terms of (L). From the first of the above 





+ a2L = 0 ( L ;. 0 as discussed} 
= 1 
Solving these two equations simultaneously gives 
= 
= 
Equation (10) can now be used in equation (9) to 




and k1 (experimentally determined) 
and this probability distribution. 
This equation is only valid if there is no feedback of 
labile radio iron from ineffective erythropoiesis or 
early random red cell destruction, as discussed in 1. 
However, this feedback may be incorporated as will be 
discussed. 
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4-3 Red Blood Cell Utilisation Curve. 
5 
In order to compute R as a function of time, equation (9) 
0 
can be integrated i.e. 
• ••• (9) 
2(t) 
•••• (11) 
Where 2(t) has units of Cpm. 
It is the aim, in developing this model, to generate the 
best fit between the observed RBCU curve, and the predicted 
RBCU curve using feedback of radio iron from ineffective 
erythropoiesis and early random red cell destruction as 
a variable parameter. This was achieved using digital 
techniques on a Univac 1106 computer. 
Computational Method. 
Input data for the model are:-
d-r 
a) the plasma iron clearance const·ant·s 
i.e. amount injected = 1007. 
concentration at t = 1007. 
0 
slope of initial exponential of PIC curve. 
b) the RBCU curve for each subject. 
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This is derived as derived under methods. Each patient 
has RBCU values calculated from each specimen taken. 
These were usually taken every day in the first week, 
and on alternate days in the second week. For the 
generation of a best least squares polynomial fit between 
the model curves and the experimental curves, it was 
necessary to smooth the experimental curve and put in 
more data. Each individual's RBCU curve was plotted 
and the best eyeball fit of the data was made. Points 
at 0.5 day intervals were read off the resultant curve 
and recorded for each subject on data cards. 
The basic procedure is as follows:-
(1) For zero feedback, the output RBCU curve is 
calculated using equation (10) and (11). 
(2) The SD between the predicted and experimentally 
derived curves are computed. 
(3) The feedback fraction is increased (this fraction 
representing the amount of radio iron label released, 
either by ineffective ~rythropoiesis or early 
random red cell destruction, back to the plasma 
and then back to the BM) by increments of 0.01%. 
(4) Steps (1), (2) and (3) are repeated until the 
standard deviation (SD) has been minimised. The 
feedback value giving the minimum SD between the 
computed and experimentally derived RBCU curves 
is a parameter describing the state of erythro-
poiesis in a particular subject. The greater 
the feedback fraction (expressed as a fraction 
of the total bone marrow output), the greater 
the degree of ineffective erythropoiesis or early 
random red cell destruction in that particular 
individual. 
A simplified flow chart of the computer progranune f or 
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the model is shown in Figure III and IV. Integration 
of equation (10) is performed numerically using Simpson's 
rule. In order to compare predicted and experimental 
RBCU curves, the experimental values are fitted using a 
second order polynomial least squares interpolation 
method devised by P.T. Haddingham, the author of the 
mathematics of this model. The use of this progrannne 
is shown in the flow chart. The fitting procedure 
involves taking groups of five successive points of data 
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i.e. 
and fitting a second order polynomial to each group. 
Each polynomial is identified by its central pivot point, 
respect{vely P3, P4, P2+2 , Pn_2, about which the data 
is fitted. 
A further computational improvement would involve 
streamlining the method of seeking an optimum fit 
between experimental and predicted RBCU values using 
. l d . . (188b) optima ynamic progranming. 
Figure III 
312 
Flow chart of computational method. Part 2. 
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Figure IV Flow Chart of Computational Method. 
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6. CRITICISM OF THE MODEL 
The limitations imposed upon this analytical system are 
of two kinds. 
(1) Experimental 
a) The plasma iron clearance curve can be accurately 
measured, and we are happy that, for the purposes 
of this model, very little error is present in the 
measurements of this parameter. 
b) The RBCU curve, as fitted by us (section 5-b), 
may contain a fair amount of experimental error. 
Even at plateau parts of the RBCU curve we often 
find a 4 - 5% range in RBCU values. The only 
way that I have been able to smooth this is by 
'eyeball' techniques using RBCU values calculated 
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experimentally as often as possible. This method, 
while not ideal, appears to me to give a reasonably 
good fit to the experimental curve without excessive 
manipulation of the data. 
2) Theoretical 
We have assumed a maturation time of 6.5 days, and have 
likewise assumed that this maturation occurs completely 
in the bone marrow. That this is not so, is well known, 
as relatively immature reticulocytes may be released into 
the circulation under 'stress' situations. This model 
could be expanded to incorporate a parameter describing 
this premature release which would then shift the computed 
RBCU curve to the left. At this stage I believe that, 
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the· fewer variable parameters · introduced . into this model, 
the more easily will I be able to interpret the data. In 
some subjects, however, when fractional feedback was 
increased from zero, an increase occurred in the SD between 
predicted and experimental RBCU curves. This probably 
represents premature reticulocyte release from the BM, 
but may in addition be caused by the shift to the left in 
the RBCU curve caused by early random haemolysis (see 
thesis section IV-5). 
Ideally, one would like to be able to compute what the 
RBCU curve of each patient should look like in the absence 
of abnormal erythropoiesis and haemolysis. By varying 
the feedback fraction, one could then compute a curve 
matching the experimental curve, and this value of feedback 
would then be used to measure in a quantitative way, the 
proportion of erythroblast iron uptake going effectively 
into the circulation, if we assume that ineffective 
erythropoiesis and random early red cell destruction 
represent a continuum of the same process. This would, 
however, necessitate some further study on the effect of 
effective erythropoietic activity upon the RBCU curve. 
It is possible that my regression equation, describing in 
normal patients the RBCU values as a function of plasma 
iron concentration, approaches this ideal. However, we 
cannot assume that the low RBCU values in aplastic anaemia 
represent an increase of ineffective erythropoietic activity. 
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Presumably, they represent an increase of non . erythroid 
iron uptake relative to normal patients at the same plasma 
iron concentration. I have been unable to study this in 
greater depth, and have assumed for now that NEIT depends 
solely upon the plasma iron concentration, and is not 
influenced by the disease state. This assumption may 
be wrong. In order to make this model work to reveal 
truely useful information, therefore, some method of 
measuring predicted RBCU values depending solely upon 
changes in effective erythroid activity as opposed to 
changes in plasma iron concentration must be generated. 
This I have not been able to do. Until this is done, 
the value derived for feedback describes only the shift 
of experimental RBCU curves to the right caused by 
ineffective erythropoiesis, and quantitates this in 
terms of a feedback fraction. The greater this feedback 
fraction, the more severe is thought to be the extent 
of ineffective erythropoiesis. At best, this data is 
only partially the truth, but it does have the merit of 
putting numbers or orders of severity upon a parameter 
which is extremely difficult to describe by other methods. 
In addition, the model has used all the input and output 
data, and has generated an intermediary function describing 
what happens in the bone marrow. To my knowledge this 
is the first attempt to do this, and seems to have some 
merit itself, by matching the plasma and red cell ferro-
kinetic behaviour of an individual. 
Analysis of the data obtained utilising this model 
can be seen in Chapter V of this thesis, 
31 7 
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